US20220039818A1 - Shallow surface cryotherapy applicators and related technology - Google Patents
Shallow surface cryotherapy applicators and related technology Download PDFInfo
- Publication number
- US20220039818A1 US20220039818A1 US17/350,972 US202117350972A US2022039818A1 US 20220039818 A1 US20220039818 A1 US 20220039818A1 US 202117350972 A US202117350972 A US 202117350972A US 2022039818 A1 US2022039818 A1 US 2022039818A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- subject
- air
- cup
- vacuum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000005516 engineering process Methods 0.000 title description 33
- 238000000315 cryotherapy Methods 0.000 title description 3
- 238000001816 cooling Methods 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 60
- 150000002632 lipids Chemical class 0.000 claims description 38
- 238000007920 subcutaneous administration Methods 0.000 claims description 29
- 239000012530 fluid Substances 0.000 claims description 24
- 238000004891 communication Methods 0.000 claims description 11
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 238000012876 topography Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 230000000717 retained effect Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 129
- 238000011282 treatment Methods 0.000 description 89
- 210000004027 cell Anatomy 0.000 description 62
- 210000003491 skin Anatomy 0.000 description 60
- 239000003570 air Substances 0.000 description 39
- 210000000577 adipose tissue Anatomy 0.000 description 18
- 239000002577 cryoprotective agent Substances 0.000 description 16
- 238000007789 sealing Methods 0.000 description 14
- 230000006378 damage Effects 0.000 description 12
- 239000002826 coolant Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 208000034656 Contusions Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 206010033675 panniculitis Diseases 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000004003 subcutaneous fat Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000001217 buttock Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 238000011176 pooling Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000009746 freeze damage Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000023184 Body fat disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000013529 heat transfer fluid Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/30—Surgical pincettes without pivotal connections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B18/0218—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques with open-end cryogenic probe, e.g. for spraying fluid directly on tissue or via a tissue-contacting porous tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00535—Surgical instruments, devices or methods, e.g. tourniquets pneumatically or hydraulically operated
- A61B2017/00561—Surgical instruments, devices or methods, e.g. tourniquets pneumatically or hydraulically operated creating a vacuum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/30—Surgical pincettes without pivotal connections
- A61B2017/306—Surgical pincettes without pivotal connections holding by means of suction
- A61B2017/308—Surgical pincettes without pivotal connections holding by means of suction with suction cups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00041—Heating, e.g. defrosting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00047—Cooling or heating of the probe or tissue immediately surrounding the probe using Peltier effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00696—Controlled or regulated parameters
- A61B2018/00714—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/007—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
- A61F2007/0075—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating using a Peltier element, e.g. near the spot to be heated or cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0093—Heating or cooling appliances for medical or therapeutic treatment of the human body programmed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0225—Compresses or poultices for effecting heating or cooling connected to the body or a part thereof
- A61F2007/0239—Compresses or poultices for effecting heating or cooling connected to the body or a part thereof using vacuum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0282—Compresses or poultices for effecting heating or cooling for particular medical treatments or effects
- A61F2007/029—Fat cell removal or destruction by non-ablative heat treatment
Definitions
- the present disclosure relates generally to treatment systems and shallow surface applicators.
- Several embodiments are directed to applicators with shallow cups with airflow features for air removal.
- Excess body fat, or adipose tissue may be present at various locations of a subject's body and may detract from personal appearance.
- Aesthetic improvement of the human body often involves the selective removal of adipose tissue located at the abdomen, thighs, buttocks, knees, submental region, face and arms, as well as other locations.
- Invasive procedures e.g., liposuction
- Injection of drugs for reducing adipose tissue can cause significant swelling, bruising, pain, numbness, and/or induration.
- non-invasive treatments for reducing adipose tissue often include regular exercise, application of topical agents, use of weight-loss drugs, dieting, or a combination of these treatments.
- One drawback of these non-invasive treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option.
- Topical agents and orally administered weight-loss drugs are not an option if, as another example, they cause an undesirable reaction, such as an allergic or negative reaction.
- non-invasive treatments may be ineffective for selectively reducing specific regions of adiposity, such as localized adipose tissue along the hips, abdomen, thighs, or the like.
- Conventional non-invasive vacuum cooling devices suck a fold of skin between two spaced apart cooled plates that are generally parallel to one another.
- the cooling device can cool and thermally damage targeted tissue. Only opposites sides of the skin fold contact the cooled plates, which limits the cooling capabilities of the cooling devices. Additionally, the end of the tissue fold located in a gap between the plates may experience pooling of blood. A vacuum may cause rupturing of blood vessels and lead to bruising of the skin located in the gap. Accordingly, conventional invasive and non-invasive treatments are not suitable for many subjects and cannot effectively target certain regions of tissue.
- FIG. 1 is a partially schematic, isometric view of a treatment system for non-invasively affecting target regions of a subject in accordance with an embodiment of the technology.
- FIG. 2 is a cross-sectional view of an applicator taken along line 2 - 2 of FIG. 1 and FIG. 5 .
- FIG. 3 is a cross-sectional view of a connector taken along line 3 - 3 of FIG. 1 .
- FIG. 4 is an isometric view of an applicator suitable for use with the system of FIG. 1 in accordance with an embodiment of the technology.
- FIG. 5 is a bottom view of the applicator of FIG. 4 .
- FIG. 6 is a cross-sectional view of an applicator taken along line 6 - 6 of FIG. 5 in accordance with an embodiment of the technology.
- FIG. 7 is a cross-sectional view of an applicator taken along line 7 - 7 of FIG. 5 in accordance with an embodiment of the technology.
- FIG. 8 is a cross-sectional view of the applicator taken along line 8 - 8 of FIG. 5 in accordance with an embodiment of the technology.
- FIG. 9 is a isometric view of a central region of a cup taken along line 9 - 9 of FIG. 2 in accordance with an embodiment of the technology.
- FIG. 10 is a bottom view of an applicator in accordance with another embodiment of the technology.
- FIG. 11 is a cross-sectional view of an airflow feature taken along line 11 - 11 of FIG. 10 .
- FIGS. 12 and 13 are cross-sectional views of airflow feature in accordance with some embodiments of the technology.
- FIG. 14 is an isometric view of an applicator with branching airflow features in accordance with another embodiment of the technology.
- FIG. 15 is a bottom view of the applicator of FIG. 14 .
- FIG. 16 is a cross-sectional view of an applicator taken along line 16 - 16 of FIG. 15 in accordance with an embodiment of the technology.
- FIGS. 17 and 18 are cross-sectional views of airflow features located along a cup in accordance with embodiments of the technology.
- FIG. 19 is a flowchart of a method for treating a subject in accordance with embodiments of the disclosed technology.
- FIG. 20 is a schematic block diagram illustrating subcomponents of a controller in accordance with embodiments of the disclosed technology.
- the present disclosure describes treatment systems, applicators, and methods for affecting targeted sites.
- Several embodiments are directed to non-invasive systems that cool/heat specific regions or volumes of tissue.
- the non-invasive systems can include applicators with thermally-conductive cooling cups for cooling the skin surface.
- An applicator can include one or more airflow features that facilitate thermal contact with the tissue.
- the airflow features can include one or more air-egress features along which air flows to reduce, limit, or substantially eliminate air between the subject's skin and the cup before and/or during treatment.
- the air-egress features can include small gaps, channels, ridges, protrusions, or other suitable features for defining fluid flow paths.
- Some aspects of the technology are directed to an apparatus that includes an applicator with a temperature-controlled patient contact surface having a topography for providing airflow channels.
- the airflow channels can extend between a vacuum port and a peripheral portion of the patient contact surface when the patient's tissue is operably received within a cavity of the applicator.
- the vacuum port can provide communication between the cavity and a pressurization device, such as a vacuum source.
- the topography of the patient contact surface can be selected to assist in the elimination or reduction of air gaps when the patient's tissue is drawn to the cavity, distribute the vacuum throughout the cavity (e.g., distribute the vacuum along the patient contact surface), and/or otherwise facilitate air removal.
- a cup and the vacuum port are configured such that when a vacuum is applied the subject's tissue substantially fills an entire volume of the cup except for small gaps created by air-egress features formed on a surface of the cup.
- the applicator can include a cup, at least one vacuum port, and air-egress features.
- the cup can define a tissue-receiving cavity and can include a temperature-controlled surface.
- the air-egress features can extend along the temperature-controlled surface to provide airflow paths to the vacuum port to enhance air removal between the subject's skin and the cup while the subject's tissue is pulled toward the temperature-controlled surface.
- the applicator can draw in air such that the subject's tissue fills most or substantially all of the tissue-receiving cavity.
- a vacuum can be drawn to pull the skin into thermal contact with a large area of the cup, thereby providing a relatively large skin/cup interface for heat transfer.
- the temperature-controlled surface can extend continuously along spaced apart sidewalls and bottom of the cooling cup and can thermally contact an area of the subject's skin that is equal to or less than about 20 cm 2 , 40 cm 2 , 80 cm 2 , 100 cm 2 , 140 cm 2 , 160 cm 2 , 180 cm 2 , 200 cm 2 , 300 cm 2 , or other suitable area. Air can escape via the air-egress features to eliminate air gaps that would impair heat-transfer with the subject's skin.
- the temperature-controlled conductive surface can be cooled to a temperature equal to or lower than a selected temperature (e.g., 5° C., 0° C., ⁇ 2° C., ⁇ 5 ° C., ⁇ 7° C., ⁇ 10° C., ⁇ 15° C., ⁇ 20° C., ⁇ 25° C., etc.).
- a selected temperature e.g., 5° C., 0° C., ⁇ 2° C., ⁇ 5 ° C., ⁇ 7° C., ⁇ 10° C., ⁇ 15° C., ⁇ 20° C., ⁇ 25° C., etc.
- most of the temperature-controlled conductive surface can be cooled to a temperature equal to or lower than about 0° C., ⁇ 2° C. ⁇ 5° C., ⁇ 10° C., or ⁇ 15° C.
- an apparatus for treating a human subject includes an applicator configured to cool the subject's skin.
- the applicator includes a cup, at least one vacuum port, and air-egress features.
- the cup defines a tissue-receiving cavity.
- the air-egress features can extend along the temperature-controlled surface to provide airflow paths to the vacuum port for removing air located between the subject's skin and the cup while the vacuum port provides a vacuum to draw the subject's tissue toward the temperature-controlled surface.
- the air-egress features include channels, ridges, protrusions, or the like.
- one or more liners, cryoprotectant, or other suitable elements can be positioned between the subject's skin and the cup.
- the liner can have an adhesive surface for adhering to the cup and can be perforated to allow airflow therethrough.
- the liner assembly can be made, in whole or in part, of plastic, rubber, or other suitable material and can include, without limitation, one or more sealing members, sensors, release liners, carriers, alignment features, or the like.
- the subject's skin can directly contact the cup.
- Some of the embodiments disclosed herein can be for cosmetically beneficial alterations of target regions.
- Some cosmetic procedures may be for the sole purpose of altering a target region to conform to a cosmetically desirable look, feel, size, shape and/or other desirable cosmetic characteristic or feature. Accordingly, at least some embodiments of the cosmetic procedures can be performed without providing an appreciable therapeutic effect (e.g., no therapeutic effect). For example, some cosmetic procedures may not include restoration of health, physical integrity, or the physical well-being of a subject.
- the cosmetic methods can target subcutaneous regions to change a human subject's appearance and can include, for example, procedures performed on a subject's submental region, abdomen, hips, legs, face, neck, ankle region, or the like. In other embodiments, however, cosmetically desirable treatments may have therapeutic outcomes (whether intended or not), such as psychological benefits, alteration of body hormone levels (by the reduction of adipose tissue), etc.
- FIG. 1 and the following discussion provide a brief, general description of a treatment system 100 in accordance with some embodiments of the technology.
- the treatment system 100 can be a temperature-controlled system for exchanging heat with a subject 101 and can include a non-invasive tissue-cooling apparatus in the form of a cooling cup applicator 102 (“applicator 102 ”) configured to selectively cool tissue to affect targeted tissue, structures, or the like.
- the illustrated applicator 102 is positioned along a subject's hip and can draw a vacuum to provide suitable thermal contact with the subject's skin to cool subcutaneous adipose tissue.
- the applicator 102 is configured to facilitate a high amount of thermal contact with the subject's skin by minimizing, limiting, or substantially eliminating air gaps at the applicator/tissue interface.
- the entire skin surface of the retained volume of tissue can be cooled for efficient treatment.
- the applicator 102 can have a relatively shallow tissue-receiving chamber to avoid or limit pooling of blood, rupturing of blood vessels, patient discomfort, and so forth.
- the applicator 102 can be used to perform medical treatments to provide therapeutic effects and/or cosmetic procedures for cosmetically beneficial effects.
- selective effects of cooling are believed to result in, for example, membrane disruption, cell shrinkage, disabling, disrupting, damaging, destroying, removing, killing and/or other methods of lipid-rich cell alteration.
- Such alteration is believed to stem from one or more mechanisms acting alone or in combination. It is thought that such mechanism(s) trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling.
- the effect of tissue cooling can be the selective reduction of lipid-rich cells by a desired mechanism of action, such as apoptosis, lipolysis, or the like.
- the applicator 102 can cool the skin surface and/or targeted tissue to cooling temperature in a range of from about ⁇ 25 ° C. to about 20° C.
- the cooling temperatures can be from about ⁇ 20° C. to about 10° C., from about ⁇ 18° C. to about 5° C., from about ⁇ 15° C. to about 5° C., or from about ⁇ 15° C. to about 0° C.
- the cooling temperatures can be equal to or less than ⁇ 5° C., ⁇ 10° C., ⁇ 15° C., or in yet another embodiment, from about ⁇ 15° C. to about ⁇ 25° C.
- Other cooling temperatures and temperature ranges can be used.
- Apoptosis also referred to as “programmed cell death” is a genetically-induced death mechanism by which cells self-destruct without incurring damage to surrounding tissues.
- An ordered series of biochemical events induce cells to morphologically change. These changes include cellular blebbing, loss of cell membrane asymmetry and attachment, cell shrinkage, chromatin condensation and chromosomal DNA fragmentation.
- Injury via an external stimulus, such as cold exposure is one mechanism that can induce cellular apoptosis in cells. Nagle, W. A., Soloff, B. L., Moss, A. J. Jr., Henle, K. J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990).
- apoptosis in contrast to cellular necrosis (a traumatic form of cell death causing local inflammation), is that apoptotic cells express and display phagocytic markers on the surface of the cell membrane, thus marking the cells for phagocytosis by macrophages.
- phagocytes can engulf and remove the dying cells (e.g., the lipid-rich cells) without eliciting an immune response.
- Temperatures that elicit these apoptotic events in lipid-rich cells may contribute to long-lasting and/or permanent reduction and reshaping of subcutaneous adipose tissue.
- apoptotic lipid-rich cell death by cooling is believed to involve localized crystallization of lipids within the adipocytes at temperatures that do not induce crystallization in non-lipid-rich cells.
- the crystallized lipids selectively may injure these cells, inducing apoptosis (and may also induce necrotic death if the crystallized lipids damage or rupture the bi-lipid membrane of the adipocyte).
- Another mechanism of injury involves the lipid phase transition of those lipids within the cell's bi-lipid membrane, which results in membrane disruption or dysfunction, thereby inducing apoptosis. This mechanism is well-documented for many cell types and may be active when adipocytes, or lipid-rich cells, are cooled.
- the targeted adipose tissue may experience a restriction in blood supply and thus be starved of oxygen due to isolation as a result of applied pressure, cooling which may affect vasoconstriction in the cooled tissue, or the like.
- cooling which may affect vasoconstriction in the cooled tissue, or the like.
- restoration of blood flow after cooling treatment may additionally produce reperfusion injury to the adipocytes due to inflammation and oxidative damage that is known to occur when oxygenated blood is restored to tissue that has undergone a period of ischemia.
- This type of injury may be accelerated by exposing the adipocytes to an energy source (via, e.g., thermal, electrical, chemical, mechanical, acoustic, or other means) or otherwise increasing the blood flow rate in connection with or after cooling treatment as described herein.
- an energy source via, e.g., thermal, electrical, chemical, mechanical, acoustic, or other means
- Increasing vasoconstriction in such adipose tissue by, e.g., various mechanical means (e.g., application of pressure or massage), chemical means or certain cooling conditions, as well as the local introduction of oxygen radical-forming compounds to stimulate inflammation and/or leukocyte activity in adipose tissue may also contribute to accelerating injury to such cells.
- Other yet-to-be understood mechanisms of injury may exist.
- lipid-rich cells in the target region can be reduced generally without collateral damage to non-lipid-rich cells in the same region.
- lipid-rich cells can be affected at low temperatures that do not affect non-lipid-rich cells.
- lipid-rich cells such as those associated with highly localized adiposity (e.g., adiposity along the abdomen, submental adiposity, submandibular adiposity, facial adiposity, etc.), can be affected while non-lipid-rich cells (e.g., myocytes) in the same generally region are not damaged.
- the unaffected non-lipid-rich cells can be located underneath lipid-rich cells (e.g., cells deeper than a subcutaneous layer of fat), in the dermis, in the epidermis, and/or at other locations.
- the treatment system 100 can remove heat from underlying tissue through the upper layers of tissue and create a thermal gradient with the coldest temperatures near the cooling surface, or surfaces, of the applicator 102 (i.e., the temperature of the upper layer(s) of the skin can be lower than that of the targeted underlying target cells). It may be challenging to reduce the temperature of the targeted cells low enough to be destructive to these target cells (e.g., induce apoptosis, cell death, etc.) while also maintaining the temperature of the upper and surface skin cells high enough so as to be protective (e.g., non-destructive). The temperature difference between these two thresholds can be small (e.g., approximately, 5° C.
- Protection of the overlying cells may include improving the freeze tolerance and/or freeze avoidance of these skin cells by using, for example, cryoprotectants for inhibiting or preventing such freeze damage.
- Tissue can be rapidly rewarmed as soon as practicable after a freeze event has occurred to limit, reduce, or prevent damage and adverse side effects associated with the freeze event.
- tissue can be rapidly warmed as soon as possible to minimize or limit damage to tissue, such as the epidermis.
- tissue is partially or completely frozen for a predetermined period of time and then warmed.
- an applicator can warm shallow tissue using, for example, thermoelectric elements in the device.
- Thermoelectric elements can include Peltier devices capable of operating to establish a desired temperature (or temperature profile) along the surface.
- the applicator outputs energy to warm tissue.
- the applicator can have electrodes that output radiofrequency energy for warming tissue.
- the tissue can be warmed at a rate of about 1° C/s, 2° C/s, 2.5° C/s, 3° C/s, 5° C/s, or other rate selected to thaw frozen tissue after the tissue has been partially or completely frozen for about 10 seconds, 30 seconds, 1 minute, 2 minutes, 5 minutes, 10 minutes, or other suitable length of time.
- FIG. 2 is a cross-sectional view of the applicator 102 taken along line 2 - 2 of FIG. 1 .
- the applicator 102 includes a contoured sealing element 151 and a base unit 152 .
- the sealing element 151 can conform closely to contours of the subject's body to sealingly engage a liner or skin surface 160 .
- the base unit 152 can include a shallow cup 168 defining a tissue-receiving cavity 170 for holding tissue.
- the cup 168 can include a temperature-controlled surface 174 , a vacuum port 176 , and airflow features in the form of air-egress features 180 extending along the bottom of the tissue-receiving cavity 170 .
- Dashed line 190 shows the position of the subject's tissue (or liner) before being drawn (indicated by arrows) into the applicator 102 . If a liner is used with the applicator 102 , the liner can line the cup 168 and can be perforated such that a vacuum can be drawn through the liner to urge the subject's skin against the liner, thereby maintaining thermal contact between the tissue and the cup 168 .
- the air-egress features 180 can help distribute the vacuum across the cup/tissue interface to enhance patient comfort and prevent air gaps at the tissue/cup interface during tissue draw. After the subject's tissue fills the tissue-receiving cavity 170 , the air-egress features 180 can distribute the vacuum across a large area of the tissue-cup interface. During subcutaneous treatments, the subject's skin can extend across the air-egress features 180 , illustrated as channels spreading outwardly from a central region 150 of the cup 168 . Constant or varying vacuum levels can be used to keep the tissue in thermal contact with the cup 168 .
- the vacuum port 176 is positioned at the central region 150 to draw the tissue into the deepest region of the tissue-receiving cavity 170 , and the air-egress features 180 extend toward a peripheral portion 181 of the temperature-controlled surface 174 .
- the air-egress features 180 can be a network of elongate protrusions, ridges, and/or channels positioned at locations at which air tends to become trapped. If ambient air is inadvertently sucked between the cup 168 and the subject's skin, it can serve as a thermal insulator and reduce heat transfer between the applicator 102 and the subject's tissue. Such air can be removed via the air-egress features 180 to maintain suitable thermal contact throughout the entire treatment session, including relatively long sessions (e.g., sessions equal to or longer than 20 minutes, 30 minutes, 45 minutes, 1 hour, or 2 hours).
- Each air-egress feature 180 can include a first end 192 spaced apart from a mouth 194 of the cup 168 , a second end 195 positioned proximate a vacuum port 197 , and a main portion 198 extending between the first and second ends 192 , 195 .
- Most or substantially all of the skin surface of the volume of tissue in the cavity 170 can be in thermal contact with the cup 168 .
- the vacuum level can be sufficiently high to keep the tissue in contact with the bottom of the cup 168 to keep the cavity 170 filled with tissue but can be sufficiently low to limit or minimize pooling of blood, vascular damage (e.g., rupturing of blood vessels), bruising, and other complications often associated with vacuum-based procedures.
- the applicator 102 can release the tissue (e.g., by reducing or stopping the vacuum) and can be used at another treatment site.
- the base unit 152 can include cooling units 200 coupled to, embedded in, or otherwise in thermal communication with the temperature-controlled surface 174 .
- the cooling units 200 can include, without limitation, one or more thermoelectric elements 202 (e.g., Peltier-type elements), fluid-cooled elements 204 , heat-exchanging units, or combinations thereof.
- thermoelectric elements 202 e.g., Peltier-type elements
- fluid-cooled elements 204 can cool the backside of the thermoelectric elements 202 to keep the thermoelectric elements 202 at or below a target temperature.
- fluid-cooled elements 200 can heat the backside of the thermoelectric elements 202 to keep the thermoelectric elements 202 at or above a target temperature.
- the cooling units 200 include only fluid-cooled elements or only non-fluid-cooled elements.
- the cooling units 200 can be embedded or otherwise disposed in the cup 168 to reduce the distance from the tissue to the thermoelectric elements 202 . Although the illustrated embodiment has two cooling units 200 , it can have any desired number of cooling units 200 . The number, positions, configurations, and operating temperatures of the cooling units can be selected based on cooling/heating suitable for treatment, desired power consumption, or the like.
- FIG. 3 is a cross-sectional view of the connector 104 taken along line 3 - 3 of FIG. 1 and shows the connector 104 including a main body 179 , a supply fluid line or lumen 180 a (“supply fluid line 180 a ”), and a return fluid line or lumen 180 b (“return fluid line 180 b ”).
- supply fluid line 180 a supply fluid line 180 a
- return fluid line 180 b return fluid line 180 b
- the main body 179 may be configured (via one or more adjustable joints) to “set” in place for the treatment of the subject 101 .
- the supply and return fluid lines 180 a , 180 b can be conduits comprising, in whole or in part, polyethylene, polyvinyl chloride, polyurethane, and/or other materials that can accommodate circulating coolant, such as water, glycol, synthetic heat transfer fluid, oil, a refrigerant, and/or any other suitable heat conducting fluid for passing through fluid-cooled element, such as the fluid-cooled elements (e.g., fluid-cooled elements 204 of FIG. 2 ), or other components.
- each fluid line 180 a , 180 b can be a flexible hose surrounded by the main body 179 .
- the connector 104 can also include one or more electrical lines 112 for providing power to the applicator 102 and one or more control lines 116 for providing communication between the control module 106 ( FIG. 1 ) and the applicator 102 ( FIGS. 1 and 2 ).
- the electrical lines 112 can provide power to the thermoelectric elements, sensors, and so forth.
- the connector 104 can include one or more vacuum lines 125 .
- the connector 104 can include a bundle of fluid conduits, a bundle of power lines, wired connections, vacuum lines, and other bundled and/or unbundled components selected to provide ergonomic comfort, minimize unwanted motion (and thus potential inefficient removal of heat from the subject), and/or to provide an aesthetic appearance to the treatment system.
- the control module 106 can include a fluid system 105 (illustrated in phantom line), a power supply 110 (illustrated in phantom line), and a controller 114 carried by a housing 124 with wheels 126 .
- the fluid system 105 can include a fluid chamber and a refrigeration unit, a cooling tower, a thermoelectric chiller, heaters, or any other device capable of controlling the temperature of coolant in the fluid chamber.
- the coolant can be continuously or intermittently delivered to the applicator 102 via the supply fluid line 180 a ( FIG. 3 ) and can circulate through the applicator 102 to absorb heat.
- the coolant which has absorbed heat, can flow from the applicator 102 back to the control module 106 via the return fluid line 180 b ( FIG. 3 ).
- the control module 106 can heat the coolant that is circulated through the applicator 102 .
- a municipal water supply e.g., tap water
- a pressurization device 123 can provide suction to the applicator 102 via the vacuum line 125 ( FIG. 3 ) and can include one or more vacuum sources (e.g., pumps). Air pockets between the subject's tissue can impair heat transfer with the tissue and, if large enough, can affect treatment.
- the pressurization device 123 can provide a sufficient vacuum to eliminate such air gaps (e.g., large air gaps between the tissue and the temperature-controlled surface 174 of FIG. 2 ) such that substantially no air gaps impair non-invasively cooling of the subject's subcutaneous lipid-rich cells to a treatment temperature.
- the tissue can be suitably cooled even though the air-egress features may contain small volumes of air and may not contact the subject's skin.
- Air pressure can be controlled by a regulator located between the pressurization device 123 and the applicator 102 .
- the control module 106 can control the vacuum level to, for example, install the liner assembly and/or draw tissue into the applicator 102 while maintaining a desired level of comfort. If the vacuum level is too low, a liner assembly, tissue, etc. may not be drawn adequately (or at all) into and/or held within the applicator 102 . If the vacuum level is too high when preparing the applicator, a liner assembly can break (e.g., rupture, tear, etc.). If the vacuum level is too high during treatment, the patient can experience discomfort, bruising, or other complications.
- approximately 0.5 inch Hg, 1 inch Hg, 2 inches Hg, 3 inches Hg, 5 inches Hg, 7 inches Hg, 8 inches Hg, 10 inches Hg, or 12 inches Hg vacuum is applied to draw or hold the liner assembly, tissue, etc.
- the air-egress features 180 can be configured to maintain the airflow paths when 12 inches Hg vacuum level is used to draw tissue into the tissue-receiving cavity 170 .
- the number, dimensions, and positions of the air-egress features 180 can be selected to achieve desired tissue contact.
- Other vacuum levels can be selected based on the characteristics of the tissue, desired level of comfort, and vacuum leakage rates.
- Vacuum leak rates of the applicator 102 can be equal to or less than about 0.2 LPM, 0.5 LPM, 1 LPM, or 2 LPM at the pressure levels disclosed herein.
- the vacuum leak rate can be equal to or less than about 0.2 LPM at 8 inches Hg, 0.5 LPM at 8 inches Hg, 1 LPM at 8 inches Hg, or 2 LPM at 8 inches Hg.
- the configuration of the pressurization device 123 and applicator 102 can be selected based on the desired vacuum levels, leakage rates, and other operating parameters.
- the power supply 110 can provide a direct current voltage for powering electrical elements of the applicator 102 via the line 112 ( FIG. 3 ).
- the electrical elements can be thermal devices, sensors, actuators, controllers (e.g., a controller integrated into the applicator 102 ), or the like.
- An operator can use an input/output device in the form of a screen 118 (“input/output device 118 ”) of the controller 114 to control operation of the treatment system 100 , and the input/output device 118 can display the state of operation of the treatment system 100 and/or progress of a treatment protocol.
- the controller 114 can exchange data with the applicator 102 via the line (e.g., link 116 of FIG.
- the controller 114 can contain instructions to perform the treatment profiles and/or patient-specific treatment plans, which can include one or more segments, and each segment can include temperature profiles, vacuum levels, and/or specified durations (e.g., 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, etc.).
- the controller 114 can be programmed to cause the pressurization device to operate to pull tissue into the applicator.
- the pressurization device can operate to hold the subject's skin in thermal contact appropriate features while the cup conductively cools tissue. If the sensor detects tissue moving out of thermal contact with the cup, the vacuum can be increased to reestablish suitable thermal contact.
- the controller 114 is programmed to cause the pressurization device to provide a sufficient vacuum to keep substantially all of each region of the temperature-controlled surface between air-egress features in thermal contact with the subject's skin. This provides a relatively large contact interface for efficient heat transfer with the target tissue.
- Different vacuum levels can be utilized during treatment sessions. For example, relatively strong vacuums can be used to pull the subject's tissue into the applicator. A weaker vacuum can be maintained to hold the subject's tissue against the thermally conductive surface. If suitable thermal contact is not maintained (e.g., the subject's skin moves away from the thermally conductive surface), the vacuum level can be increased to reestablish suitable thermal contact. In other procedures, a generally constant vacuum level can be used throughout the treatment session.
- a treatment profile can include specific profiles for each applicator to concurrently or sequentially treat multiple treatment sites, including, but not limited to, sites along the subject's torso, abdomen, legs, buttock, legs, face and/or neck (e.g., submental sites, submandibular sites, etc.), knees, back, arms, ankle region, or other treatment sites.
- the vacuum levels can be selected based on the configuration of the cup. Strong vacuum levels can be used with relatively deep cups whereas weak vacuum levels can be used with relatively shallow cups.
- the vacuum level and cup configuration can be selected based on the treatment site and desired volume of tissue to be treated.
- the controller 114 can be incorporated into the applicator 102 or another component of the treatment system 100 .
- FIG. 4 is an isometric view of an applicator 102
- FIG. 5 is a bottom plan view of the applicator 102
- the cup 168 has a topography for removing air from the cavity 170 because it has air-egress features 180 extending outwardly from the central region 150 such that a significant portion of the temperature-controlled surface 174 is located directly between the air-egress features 180 .
- the subject's skin or liner can be pulled against the areas (e.g., one area 230 is indicated in dashed line) of the temperature-controlled surface 174 located between adjacent air-egress features 180 .
- At least 50%, 60%, 70%, 80%, 90%, or 95% of total area of the exposed temperature-controlled surface 174 facing the tissue-receiving cavity 170 can be located between the air-egress features 180 .
- a ratio of a sum of areas of the temperature-controlled surface 174 located directly between the air-egress features 180 to a total area of the temperature-controlled surface 174 is equal to or greater than 0.5, 0.6, 0.7, 0.8, or 0.9. The ratio can be selected based on the tendency of air pockets to be present when the applicator 102 initially seals with the subject's skin.
- a highly contoured temperature-controlled surface 174 can be prone to producing a large number of air pockets, so the ratio can be increased whereas the ratio can be reduced for a relatively shallow flat cup 168 with a gradually contoured temperature-controlled surface 174 .
- the air-egress features 180 can be spaced apart from one another or interconnected to define an airflow pattern suitable for evacuating air. Referring now to FIG. 5 , air-egress features 180 can extend across most of a width W and/or length L of the tissue-receiving cavity 170 . A distance D between outermost ends of opposing air-egress features 180 can be equal to or greater than about half the width W. The distance D can be measured in a direction generally perpendicular to the longitudinal length of the cavity 170 . A ratio of the distance D to the width W can be equal to or greater than about 0.5, 0.6, 0.7, 0.8, or 0.9.
- the temperature-controlled surface 174 can be gradually sloped to help avoid air pockets at its periphery, so the air-egress features 180 can be located at the central region 150 and may not extend across most of the width W and/or length L. Accordingly, the air-egress features 180 or portions thereof can be localized at locations susceptible to air pocket formation.
- FIG. 6 is a cross-sectional view of the applicator 102 taken along line 6 - 6 of FIG. 5 in accordance with an embodiment of the technology.
- FIG. 7 is a cross-sectional view of the applicator 102 taken along line 7 - 7 of FIG. 5 .
- lines 240 , 242 can be in fluid communication with the cavity 170 via a manifold device 250 .
- the manifold device 250 can include vacuum ports, channels, valves, regulators, sensors, or the like.
- An internal controller or circuitry assembly of the manifold device 250 can be in electrical communication with sensors, valves, or other components.
- air-egress features 180 can be in fluid communication with corresponding vacuum ports 197 .
- air can flow along the air-egress features 180 (indicated by arrows) and through the vacuum ports 197 , manifold device 250 , and lines 240 , 242 ( FIG. 6 ).
- the lines 240 , 242 can be in fluid communication with conduits (e.g., conduits 180 a , 180 b of FIG. 3 ) or other components of the connector 104 .
- air-egress features 180 can be connected to a single vacuum port, such as a slot, an opening, or other aperture.
- the number, positions, and configuration of the vacuum ports can be selected based on the desired flow rates, vacuum distribution, and/or characteristics of applied substances at the tissue/applicator interface.
- FIG. 8 is a cross-sectional view of the applicator 102 taken along line 8 - 8 of FIG. 5 in accordance with an embodiment of the technology.
- Dimensions of the air-egress features 180 can be selected to limit the area of the subject's tissue (or liner) not in direct contact with the surface 174 .
- the air-egress feature 180 has a height H of about 1 mm to about 2 mm, a width W of about 1 mm to about 2 mm, and a length L (FIG. 5) of at least 10 mm and can be generally U-shaped, V-shaped, or other suitable shape.
- the air-egress feature 180 is a U-shaped channel having a generally uniform cross-sectional profile along its longitudinal length.
- the height H and/or width W can decrease in the direction away from the vacuum port 197 .
- the dimensions, configuration, and characteristics of the air-egress feature 180 can be selected based on the desired airflow rates, position of the air-egress feature, or the like.
- FIG. 9 is a isometric view of the central region 150 of the cup 168 taken along line 9 - 9 of FIG. 5 in accordance with an embodiment of the technology.
- a flow distributor 300 is positioned within an elongate central opening 310 of the cup 168 .
- the flow distributor 300 can include an array of vacuum ports 197 , sealing elements 320 , valves, and other suitable elements for providing a desired vacuum.
- the flow distributor 300 can include an air inlet 340 for drawing tissue against an upper region or plate 330 and can serve as a gel trap to prevent a cryoprotectant gel from flowing through the applicator 102 .
- the cup 168 can be made of one or more thermally conductive materials, including, without limitation, metal (e.g., aluminum, stainless steel, pure copper, copper alloys, etc.) or other rigid or flexible high heat transfer materials, such as thermally conductive plastics.
- the thermally conductive material of the cup 168 at room temperature has a thermal conductivity equal to or greater than about 25 W/(mK), 50 W/(mK), 100 W/(mK), 200 W/(mK), 300 W/(mK), 350 W/(mK), and ranges encompassing such thermal conductivities.
- the cup 168 can have a multi-piece construction with various pieces made of materials selected to provide different amounts of heat flow at different locations.
- the cup 168 has a unitary construction and is made of a single material, such as metal. Additional vacuum ports can be positioned at suitable locations along the cup 168 based on, for example, considerations of patient comfort, desired vacuum levels, and/or other treatment parameters.
- FIG. 10 is a bottom view of an applicator 308 in accordance with an embodiment of the technology.
- the applicator 308 can include an airflow features 310 in the form of air-egress features 314 (two identified) and branching air-egress features 320 (two identified).
- the air-egress features 320 , 314 can have geometrically congruent cross sections. In other embodiments, air-egress features 320 , 314 can have geometries selected based on their location within the cavity. As shown in FIGS. 10 and 11 , air-egress features 320 can be V-shaped channels extending along a cup 332 . FIG.
- FIG. 11 shows the position 321 (illustrated in dashed line) of the skin surface extending across and covering the open end of the air-egress feature 320 such that air can flow along an air path (e.g., air path 323 is illustrated in dashed line in FIG. 10 ).
- Each air-egress feature 320 can maintain such an air path while the subject's tissue is held firmly against a surface 333 of the cup 332 .
- FIGS. 12 and 13 show cross-sectional profiles for the air-egress feature 320 in other embodiments.
- the air-egress feature 320 can have a semicircular cross-section and can be formed via machining or molding processes.
- air-egress feature 320 can have a polygonal or generally rectangular cross section formed via machining or molding processes.
- FIG. 14 is an isometric view of an applicator 340 in accordance with another embodiment.
- FIG. 15 is a bottom view of the applicator 340 .
- applicator 340 can include a cup 342 and airflow features in the form of air-egress features 350 a , 350 b , 350 c (collectively “air-egress features 350 ”) that extend outwardly from a central region 360 .
- Air-egress features 350 a extend away from a central region 392 toward periphery portions 382 at longitudinal sides 384 of the cup 342 .
- Air-egress features 350 b extend toward corresponding rounded corners 396 of the cup 342 and branch to form terminal portions 355 a , 355 b .
- Air-egress features 350 c can extend in a direction generally parallel to a longitudinal length of the cup 342 .
- FIG. 16 is a cross-sectional view of the applicator 340 taken along line 16 - 16 of FIG. 15 .
- Air-egress features 350 can be elongate protrusions coupled to or integrally formed with the cup 342 .
- the cup 342 can include or be coupled to one or more thermal elements for controlling the temperature of a temperature-controlled surface 377 .
- FIG. 17 is a cross-sectional view of one of the air-egress features 350 .
- the air-egress feature 350 has a rounded cross-sectional profile and can have a height H selected to maintain a gap between the surface 377 and the subject's skin 390 (illustrated in phantom line).
- a vacuum is applied to draw the subject's skin 390 toward the surface 377
- air flow paths 396 can be maintained along the longitudinal length of the air-egress feature 350 .
- air flow paths 396 are located on opposite sides of the air-egress feature 350 .
- the height H can be about 1 mm to about 2 mm
- a width W can be about 1 mm to about 2 mm. Other dimensions can be selected.
- FIG. 18 is a cross-sectional view an air-egress feature 400 having a rounded triangular cross-sectional profile.
- the height H of the feature 400 can be selected to maintain a gap between a cup surface 402 and the subject's skin 404 (illustrated in phantom line). In some embodiments, the height H can be about 1 mm to about 3 mm, and a width W can be about 0.5 mm to about 2 mm.
- a vacuum is applied to draw the subject's skin 404 toward the surface 402 , air flow paths can be maintained along the longitudinal length of the air-egress feature 400 .
- FIG. 16 shows the applicator with protrusion air-egress features, applicators can include both channel airflow features and protrusion airflow features.
- FIG. 19 is a flowchart of a method 500 for treating a subject in accordance with embodiments of the disclosed technology.
- an applicator can be applied to the treatment site and a vacuum can be drawn to pull tissue into a tissue-receiving cavity of the applicator.
- the subject's skin can be drawn toward a conductive surface of a temperature-controlled cup while air-egress features maintain airflow paths for removing air from the cavity.
- heat is extracted from the subject's tissue to cool the tissue an amount sufficient to be biologically effective in selectively damaging and/or reducing the subject's subcutaneous lipid-rich cells. Details of the method 500 are discussed in connection the embodiments shown in FIGS. 1-13 .
- an applicator can be applied to the subject's skin.
- the applicator can be prepared for treatment by installing an appropriate contoured lip, liner, etc. for the treatment site.
- the sealing element 151 can be placed against the subject to form a seal suitable for maintaining a desired vacuum within the tissue-receiving cavity 170 .
- the sealing element 151 can include a contoured lip 530 and a body 532 .
- the lip 530 can define an entrance and can be configured to sealingly engage, for example, the subject's skin.
- the lip 530 can be configured for forming airtight seals with the subject's skin and can be made, in whole or in part, of silicon, rubber, soft plastic, or other suitable highly compliant materials.
- the mechanical properties, thermal properties, shape, and/or dimensions of the contoured lip 530 can be selected based on, for example, whether it contacts the subject's skin, liner assembly, a cryoprotectant gel pad, or the like.
- the body 532 is coupled to a housing 544 . As tissue is pulled through the entrance of the sealing element 151 and toward the cup 168 , the flared lip 530 can deflect outwardly.
- Different sealing elements or cups can be installed on the base unit 152 for treatment flexibility.
- the geometries of the contoured sealing element 151 and cup 168 which can be replaced, can be selected to conform to a contour of a cutaneous layer.
- the sides, waistline, and other features of the contoured heads can be selected to facilitate conformation of heads to the contours of individual target areas.
- the shape of a typical human torso may vary between having a relative large radius of curvature, e.g., on the stomach or back, and having a relatively small radius of curvature, e.g., on the abdominal sides.
- the size of a cup having an approximately consistent curvature may vary.
- the sealing elements may be fitted to individual lipid-rich cell deposits to achieve an approximately air-tight seal, achieve the vacuum pressure for drawing tissue into an interior cavity for treatment, maintain suction to hold the tissue, massage tissue (e.g., by altering pressure levels), and use little or no force to maintain contact between an applicator and a patient.
- Components can be attached and detached in a plurality of combinations to achieve a desired contour for a treatment. Accordingly, a single base unit and/or umbilical cable may be combined with a set of interchangeable heads and/or cups to form a wide variety of contours for treating different lipid-rich cell deposits in a cost effective manner. Further, a practitioner performing the treatment can demonstrate their expertise to the patient by tailoring the applicator contour to the specific body parts being treated. In this manner, the patient understands that their treatment is customized to their body for better comfort and for better treatment results.
- Tissue-receiving cavities disclosed herein can have substantially U-shaped cross sections, V-shaped cross sections, or partially circular/elliptical cross-sections, as well as or other cross sections suitable for receiving tissue.
- thermal properties, shape, and/or configuration of the cup 168 can be selected based on, for example, target treatment temperatures and/or volume of the targeted tissue.
- Embodiments of the base units for treating large volumes of tissue e.g., adipose tissue along the abdomen, hips, buttock, etc.
- Embodiments of the base units for treating small volumes can have a maximum depth equal to or less than about 0.5 cm, 2 cm, 2.5 cm, 3 cm, or 5 cm, for example.
- the maximum depth of the tissue-receiving cavity 170 can be selected based on, for example, the volume of targeted tissue, characteristics of the targeted tissue, and/or desired level of patient comfort.
- a vacuum can be drawn while the sealing element 151 can be held against the subject.
- the pressurization device 123 FIG. 1
- the pressurization device 123 can operate to remove air from the tissue-receiving cavity 170 ( FIG. 3 ) to urge tissue into the applicator 102 .
- the pressure level can be selected to partially or completely fill the tissue-receiving cavity 170 with tissue. If the vacuum level is too low, tissue will not be drawn adequately into the cavity 170 .
- the vacuum level can be increased to reduce or eliminate gaps between the skin surface and the temperature-controlled surface 174 . If the vacuum level is too high, undesirable discomfort to the patient and/or tissue damage could occur.
- the vacuum level can be selected to comfortably pull the tissue into contact with the desired area of the applicator, and the skin and underlying tissue can be pulled away from the subject's body which can assist in cooling underlying tissue by, e.g., lengthening the distance between targeted subcutaneous fat and the muscle tissue.
- tissue can be drawn into the tissue-receiving cavity 170 such that substantially all of the skin surface within the cavity 170 overlies the temperature-controlled surface 174 .
- tissue can be drawn into the tissue-receiving cavity 170 such that substantially all of the skin surface within the cavity 170 overlies the temperature-controlled surface 174 .
- 90%, 95%, 95%, or more of the surface area of the skin located in the cavity 170 can overlie the temperature-controlled surface 174 .
- the number and dimensions of the air-egress features 180 can be increased or decreased to achieve desired thermal contact for a particular vacuum level. After a sufficient amount of tissue fills most or all of the cavity 170 , the pressure level can be controlled to comfortably hold the tissue.
- the applicator 102 can extract heat from the tissue.
- the cup 168 can be designed for rapid cooling and/or heating to, for example, reduce treatment times and/or produce generally flat temperature profiles over the heat-exchanging surface 174 or a portion thereof. Because the subject's body heat can be rapidly conducted to the cup 168 , the cooled skin can be kept at a generally flat temperature profile (e.g., ⁇ 3° C. of a target temperature) even though regions of the skin, or underlying tissue, may experience different amounts of blood flow.
- a generally flat temperature profile e.g., ⁇ 3° C. of a target temperature
- subcutaneous lipid-rich cells can be injured selectively while maintaining the non-lipid-rich cells (e.g., non-lipid-rich cells in the dermis and epidermis). Accordingly, subcutaneous lipid-rich cells in a subcutaneous layer can be cooled an amount sufficient to be biologically effective in affecting (e.g., damaging and/or reducing) such lipid-rich cells without affecting non-target cells to the same or greater extent. During cooling/heating, the tissue can fill substantially the entire cavity 170 .
- the air-egress features 180 can maintain airflow paths extending to the peripheral portion of the cup 168 such that the tissue occupies at least 80%, 90%, 92.5%, or 95% of the volume of the cavity 170 . Accordingly, the subject's tissue can substantially fill an entire volume of the cavity 170 . In one application, the subject's tissue fills 90% or more of the volume of the cavity 170 .
- the temperature-controlled surface 174 can thermally contact an area of the subject's skin equal to or less than about 20 cm 2 , 40 cm 2 , 80 cm 2 , 100 cm 2 , 140 cm 2 , 160 cm 2 , 180 cm 2 , 200 cm 2 , 300 cm 2 , 500 cm 2 , or other suitable area.
- the temperature-controlled surface area can be, for example, equal to or less than 20 cm 2 , 40 cm 2 , 80 cm 2 , 100 cm 2 , 140 cm 2 , 160 cm 2 , 180 cm 2 , 200 cm 2 , 300 cm 2 , or another suitable area.
- the temperature-controlled conductive surface 174 can be cooled to a temperature equal to or less than a selected temperature (e.g., 5° C., 0° C., ⁇ 2° C., ⁇ 5° C., ⁇ 7° C., ⁇ 10° C., ⁇ 15° C., ⁇ 20° C., ⁇ 25° C., etc.) to cool most of the skin surface of the retained tissue.
- a selected temperature e.g., 5° C., 0° C., ⁇ 2° C., ⁇ 5° C., ⁇ 7° C., ⁇ 10° C., ⁇ 15° C., ⁇ 20° C., ⁇ 25° C., etc.
- most of a heat-exchanging surface 161 can be cooled to a temperature equal to or less than about 0° C., ⁇ 2° C., ⁇ 5° C., ⁇ 10° C., or ⁇ 15° C.
- the smooth temperature-controlled surface 174 can conductively cool tissue to produce a desired temperature in target tissue without bruising, pain, or other problems caused by injections and perfusion of injected fluid.
- perfusion of injected fluid can affect the thermal characteristics of the treatment site and result in undesired temperature profiles.
- the non-invasive conductive cooling provided by the applicator 102 can be more accurate than invasive procedures that rely on injecting fluids.
- Targeted tissue can be cooled from about ⁇ 20° C. to about 10° C., from about 0° C. to about 20° C., from about ⁇ 15° C. to about 5° C., from about ⁇ 5° C.
- liner can be kept at a temperature less than about 0° C. to extract heat from subcutaneous lipid-rich cells such that those cells are selectively reduced or damaged.
- applicators can also be positioned to treat tissue at the thighs, buttock, abdomen, submandibular region, neck region, or other target regions. Applicators can reduce localized adipose tissue along the abdomen, hips, submental region, or the like. In procedures for reducing a double chin, the applicator can be sized and then aligned with and placed generally at the submental region (i.e., the submental triangle). It will be appreciated that the applicators disclosed herein can be placed at other locations along the patient's body and the orientation of the applicator can be selected to facilitate a relatively close fit.
- the control module 106 can automatically select a pressurization level suitable for drawing the liner into the base unit. Once the liner has been applied to the conductive cup, the control module 106 can notify a user to, for example, inspect the liner, apply the applicator, or perform another task. The control module 106 ( FIG. 1 ) can then command the pressurization device 123 to draw tissue into the applicator 102 . The control module 106 can notify the operator that the applicator 102 is ready for treatment based on sensor reading. The operator can inspect the applicator 102 and can begin treatment using the control module 106 .
- region of the body may be close but not equal to the target temperature, e.g., because of the body's natural heating and cooling variations.
- the applicator 102 may attempt to heat or cool the target tissue to the target temperature or to provide a target heat flux
- sensors 512 FIGS. 4
- operation of the cooling unit can be adjusted to change the heat flux to maintain the target temperature or “set-point” selectively to affect targeted tissue.
- the prescribed segment duration expires, the next treatment profile segment can be performed.
- Sensors 512 can be temperature sensors, such as thermistors, positioned to detect temperature changes associated with warm tissue being drawn into and/or located in the cup 168 .
- a control module e.g., control module 106 of FIG. 1
- sensors 512 can be adjacent to the air-egress features 180 and can measure heat flux and/or pressure (e.g., contact pressure) with the skin of the patient.
- the sensors 512 can be tissue impedance sensors, contact sensors, or other sensors used to determine the presence of tissue and/or whether tissue has been adequately drawn into the applicator so as to completely fill the cavity 170 to achieve a suitable level of thermal contact, limit or reduce voids or gaps, and/or hold tissue while limiting or reducing, for example, pooling of blood, discomfort, and so forth.
- Sensor feedback can be collected in real-time and used in concert with treatment administration to efficaciously target specific tissue.
- the sensor measurements can also indicate other changes or anomalies that can occur during treatment administration.
- an increase in temperature detected by the sensors 512 can indicate either a freezing event at the skin or movement of the applicator 102 .
- An operator can inspect the subject's skin and/or applicator 102 in response to a detected increase in temperature. Methods and systems for collection of feedback data and monitoring of temperature measurements are described in commonly assigned U.S. Pat. No. 8,285,390.
- the treatment procedures disclosed herein can also involve use of cryoprotectant between the applicator and skin.
- the cryoprotectant can be a freezing point temperature depressant that may additionally include a thickening agent, a pH buffer, a humectant, a surfactant, and/or other additives.
- the temperature depressant may include, for example, polypropylene glycol (PPG), polyethylene glycol (PEG), dimethyl sulfoxide (DMSO), or other suitable alcohol compounds.
- a cryoprotectant may include about 30% polypropylene glycol, about 30% glycerin (a humectant), and about 40% ethanol.
- a cryoprotectant may include about 40% propylene glycol, about 0.8% hydroxyethylcellulose (a thickening agent), and about 59.2% water.
- a cryoprotectant may include about 50% polypropylene glycol, about 40% glycerin, and about 10% ethanol.
- Other cryoprotectants or agents can also be used and can be carried by a cotton pad or other element.
- U.S. application Ser. No. 14/610,807 is incorporated by reference in its entirety and discloses various compositions that can be used as cryoprotectants.
- adipocytes may take a few days to a few weeks, or longer, for the adipocytes to break down and be absorbed. A significant decrease in fat thickness may occur gradually over 1-3 months following treatment. Additional treatments can be performed until a desired result is achieved. For example, one or more treatments can be performed to substantially reduce (e.g., visibly reduce) or eliminate targeted tissue.
- contoured heads, line assemblies, and other components can be quickly replaced any number of times.
- Other types of heads, contours, and engagement features can be attached to the base unit 103 .
- contour elements disclosed in U.S. Publication 2010/0280582 can be used with the base unit 103 , which may have magnets or other alignment features and can provide desired sealing, including generally air-tight seal cincturing.
- U.S. Publication 2010/0280582 is incorporated by reference in its entirety.
- Liners can be used and can include films, sheets, sleeves, or other components suitable for defining an interface surface to prevent direct contact between surfaces of the applicator and the subject's skin to reduce the likelihood of cross-contamination between patients, minimize cleaning requirements, etc.
- Exemplary protective liners can be sheets, sleeves, or other components constructed from latex, rubber, nylon, Kevlar®, or other substantially impermeable or semi-permeable material.
- the liner can be a latex sheet coated with a pressure-sensitive adhesive. Further details regarding a patient protection device may be found in U.S. Patent Publication No. 2008/0077201.
- a liner or protective sleeve may be positioned between an absorbent and the applicator to shield the applicator and to provide a sanitary barrier that is, in some embodiments, inexpensive and thus disposable.
- gel traps, filters, valves, and other components can be installed to keep applied substances (e.g., coupling gels, cryoprotectants, etc.) from being sucked into and/or through the base unit 103 .
- the liner 119 is configured to allow air to pass when drawing a vacuum and to restrict passage of a gel.
- Embodiments according to the present disclosure may provide one or more additional advantages.
- the size, shapes, and other physical properties of the base units, liner assemblies, sealing members, gaskets, contoured heads, and components of the applicators may be selected to accommodate heat removal sources (e.g., thermal devices, cooling devices, etc.) that may be used/reused with individual applicators.
- Heat removal sources e.g., thermal devices, cooling devices, etc.
- Modifications to flexible portions of individual applicators may enable the use of a standard heat removal source and accommodate different contours of individual cutaneous layers. In turn, this may make it possible to reuse base units, sealing members, liners, and/or contoured heads for different treatments.
- the rigid portions of the applicators (e.g., edge or mounting region of base unit), which are relatively stiff with respect to the flexible portions, provide an attachment point for heat removal sources that may resist bowing into the interior cavity and possibly separating from the heat removal sources when a vacuum (including a partial vacuum) is drawn into the applicators.
- Disposing temperature sensors inside the applicators, along temperature-controlled surfaces, within contoured heads, along liner assemblies, etc. may more accurately measure the temperature of skin surface, subcutaneous tissue, and so forth.
- the flexible portions of the applicator (e.g., flexible mouth) also allows some compliance to different subject body contours or geometries.
- FIG. 20 is a schematic block diagram illustrating subcomponents of a controller in accordance with an embodiment of the disclosure.
- the controller can be part of the control module 106 ( FIG. 1 ).
- a controller 790 can be the controller 114 of FIG. 1 or can be incorporated into the applicators or other components disclosed herein.
- the controller 790 can include a computing device 800 having a processor 801 , a memory 802 , input/output devices 803 , and/or subsystems and other components 804 .
- the computing device 800 can perform any of a wide variety of computing processing, storage, sensing, imaging, and/or other functions.
- Components of the computing device 800 may be housed in a single unit or distributed over multiple, interconnected units (e.g., though a communications network).
- the components of the computing device 800 can accordingly include local and/or remote memory storage devices and any of a wide variety of computer-readable media.
- the processor 801 can include a plurality of functional modules 806 , such as software modules, for execution by the processor 801 .
- the various implementations of source code i.e., in a conventional programming language
- the modules 806 of the processor can include an input module 808 , a database module 810 , a process module 812 , an output module 814 , and, optionally, a display module 816 .
- the input module 808 accepts an operator input 819 via the one or more input devices, and communicates the accepted information or selections to other components for further processing.
- the database module 810 organizes records, including patient records, treatment data sets, treatment profiles and operating records and other operator activities, and facilitates storing and retrieving of these records to and from a data storage device (e.g., internal memory 802 , an external database, etc.). Any type of database organization can be utilized, including a flat file system, hierarchical database, relational database, distributed database, etc.
- the process module 812 can generate control variables based on sensor readings 818 from sensors and/or other data sources, and the output module 814 can communicate operator input to external computing devices and control variables to the controller.
- the display module 816 can be configured to convert and transmit processing parameters, sensor readings 818 , output signals 820 , input data, treatment profiles and prescribed operational parameters through one or more connected display devices, such as a display screen 118 ( FIG. 1 ), printer, speaker system, etc.
- the processor 801 can be a standard central processing unit or a secure processor.
- Secure processors can be special-purpose processors (e.g., reduced instruction set processor) that can withstand sophisticated attacks that attempt to extract data or programming logic.
- the secure processors may not have debugging pins that enable an external debugger to monitor the secure processor's execution or registers.
- the system may employ a secure field programmable gate array, a smartcard, or other secure devices.
- the memory 802 can be standard memory, secure memory, or a combination of both memory types. By employing a secure processor and/or secure memory, the system can ensure that data and instructions are both highly secure and sensitive operations such as decryption are shielded from observation.
- the memory 802 can be flash memory, secure serial EEPROM, secure field programmable gate array, or secure application-specific integrated circuit.
- the memory 802 can store instructions for causing the applicators to cool/heat tissue, pressurization devices to draw a vacuum, or other acts disclosed herein. Vacuum levels can be selected based on characteristics of the applicator, airflow features, and/or treatment site.
- the memory 802 stores instructions executable by the controller 790 for the thermal device to sufficiently cool conductive cups disclosed herein such that vacuum applicators non-invasively cool the subcutaneous lipid-rich cells to a desired temperature, such as a temperature less than about 0° C.
- the memory 802 can contain liner installation or draw instructions for causing the liner to drawn into a, tissue draw instructions for causing the applicator to draw tissue into the applicator, treatment instructions for heating/cooling tissue, tissue release instructions for releasing tissue, and instructions for monitoring treatment.
- the liner installation or draw instructions can be executed by the controller 790 to command the pressurization device 123 to suck the liner against a conductive surface of the conductive cup.
- the input/output device 118 can include, without limitation, a touchscreen, a keyboard, a mouse, a stylus, a push button, a switch, a potentiometer, a scanner, an audio component such as a microphone, or any other device suitable for accepting user input and can also include one or more video monitor, a medium reader, an audio device such as a speaker, any combination thereof, and any other device or devices suitable for providing user feedback. For example, if an applicator moves an undesirable amount during a treatment session, the input/output device 803 can alert the subject and/or operator via an audible alarm.
- the input/output device 118 can be a touch screen that functions as both an input device and an output device.
- the control panel can include visual indicator devices or controls (e.g., indicator lights, numerical displays, etc.) and/or audio indicator devices or controls.
- the control panel may be a component separate from the input/output device 118 and/or output device 120 , may be integrated applicators, may be partially integrated with one or more of the devices, may be in another location, and so on.
- the controller 114 can be contained in, attached to, or integrated with the applicators. Further details with respect to components and/or operation of applicators, control modules (e.g., treatment units), and other components may be found in commonly-assigned U.S. Patent Publication No. 2008/0287839.
- the controller 790 can include any processor, Programmable Logic Controller, Distributed Control System, secure processor, and the like.
- a secure processor can be implemented as an integrated circuit with access-controlled physical interfaces; tamper resistant containment; means of detecting and responding to physical tampering; secure storage; and shielded execution of computer-executable instructions. Some secure processors also provide cryptographic accelerator circuitry. Suitable computing environments and other computing devices and user interfaces are described in commonly assigned U.S. Pat. No. 8,275,442, entitled “TREATMENT PLANNING SYSTEMS AND METHODS FOR BODY CONTOURING APPLICATIONS,” which is incorporated herein in its entirety by reference.
- the treatment systems, applicators, and methods of treatment can be used reduce adipose tissue or treat subcutaneous tissue, acne, hyperhidrosis, wrinkles, structures (e.g., structures in the epidermis, dermis, subcutaneous fat, muscle, nerve tissue, etc.), and so on.
- structures e.g., structures in the epidermis, dermis, subcutaneous fat, muscle, nerve tissue, etc.
- Systems, components, and techniques for reducing subcutaneous adipose tissue are disclosed in U.S. Pat. No. 7,367,341 titled “METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al., U.S. Patent Publication No.
- Vacuum applicators can stretch, stress, and/or mechanically alter skin to increase damage and fibrosis in the skin, affect glands, control freeze events (including initiating freeze events), etc.
- Methods for cooling tissue and related devices and systems in accordance with embodiments of the present invention can at least partially address one or more problems associated with conventional technologies as discussed above and/or other problems whether or not such problems are stated herein.
Abstract
Systems for treating a subject's tissue can include a thermally conductive cup with vacuum features configured to facilitate removal of air located between the cup and the subject's skin. The vacuum features can extend along cup to provide airflow paths to a vacuum port. The applicator can cool and/or heat the retained tissue to affect targeted tissue. After the treat period, the vacuum can be reduced or stop and the applicator can be removed from the subject.
Description
- The present application is a continuation of U.S. application Ser. No. 15/962,811, filed Apr. 25, 2018, which claims the benefit of the earlier filing date of U.S. Provisional Patent Application No. 62/490,421, filed Apr. 26, 2017, which are incorporated herein by reference in their entireties.
- The following commonly assigned U.S. Patent Applications and U.S. Patents are incorporated herein by reference in their entireties:
- U.S. Patent Publication No. 2008/0287839 entitled “METHOD OF ENHANCED REMOVAL OF HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS AND TREATMENT APPARATUS HAVING AN ACTUATOR”;
- U.S. Pat. No. 6,032,675 entitled “FREEZING METHOD FOR CONTROLLED REMOVAL OF FATTY TISSUE BY LIPOSUCTION”;
- U.S. Patent Publication No. 2007/0255362 entitled “CRYOPROTECTANT FOR USE WITH A TREATMENT DEVICE FOR IMPROVED COOLING OF SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. Pat. No. 7,854,754 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. Pat. No. 8,337,539 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. Patent Publication No. 2008/0077201 entitled “COOLING DEVICES WITH FLEXIBLE SENSORS”;
- U.S. Pat. No. 9,132,031 entitled “COOLING DEVICE HAVING A PLURALITY OF CONTROLLABLE COOLING ELEMENTS TO PROVIDE A PREDETERMINED COOLING PROFILE”;
- U.S. Patent Publication No. 2009/0118722, filed Oct. 31, 2007, entitled “METHOD AND APPARATUS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS OR TISSUE”;
- U.S. Patent Publication No. 2009/0018624 entitled “LIMITING USE OF DISPOSABLE SYSTEM PATIENT PROTECTION DEVICES”;
- U.S. Pat. No. 8,523,927 entitled “SYSTEM FOR TREATING LIPID-RICH REGIONS”;
- U.S. Patent Publication No. 2009/0018625 entitled “MANAGING SYSTEM TEMPERATURE TO REMOVE HEAT FROM LIPID-RICH REGIONS”;
- U.S. Patent Publication No. 2009/0018627 entitled “SECURE SYSTEM FOR REMOVING HEAT FROM LIPID-RICH REGIONS”;
- U.S. Patent Publication No. 2009/0018626 entitled “USER INTERFACES FOR A SYSTEM THAT REMOVES HEAT FROM LIPID-RICH REGIONS”;
- U.S. Pat. No. 6,041,787 entitled “USE OF CRYOPROTECTIVE AGENT COMPOUNDS DURING CRYOSURGERY”;
- U.S. Pat. No. 8,285,390 entitled “MONITORING THE COOLING OF SUBCUTANEOUS LIPID-RICH CELLS, SUCH AS THE COOLING OF ADIPOSE TISSUE”;
- U.S. Pat. No. 8,275,442 entitled “TREATMENT PLANNING SYSTEMS AND METHODS FOR BODY CONTOURING APPLICATIONS”;
- U.S. patent application Ser. No. 12/275,002 entitled “APPARATUS WITH HYDROPHILIC RESERVOIRS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. patent application Ser. No. 12/275,014 entitled “APPARATUS WITH HYDROPHOBIC FILTERS FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. Pat. No. 8,603,073 entitled “SYSTEMS AND METHODS WITH INTERRUPT/RESUME CAPABILITIES FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. Pat. No. 8,192,474 entitled “TISSUE TREATMENT METHODS”;
- U.S. Pat. No. 8,702,774 entitled “DEVICE, SYSTEM AND METHOD FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. Pat. No. 8,676,338 entitled “COMBINED MODALITY TREATMENT SYSTEMS, METHODS AND APPARATUS FOR BODY CONTOURING APPLICATIONS”;
- U.S. Pat. No. 9,314,368 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”;
- U.S. Pat. No. 9,844,461 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”;
- U.S. Publication No. 2012/0239123 entitled “DEVICES, APPLICATION SYSTEMS AND METHODS WITH LOCALIZED HEAT FLUX ZONES FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
- U.S. Pat. No. 9,545,523 entitled “MULTI-MODALITY TREATMENT SYSTEMS, METHODS AND APPARATUS FOR ALTERING SUBCUTANEOUS LIPID-RICH TISSUE”;
- U.S. Pat. No. 9,844,460 entitled “TREATMENT SYSTEMS WITH FLUID MIXING SYSTEMS AND FLUID-COOLED APPLICATORS AND METHODS OF USING THE SAME”;
- U.S. Pat. No. 9,132,031 entitled “COOLING DEVICE HAVING A PLURALITY OF CONTROLLABLE COOLING ELEMENTS TO PROVIDE A PREDETERMINED COOLING PROFILE,”
- U.S. Pat. No. 8,285,390 entitled “MONITORING THE COOLING OF SUBCUTANEOUS LIPID-RICH CELLS, SUCH AS THE COOLING OF ADIPOSE TISSUE;” and
- U.S. Pat. No. 9,752,856 entitled “TREATMENT SYSTEMS, SMALL VOLUME APPLICATORS, AND METHODS FOR TREATING SUBMENTAL TISSUE.”
- The present disclosure relates generally to treatment systems and shallow surface applicators. Several embodiments are directed to applicators with shallow cups with airflow features for air removal.
- Excess body fat, or adipose tissue, may be present at various locations of a subject's body and may detract from personal appearance. Aesthetic improvement of the human body often involves the selective removal of adipose tissue located at the abdomen, thighs, buttocks, knees, submental region, face and arms, as well as other locations. Invasive procedures (e.g., liposuction), however, tend to be associated with relative high costs, long recovery times, and increased risk of complications. Injection of drugs for reducing adipose tissue can cause significant swelling, bruising, pain, numbness, and/or induration.
- Conventional non-invasive treatments for reducing adipose tissue often include regular exercise, application of topical agents, use of weight-loss drugs, dieting, or a combination of these treatments. One drawback of these non-invasive treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Topical agents and orally administered weight-loss drugs are not an option if, as another example, they cause an undesirable reaction, such as an allergic or negative reaction. Additionally, non-invasive treatments may be ineffective for selectively reducing specific regions of adiposity, such as localized adipose tissue along the hips, abdomen, thighs, or the like.
- Conventional non-invasive vacuum cooling devices suck a fold of skin between two spaced apart cooled plates that are generally parallel to one another. The cooling device can cool and thermally damage targeted tissue. Only opposites sides of the skin fold contact the cooled plates, which limits the cooling capabilities of the cooling devices. Additionally, the end of the tissue fold located in a gap between the plates may experience pooling of blood. A vacuum may cause rupturing of blood vessels and lead to bruising of the skin located in the gap. Accordingly, conventional invasive and non-invasive treatments are not suitable for many subjects and cannot effectively target certain regions of tissue.
- In the drawings, identical reference numbers identify similar elements or acts.
-
FIG. 1 is a partially schematic, isometric view of a treatment system for non-invasively affecting target regions of a subject in accordance with an embodiment of the technology. -
FIG. 2 is a cross-sectional view of an applicator taken along line 2-2 ofFIG. 1 andFIG. 5 . -
FIG. 3 is a cross-sectional view of a connector taken along line 3-3 ofFIG. 1 . -
FIG. 4 is an isometric view of an applicator suitable for use with the system ofFIG. 1 in accordance with an embodiment of the technology. -
FIG. 5 is a bottom view of the applicator ofFIG. 4 . -
FIG. 6 is a cross-sectional view of an applicator taken along line 6-6 ofFIG. 5 in accordance with an embodiment of the technology. -
FIG. 7 is a cross-sectional view of an applicator taken along line 7-7 ofFIG. 5 in accordance with an embodiment of the technology. -
FIG. 8 is a cross-sectional view of the applicator taken along line 8-8 ofFIG. 5 in accordance with an embodiment of the technology. -
FIG. 9 is a isometric view of a central region of a cup taken along line 9-9 ofFIG. 2 in accordance with an embodiment of the technology. -
FIG. 10 is a bottom view of an applicator in accordance with another embodiment of the technology. -
FIG. 11 is a cross-sectional view of an airflow feature taken along line 11-11 ofFIG. 10 . -
FIGS. 12 and 13 are cross-sectional views of airflow feature in accordance with some embodiments of the technology. -
FIG. 14 is an isometric view of an applicator with branching airflow features in accordance with another embodiment of the technology. -
FIG. 15 is a bottom view of the applicator ofFIG. 14 . -
FIG. 16 is a cross-sectional view of an applicator taken along line 16-16 ofFIG. 15 in accordance with an embodiment of the technology. -
FIGS. 17 and 18 are cross-sectional views of airflow features located along a cup in accordance with embodiments of the technology. -
FIG. 19 is a flowchart of a method for treating a subject in accordance with embodiments of the disclosed technology. -
FIG. 20 is a schematic block diagram illustrating subcomponents of a controller in accordance with embodiments of the disclosed technology. - The present disclosure describes treatment systems, applicators, and methods for affecting targeted sites. Several embodiments are directed to non-invasive systems that cool/heat specific regions or volumes of tissue. The non-invasive systems can include applicators with thermally-conductive cooling cups for cooling the skin surface. An applicator can include one or more airflow features that facilitate thermal contact with the tissue. The airflow features can include one or more air-egress features along which air flows to reduce, limit, or substantially eliminate air between the subject's skin and the cup before and/or during treatment. The air-egress features can include small gaps, channels, ridges, protrusions, or other suitable features for defining fluid flow paths. Several of the details set forth below are provided to describe the following examples and methods in a manner sufficient to enable a person skilled in the relevant art to practice, make, and use them. Several of the details and advantages described below, however, may not be necessary to practice certain examples and methods of the technology. Additionally, the technology may include other examples and methods that are within the scope of the technology but are not described in detail.
- Some aspects of the technology are directed to an apparatus that includes an applicator with a temperature-controlled patient contact surface having a topography for providing airflow channels. The airflow channels can extend between a vacuum port and a peripheral portion of the patient contact surface when the patient's tissue is operably received within a cavity of the applicator. The vacuum port can provide communication between the cavity and a pressurization device, such as a vacuum source. The topography of the patient contact surface can be selected to assist in the elimination or reduction of air gaps when the patient's tissue is drawn to the cavity, distribute the vacuum throughout the cavity (e.g., distribute the vacuum along the patient contact surface), and/or otherwise facilitate air removal. In some embodiments, a cup and the vacuum port are configured such that when a vacuum is applied the subject's tissue substantially fills an entire volume of the cup except for small gaps created by air-egress features formed on a surface of the cup.
- One aspect the technology is directed to an applicator configured to cool tissue. The applicator can include a cup, at least one vacuum port, and air-egress features. The cup can define a tissue-receiving cavity and can include a temperature-controlled surface. The air-egress features can extend along the temperature-controlled surface to provide airflow paths to the vacuum port to enhance air removal between the subject's skin and the cup while the subject's tissue is pulled toward the temperature-controlled surface. The applicator can draw in air such that the subject's tissue fills most or substantially all of the tissue-receiving cavity. In some embodiments, a vacuum can be drawn to pull the skin into thermal contact with a large area of the cup, thereby providing a relatively large skin/cup interface for heat transfer. For example, the temperature-controlled surface can extend continuously along spaced apart sidewalls and bottom of the cooling cup and can thermally contact an area of the subject's skin that is equal to or less than about 20 cm2, 40 cm2, 80 cm2, 100 cm2, 140 cm2, 160 cm2, 180 cm2, 200 cm2, 300 cm2, or other suitable area. Air can escape via the air-egress features to eliminate air gaps that would impair heat-transfer with the subject's skin. The temperature-controlled conductive surface, including the airflow features, can be cooled to a temperature equal to or lower than a selected temperature (e.g., 5° C., 0° C., −2° C., −5° C., −7° C., −10° C., −15° C., −20° C., −25° C., etc.). In some embodiments, most of the temperature-controlled conductive surface can be cooled to a temperature equal to or lower than about 0° C., −2° C. −5° C., −10° C., or −15° C.
- In some embodiments, an apparatus for treating a human subject includes an applicator configured to cool the subject's skin. The applicator includes a cup, at least one vacuum port, and air-egress features. The cup defines a tissue-receiving cavity. The air-egress features can extend along the temperature-controlled surface to provide airflow paths to the vacuum port for removing air located between the subject's skin and the cup while the vacuum port provides a vacuum to draw the subject's tissue toward the temperature-controlled surface. In some embodiments, the air-egress features include channels, ridges, protrusions, or the like.
- In certain procedures, one or more liners, cryoprotectant, or other suitable elements can be positioned between the subject's skin and the cup. The liner can have an adhesive surface for adhering to the cup and can be perforated to allow airflow therethrough. The liner assembly can be made, in whole or in part, of plastic, rubber, or other suitable material and can include, without limitation, one or more sealing members, sensors, release liners, carriers, alignment features, or the like. In other procedures, the subject's skin can directly contact the cup.
- Some of the embodiments disclosed herein can be for cosmetically beneficial alterations of target regions. Some cosmetic procedures may be for the sole purpose of altering a target region to conform to a cosmetically desirable look, feel, size, shape and/or other desirable cosmetic characteristic or feature. Accordingly, at least some embodiments of the cosmetic procedures can be performed without providing an appreciable therapeutic effect (e.g., no therapeutic effect). For example, some cosmetic procedures may not include restoration of health, physical integrity, or the physical well-being of a subject. The cosmetic methods can target subcutaneous regions to change a human subject's appearance and can include, for example, procedures performed on a subject's submental region, abdomen, hips, legs, face, neck, ankle region, or the like. In other embodiments, however, cosmetically desirable treatments may have therapeutic outcomes (whether intended or not), such as psychological benefits, alteration of body hormone levels (by the reduction of adipose tissue), etc.
- Reference throughout this specification to “one example,” “an example,” “one embodiment,” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present technology. Thus, the occurrences of the phrases “in one example,” “in an example,” “one embodiment,” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, structures, routines, stages, or characteristics may be combined in any suitable manner in one or more examples of the technology. The headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the technology.
-
FIG. 1 and the following discussion provide a brief, general description of atreatment system 100 in accordance with some embodiments of the technology. Thetreatment system 100 can be a temperature-controlled system for exchanging heat with a subject 101 and can include a non-invasive tissue-cooling apparatus in the form of a cooling cup applicator 102 (“applicator 102”) configured to selectively cool tissue to affect targeted tissue, structures, or the like. The illustratedapplicator 102 is positioned along a subject's hip and can draw a vacuum to provide suitable thermal contact with the subject's skin to cool subcutaneous adipose tissue. Theapplicator 102 is configured to facilitate a high amount of thermal contact with the subject's skin by minimizing, limiting, or substantially eliminating air gaps at the applicator/tissue interface. The entire skin surface of the retained volume of tissue can be cooled for efficient treatment. Theapplicator 102 can have a relatively shallow tissue-receiving chamber to avoid or limit pooling of blood, rupturing of blood vessels, patient discomfort, and so forth. - The
applicator 102 can be used to perform medical treatments to provide therapeutic effects and/or cosmetic procedures for cosmetically beneficial effects. Without being bound by theory, selective effects of cooling are believed to result in, for example, membrane disruption, cell shrinkage, disabling, disrupting, damaging, destroying, removing, killing and/or other methods of lipid-rich cell alteration. Such alteration is believed to stem from one or more mechanisms acting alone or in combination. It is thought that such mechanism(s) trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling. In any of these embodiments, the effect of tissue cooling can be the selective reduction of lipid-rich cells by a desired mechanism of action, such as apoptosis, lipolysis, or the like. In some procedures, theapplicator 102 can cool the skin surface and/or targeted tissue to cooling temperature in a range of from about −25° C. to about 20° C. In other embodiments, the cooling temperatures can be from about −20° C. to about 10° C., from about −18° C. to about 5° C., from about −15° C. to about 5° C., or from about −15° C. to about 0° C. In further embodiments, the cooling temperatures can be equal to or less than −5° C., −10° C., −15° C., or in yet another embodiment, from about −15° C. to about −25° C. Other cooling temperatures and temperature ranges can be used. - Apoptosis, also referred to as “programmed cell death”, is a genetically-induced death mechanism by which cells self-destruct without incurring damage to surrounding tissues. An ordered series of biochemical events induce cells to morphologically change. These changes include cellular blebbing, loss of cell membrane asymmetry and attachment, cell shrinkage, chromatin condensation and chromosomal DNA fragmentation. Injury via an external stimulus, such as cold exposure, is one mechanism that can induce cellular apoptosis in cells. Nagle, W. A., Soloff, B. L., Moss, A. J. Jr., Henle, K. J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990).
- One aspect of apoptosis, in contrast to cellular necrosis (a traumatic form of cell death causing local inflammation), is that apoptotic cells express and display phagocytic markers on the surface of the cell membrane, thus marking the cells for phagocytosis by macrophages. As a result, phagocytes can engulf and remove the dying cells (e.g., the lipid-rich cells) without eliciting an immune response. Temperatures that elicit these apoptotic events in lipid-rich cells may contribute to long-lasting and/or permanent reduction and reshaping of subcutaneous adipose tissue.
- One mechanism of apoptotic lipid-rich cell death by cooling is believed to involve localized crystallization of lipids within the adipocytes at temperatures that do not induce crystallization in non-lipid-rich cells. The crystallized lipids selectively may injure these cells, inducing apoptosis (and may also induce necrotic death if the crystallized lipids damage or rupture the bi-lipid membrane of the adipocyte). Another mechanism of injury involves the lipid phase transition of those lipids within the cell's bi-lipid membrane, which results in membrane disruption or dysfunction, thereby inducing apoptosis. This mechanism is well-documented for many cell types and may be active when adipocytes, or lipid-rich cells, are cooled. Mazur, P., “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970); Quinn, P. J., “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147 (1985); Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003). Other possible mechanisms of adipocyte damage, described in U.S. Pat. No. 8,192,474, relate to ischemia/reperfusion injury that may occur under certain conditions when such cells are cooled as described herein. For instance, during treatment by cooling as described herein, the targeted adipose tissue may experience a restriction in blood supply and thus be starved of oxygen due to isolation as a result of applied pressure, cooling which may affect vasoconstriction in the cooled tissue, or the like. In addition to the ischemic damage caused by oxygen starvation and the buildup of metabolic waste products in the tissue during the period of restricted blood flow, restoration of blood flow after cooling treatment may additionally produce reperfusion injury to the adipocytes due to inflammation and oxidative damage that is known to occur when oxygenated blood is restored to tissue that has undergone a period of ischemia. This type of injury may be accelerated by exposing the adipocytes to an energy source (via, e.g., thermal, electrical, chemical, mechanical, acoustic, or other means) or otherwise increasing the blood flow rate in connection with or after cooling treatment as described herein. Increasing vasoconstriction in such adipose tissue by, e.g., various mechanical means (e.g., application of pressure or massage), chemical means or certain cooling conditions, as well as the local introduction of oxygen radical-forming compounds to stimulate inflammation and/or leukocyte activity in adipose tissue may also contribute to accelerating injury to such cells. Other yet-to-be understood mechanisms of injury may exist.
- In addition to the apoptotic mechanisms involved in lipid-rich cell death, local cold exposure is also believed to induce lipolysis (i.e., fat metabolism) of lipid-rich cells and has been shown to enhance existing lipolysis which serves to further increase the reduction in subcutaneous lipid-rich cells. Vallerand, A. L., Zamecnik. J., Jones, P. J. H., Jacobs, I. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans” Aviation, Space and Environmental Medicine 70, 42-50 (1999).
- One expected advantage of the foregoing techniques is that the subcutaneous lipid-rich cells in the target region can be reduced generally without collateral damage to non-lipid-rich cells in the same region. In general, lipid-rich cells can be affected at low temperatures that do not affect non-lipid-rich cells. As a result, lipid-rich cells, such as those associated with highly localized adiposity (e.g., adiposity along the abdomen, submental adiposity, submandibular adiposity, facial adiposity, etc.), can be affected while non-lipid-rich cells (e.g., myocytes) in the same generally region are not damaged. The unaffected non-lipid-rich cells can be located underneath lipid-rich cells (e.g., cells deeper than a subcutaneous layer of fat), in the dermis, in the epidermis, and/or at other locations.
- In some procedures, the
treatment system 100 can remove heat from underlying tissue through the upper layers of tissue and create a thermal gradient with the coldest temperatures near the cooling surface, or surfaces, of the applicator 102 (i.e., the temperature of the upper layer(s) of the skin can be lower than that of the targeted underlying target cells). It may be challenging to reduce the temperature of the targeted cells low enough to be destructive to these target cells (e.g., induce apoptosis, cell death, etc.) while also maintaining the temperature of the upper and surface skin cells high enough so as to be protective (e.g., non-destructive). The temperature difference between these two thresholds can be small (e.g., approximately, 5° C. to about 10° C., less than 10° C., less than 15° C., etc.). Protection of the overlying cells (e.g., typically water-rich dermal and epidermal skin cells) from freeze damage during dermatological and related aesthetic procedures that involve sustained exposure to cold temperatures may include improving the freeze tolerance and/or freeze avoidance of these skin cells by using, for example, cryoprotectants for inhibiting or preventing such freeze damage. - Tissue can be rapidly rewarmed as soon as practicable after a freeze event has occurred to limit, reduce, or prevent damage and adverse side effects associated with the freeze event. After freezing begins, tissue can be rapidly warmed as soon as possible to minimize or limit damage to tissue, such as the epidermis. In some procedures, tissue is partially or completely frozen for a predetermined period of time and then warmed. According to one embodiment, an applicator can warm shallow tissue using, for example, thermoelectric elements in the device. Thermoelectric elements can include Peltier devices capable of operating to establish a desired temperature (or temperature profile) along the surface. In other embodiments, the applicator outputs energy to warm tissue. For example, the applicator can have electrodes that output radiofrequency energy for warming tissue. In some procedures, the tissue can be warmed at a rate of about 1° C/s, 2° C/s, 2.5° C/s, 3° C/s, 5° C/s, or other rate selected to thaw frozen tissue after the tissue has been partially or completely frozen for about 10 seconds, 30 seconds, 1 minute, 2 minutes, 5 minutes, 10 minutes, or other suitable length of time.
-
FIG. 2 is a cross-sectional view of theapplicator 102 taken along line 2-2 ofFIG. 1 . Theapplicator 102 includes a contoured sealing element 151 and abase unit 152. The sealing element 151 can conform closely to contours of the subject's body to sealingly engage a liner orskin surface 160. Thebase unit 152 can include ashallow cup 168 defining a tissue-receivingcavity 170 for holding tissue. Thecup 168 can include a temperature-controlledsurface 174, avacuum port 176, and airflow features in the form of air-egress features 180 extending along the bottom of the tissue-receivingcavity 170. Dashedline 190 shows the position of the subject's tissue (or liner) before being drawn (indicated by arrows) into theapplicator 102. If a liner is used with theapplicator 102, the liner can line thecup 168 and can be perforated such that a vacuum can be drawn through the liner to urge the subject's skin against the liner, thereby maintaining thermal contact between the tissue and thecup 168. - The air-egress features 180 can help distribute the vacuum across the cup/tissue interface to enhance patient comfort and prevent air gaps at the tissue/cup interface during tissue draw. After the subject's tissue fills the tissue-receiving
cavity 170, the air-egress features 180 can distribute the vacuum across a large area of the tissue-cup interface. During subcutaneous treatments, the subject's skin can extend across the air-egress features 180, illustrated as channels spreading outwardly from acentral region 150 of thecup 168. Constant or varying vacuum levels can be used to keep the tissue in thermal contact with thecup 168. In some embodiments, thevacuum port 176 is positioned at thecentral region 150 to draw the tissue into the deepest region of the tissue-receivingcavity 170, and the air-egress features 180 extend toward aperipheral portion 181 of the temperature-controlledsurface 174. The air-egress features 180 can be a network of elongate protrusions, ridges, and/or channels positioned at locations at which air tends to become trapped. If ambient air is inadvertently sucked between thecup 168 and the subject's skin, it can serve as a thermal insulator and reduce heat transfer between theapplicator 102 and the subject's tissue. Such air can be removed via the air-egress features 180 to maintain suitable thermal contact throughout the entire treatment session, including relatively long sessions (e.g., sessions equal to or longer than 20 minutes, 30 minutes, 45 minutes, 1 hour, or 2 hours). - Each air-
egress feature 180 can include afirst end 192 spaced apart from amouth 194 of thecup 168, asecond end 195 positioned proximate avacuum port 197, and amain portion 198 extending between the first and second ends 192, 195. Most or substantially all of the skin surface of the volume of tissue in thecavity 170 can be in thermal contact with thecup 168. In some procedures, the vacuum level can be sufficiently high to keep the tissue in contact with the bottom of thecup 168 to keep thecavity 170 filled with tissue but can be sufficiently low to limit or minimize pooling of blood, vascular damage (e.g., rupturing of blood vessels), bruising, and other complications often associated with vacuum-based procedures. Upon completion of the cryotherapy procedure, theapplicator 102 can release the tissue (e.g., by reducing or stopping the vacuum) and can be used at another treatment site. - The
base unit 152 can include coolingunits 200 coupled to, embedded in, or otherwise in thermal communication with the temperature-controlledsurface 174. The coolingunits 200 can include, without limitation, one or more thermoelectric elements 202 (e.g., Peltier-type elements), fluid-cooledelements 204, heat-exchanging units, or combinations thereof. In a cooling mode, fluid-cooledelements 204 can cool the backside of thethermoelectric elements 202 to keep thethermoelectric elements 202 at or below a target temperature. In a heating mode, fluid-cooledelements 200 can heat the backside of thethermoelectric elements 202 to keep thethermoelectric elements 202 at or above a target temperature. In some embodiments, the coolingunits 200 include only fluid-cooled elements or only non-fluid-cooled elements. The coolingunits 200 can be embedded or otherwise disposed in thecup 168 to reduce the distance from the tissue to thethermoelectric elements 202. Although the illustrated embodiment has two coolingunits 200, it can have any desired number of coolingunits 200. The number, positions, configurations, and operating temperatures of the cooling units can be selected based on cooling/heating suitable for treatment, desired power consumption, or the like. - Referring again to
FIG. 1 , theconnector 104 extends from thecontrol module 106 to theapplicator 102 and can provide suction for drawing tissue into theapplicator 102 and energy (e.g., electrical energy) and fluid (e.g., coolant) from thecontrol module 106 to theapplicator 102.FIG. 3 is a cross-sectional view of theconnector 104 taken along line 3-3 ofFIG. 1 and shows theconnector 104 including amain body 179, a supply fluid line orlumen 180 a (“supply fluid line 180 a”), and a return fluid line orlumen 180 b (“returnfluid line 180 b”). Referring now toFIG. 3 , themain body 179 may be configured (via one or more adjustable joints) to “set” in place for the treatment of the subject 101. The supply and returnfluid lines elements 204 ofFIG. 2 ), or other components. In one embodiment, eachfluid line main body 179. - The
connector 104 can also include one or moreelectrical lines 112 for providing power to theapplicator 102 and one ormore control lines 116 for providing communication between the control module 106 (FIG. 1 ) and the applicator 102 (FIGS. 1 and 2 ). Theelectrical lines 112 can provide power to the thermoelectric elements, sensors, and so forth. To provide suction, theconnector 104 can include one or more vacuum lines 125. In various embodiments, theconnector 104 can include a bundle of fluid conduits, a bundle of power lines, wired connections, vacuum lines, and other bundled and/or unbundled components selected to provide ergonomic comfort, minimize unwanted motion (and thus potential inefficient removal of heat from the subject), and/or to provide an aesthetic appearance to the treatment system. - Referring again to
FIG. 1 , thecontrol module 106 can include a fluid system 105 (illustrated in phantom line), a power supply 110 (illustrated in phantom line), and acontroller 114 carried by ahousing 124 withwheels 126. Thefluid system 105 can include a fluid chamber and a refrigeration unit, a cooling tower, a thermoelectric chiller, heaters, or any other device capable of controlling the temperature of coolant in the fluid chamber. The coolant can be continuously or intermittently delivered to theapplicator 102 via thesupply fluid line 180 a (FIG. 3 ) and can circulate through theapplicator 102 to absorb heat. The coolant, which has absorbed heat, can flow from theapplicator 102 back to thecontrol module 106 via thereturn fluid line 180 b (FIG. 3 ). For warming periods, thecontrol module 106 can heat the coolant that is circulated through theapplicator 102. Alternatively, a municipal water supply (e.g., tap water) can be used in place of or in conjunction with thecontrol module 106. - A
pressurization device 123 can provide suction to theapplicator 102 via the vacuum line 125 (FIG. 3 ) and can include one or more vacuum sources (e.g., pumps). Air pockets between the subject's tissue can impair heat transfer with the tissue and, if large enough, can affect treatment. Thepressurization device 123 can provide a sufficient vacuum to eliminate such air gaps (e.g., large air gaps between the tissue and the temperature-controlledsurface 174 ofFIG. 2 ) such that substantially no air gaps impair non-invasively cooling of the subject's subcutaneous lipid-rich cells to a treatment temperature. When the air pockets are eliminate, the tissue can be suitably cooled even though the air-egress features may contain small volumes of air and may not contact the subject's skin. - Air pressure can be controlled by a regulator located between the
pressurization device 123 and theapplicator 102. Thecontrol module 106 can control the vacuum level to, for example, install the liner assembly and/or draw tissue into theapplicator 102 while maintaining a desired level of comfort. If the vacuum level is too low, a liner assembly, tissue, etc. may not be drawn adequately (or at all) into and/or held within theapplicator 102. If the vacuum level is too high when preparing the applicator, a liner assembly can break (e.g., rupture, tear, etc.). If the vacuum level is too high during treatment, the patient can experience discomfort, bruising, or other complications. According to certain embodiments, approximately 0.5 inch Hg, 1 inch Hg, 2 inches Hg, 3 inches Hg, 5 inches Hg, 7 inches Hg, 8 inches Hg, 10 inches Hg, or 12 inches Hg vacuum is applied to draw or hold the liner assembly, tissue, etc. In some embodiments, the air-egress features 180 can be configured to maintain the airflow paths when 12 inches Hg vacuum level is used to draw tissue into the tissue-receivingcavity 170. The number, dimensions, and positions of the air-egress features 180 can be selected to achieve desired tissue contact. Other vacuum levels can be selected based on the characteristics of the tissue, desired level of comfort, and vacuum leakage rates. Vacuum leak rates of theapplicator 102 can be equal to or less than about 0.2 LPM, 0.5 LPM, 1 LPM, or 2 LPM at the pressure levels disclosed herein. For example, the vacuum leak rate can be equal to or less than about 0.2 LPM at 8 inches Hg, 0.5 LPM at 8 inches Hg, 1 LPM at 8 inches Hg, or 2 LPM at 8 inches Hg. The configuration of thepressurization device 123 andapplicator 102 can be selected based on the desired vacuum levels, leakage rates, and other operating parameters. - The
power supply 110 can provide a direct current voltage for powering electrical elements of theapplicator 102 via the line 112 (FIG. 3 ). The electrical elements can be thermal devices, sensors, actuators, controllers (e.g., a controller integrated into the applicator 102), or the like. An operator can use an input/output device in the form of a screen 118 (“input/output device 118”) of thecontroller 114 to control operation of thetreatment system 100, and the input/output device 118 can display the state of operation of thetreatment system 100 and/or progress of a treatment protocol. In some embodiments, thecontroller 114 can exchange data with theapplicator 102 via the line (e.g., link 116 ofFIG. 3 ), a wireless communication link, or an optical communication link and can monitor and adjust treatment based on, without limitation, one or more treatment profiles and/or patient-specific treatment plans, such as those described, for example, in commonly assigned U.S. Pat. No. 8,275,442. Thecontroller 114 can contain instructions to perform the treatment profiles and/or patient-specific treatment plans, which can include one or more segments, and each segment can include temperature profiles, vacuum levels, and/or specified durations (e.g., 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, etc.). For example, thecontroller 114 can be programmed to cause the pressurization device to operate to pull tissue into the applicator. After tissue draw, the pressurization device can operate to hold the subject's skin in thermal contact appropriate features while the cup conductively cools tissue. If the sensor detects tissue moving out of thermal contact with the cup, the vacuum can be increased to reestablish suitable thermal contact. In some embodiments, thecontroller 114 is programmed to cause the pressurization device to provide a sufficient vacuum to keep substantially all of each region of the temperature-controlled surface between air-egress features in thermal contact with the subject's skin. This provides a relatively large contact interface for efficient heat transfer with the target tissue. - Different vacuum levels can be utilized during treatment sessions. For example, relatively strong vacuums can be used to pull the subject's tissue into the applicator. A weaker vacuum can be maintained to hold the subject's tissue against the thermally conductive surface. If suitable thermal contact is not maintained (e.g., the subject's skin moves away from the thermally conductive surface), the vacuum level can be increased to reestablish suitable thermal contact. In other procedures, a generally constant vacuum level can be used throughout the treatment session.
- If the
treatment system 100 includes multiple applicators, a treatment profile can include specific profiles for each applicator to concurrently or sequentially treat multiple treatment sites, including, but not limited to, sites along the subject's torso, abdomen, legs, buttock, legs, face and/or neck (e.g., submental sites, submandibular sites, etc.), knees, back, arms, ankle region, or other treatment sites. The vacuum levels can be selected based on the configuration of the cup. Strong vacuum levels can be used with relatively deep cups whereas weak vacuum levels can be used with relatively shallow cups. The vacuum level and cup configuration can be selected based on the treatment site and desired volume of tissue to be treated. In some embodiments, thecontroller 114 can be incorporated into theapplicator 102 or another component of thetreatment system 100. -
FIG. 4 is an isometric view of anapplicator 102, andFIG. 5 is a bottom plan view of theapplicator 102. Thecup 168 has a topography for removing air from thecavity 170 because it has air-egress features 180 extending outwardly from thecentral region 150 such that a significant portion of the temperature-controlledsurface 174 is located directly between the air-egress features 180. The subject's skin (or liner) can be pulled against the areas (e.g., onearea 230 is indicated in dashed line) of the temperature-controlledsurface 174 located between adjacent air-egress features 180. In various embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of total area of the exposed temperature-controlledsurface 174 facing the tissue-receivingcavity 170 can be located between the air-egress features 180. In some embodiments, a ratio of a sum of areas of the temperature-controlledsurface 174 located directly between the air-egress features 180 to a total area of the temperature-controlledsurface 174 is equal to or greater than 0.5, 0.6, 0.7, 0.8, or 0.9. The ratio can be selected based on the tendency of air pockets to be present when theapplicator 102 initially seals with the subject's skin. For example, a highly contoured temperature-controlledsurface 174 can be prone to producing a large number of air pockets, so the ratio can be increased whereas the ratio can be reduced for a relatively shallowflat cup 168 with a gradually contoured temperature-controlledsurface 174. - The air-egress features 180 can be spaced apart from one another or interconnected to define an airflow pattern suitable for evacuating air. Referring now to
FIG. 5 , air-egress features 180 can extend across most of a width W and/or length L of the tissue-receivingcavity 170. A distance D between outermost ends of opposing air-egress features 180 can be equal to or greater than about half the width W. The distance D can be measured in a direction generally perpendicular to the longitudinal length of thecavity 170. A ratio of the distance D to the width W can be equal to or greater than about 0.5, 0.6, 0.7, 0.8, or 0.9. In some embodiments, the temperature-controlledsurface 174 can be gradually sloped to help avoid air pockets at its periphery, so the air-egress features 180 can be located at thecentral region 150 and may not extend across most of the width W and/or length L. Accordingly, the air-egress features 180 or portions thereof can be localized at locations susceptible to air pocket formation. -
FIG. 6 is a cross-sectional view of theapplicator 102 taken along line 6-6 ofFIG. 5 in accordance with an embodiment of the technology.FIG. 7 is a cross-sectional view of theapplicator 102 taken along line 7-7 ofFIG. 5 . Referring now toFIG. 6 ,lines cavity 170 via amanifold device 250. Themanifold device 250 can include vacuum ports, channels, valves, regulators, sensors, or the like. An internal controller or circuitry assembly of themanifold device 250 can be in electrical communication with sensors, valves, or other components. - Referring now to
FIG. 7 , air-egress features 180 can be in fluid communication withcorresponding vacuum ports 197. During use, air can flow along the air-egress features 180 (indicated by arrows) and through thevacuum ports 197,manifold device 250, andlines 240, 242 (FIG. 6 ). Thelines conduits FIG. 3 ) or other components of theconnector 104. In other embodiments, air-egress features 180 can be connected to a single vacuum port, such as a slot, an opening, or other aperture. The number, positions, and configuration of the vacuum ports can be selected based on the desired flow rates, vacuum distribution, and/or characteristics of applied substances at the tissue/applicator interface. -
FIG. 8 is a cross-sectional view of theapplicator 102 taken along line 8-8 ofFIG. 5 in accordance with an embodiment of the technology. Dimensions of the air-egress features 180 can be selected to limit the area of the subject's tissue (or liner) not in direct contact with thesurface 174. In some embodiments, the air-egress feature 180 has a height H of about 1 mm to about 2 mm, a width W of about 1 mm to about 2 mm, and a length L (FIG. 5) of at least 10 mm and can be generally U-shaped, V-shaped, or other suitable shape. In an another embodiment, the air-egress feature 180 is a U-shaped channel having a generally uniform cross-sectional profile along its longitudinal length. In other embodiments, the height H and/or width W can decrease in the direction away from thevacuum port 197. The dimensions, configuration, and characteristics of the air-egress feature 180 can be selected based on the desired airflow rates, position of the air-egress feature, or the like. -
FIG. 9 is a isometric view of thecentral region 150 of thecup 168 taken along line 9-9 ofFIG. 5 in accordance with an embodiment of the technology. Aflow distributor 300 is positioned within an elongatecentral opening 310 of thecup 168. Theflow distributor 300 can include an array ofvacuum ports 197, sealingelements 320, valves, and other suitable elements for providing a desired vacuum. As shown inFIG. 5 , theflow distributor 300 can include anair inlet 340 for drawing tissue against an upper region orplate 330 and can serve as a gel trap to prevent a cryoprotectant gel from flowing through theapplicator 102. - With reference to
FIG. 9 , thecup 168 can be made of one or more thermally conductive materials, including, without limitation, metal (e.g., aluminum, stainless steel, pure copper, copper alloys, etc.) or other rigid or flexible high heat transfer materials, such as thermally conductive plastics. In some embodiments, the thermally conductive material of thecup 168 at room temperature has a thermal conductivity equal to or greater than about 25 W/(mK), 50 W/(mK), 100 W/(mK), 200 W/(mK), 300 W/(mK), 350 W/(mK), and ranges encompassing such thermal conductivities. Thecup 168 can have a multi-piece construction with various pieces made of materials selected to provide different amounts of heat flow at different locations. In other embodiments, thecup 168 has a unitary construction and is made of a single material, such as metal. Additional vacuum ports can be positioned at suitable locations along thecup 168 based on, for example, considerations of patient comfort, desired vacuum levels, and/or other treatment parameters. -
FIG. 10 is a bottom view of anapplicator 308 in accordance with an embodiment of the technology. Theapplicator 308 can include an airflow features 310 in the form of air-egress features 314 (two identified) and branching air-egress features 320 (two identified). The air-egress features 320, 314 can have geometrically congruent cross sections. In other embodiments, air-egress features 320, 314 can have geometries selected based on their location within the cavity. As shown inFIGS. 10 and 11 , air-egress features 320 can be V-shaped channels extending along acup 332.FIG. 11 shows the position 321 (illustrated in dashed line) of the skin surface extending across and covering the open end of the air-egress feature 320 such that air can flow along an air path (e.g.,air path 323 is illustrated in dashed line inFIG. 10 ). Each air-egress feature 320 can maintain such an air path while the subject's tissue is held firmly against asurface 333 of thecup 332. -
FIGS. 12 and 13 show cross-sectional profiles for the air-egress feature 320 in other embodiments. Referring now toFIG. 12 , the air-egress feature 320 can have a semicircular cross-section and can be formed via machining or molding processes. Referring now toFIG. 13 , air-egress feature 320 can have a polygonal or generally rectangular cross section formed via machining or molding processes. -
FIG. 14 is an isometric view of anapplicator 340 in accordance with another embodiment.FIG. 15 is a bottom view of theapplicator 340. Relevant description of the applicators discussed in connection withFIGS. 1-13 applies to theapplicator 340. Referring now toFIG. 14 ,applicator 340 can include acup 342 and airflow features in the form of air-egress features 350 a, 350 b, 350 c (collectively “air-egress features 350”) that extend outwardly from acentral region 360. Air-egress features 350 a extend away from acentral region 392 towardperiphery portions 382 atlongitudinal sides 384 of thecup 342. Air-egress features 350 b extend toward correspondingrounded corners 396 of thecup 342 and branch to formterminal portions cup 342. -
FIG. 16 is a cross-sectional view of theapplicator 340 taken along line 16-16 ofFIG. 15 . Air-egress features 350 can be elongate protrusions coupled to or integrally formed with thecup 342. Thecup 342 can include or be coupled to one or more thermal elements for controlling the temperature of a temperature-controlledsurface 377. -
FIG. 17 is a cross-sectional view of one of the air-egress features 350. The air-egress feature 350 has a rounded cross-sectional profile and can have a height H selected to maintain a gap between thesurface 377 and the subject's skin 390 (illustrated in phantom line). When a vacuum is applied to draw the subject'sskin 390 toward thesurface 377,air flow paths 396 can be maintained along the longitudinal length of the air-egress feature 350. In the illustrated embodiment,air flow paths 396 are located on opposite sides of the air-egress feature 350. In some embodiments, the height H can be about 1 mm to about 2 mm, and a width W can be about 1 mm to about 2 mm. Other dimensions can be selected. -
FIG. 18 is a cross-sectional view an air-egress feature 400 having a rounded triangular cross-sectional profile. The height H of thefeature 400 can be selected to maintain a gap between acup surface 402 and the subject's skin 404 (illustrated in phantom line). In some embodiments, the height H can be about 1 mm to about 3 mm, and a width W can be about 0.5 mm to about 2 mm. When a vacuum is applied to draw the subject'sskin 404 toward thesurface 402, air flow paths can be maintained along the longitudinal length of the air-egress feature 400. AlthoughFIG. 16 shows the applicator with protrusion air-egress features, applicators can include both channel airflow features and protrusion airflow features. -
FIG. 19 is a flowchart of amethod 500 for treating a subject in accordance with embodiments of the disclosed technology. Generally, an applicator can be applied to the treatment site and a vacuum can be drawn to pull tissue into a tissue-receiving cavity of the applicator. The subject's skin can be drawn toward a conductive surface of a temperature-controlled cup while air-egress features maintain airflow paths for removing air from the cavity. After the skin is in thermal contact with the temperature-controlled cup, heat is extracted from the subject's tissue to cool the tissue an amount sufficient to be biologically effective in selectively damaging and/or reducing the subject's subcutaneous lipid-rich cells. Details of themethod 500 are discussed in connection the embodiments shown inFIGS. 1-13 . - At
block 502, an applicator can be applied to the subject's skin. The applicator can be prepared for treatment by installing an appropriate contoured lip, liner, etc. for the treatment site. As discussed in connection withFIG. 2 , the sealing element 151 can be placed against the subject to form a seal suitable for maintaining a desired vacuum within the tissue-receivingcavity 170. - With reference to
FIG. 2 , the sealing element 151 can include acontoured lip 530 and abody 532. Thelip 530 can define an entrance and can be configured to sealingly engage, for example, the subject's skin. For example, thelip 530 can be configured for forming airtight seals with the subject's skin and can be made, in whole or in part, of silicon, rubber, soft plastic, or other suitable highly compliant materials. The mechanical properties, thermal properties, shape, and/or dimensions of the contouredlip 530 can be selected based on, for example, whether it contacts the subject's skin, liner assembly, a cryoprotectant gel pad, or the like. Thebody 532 is coupled to ahousing 544. As tissue is pulled through the entrance of the sealing element 151 and toward thecup 168, the flaredlip 530 can deflect outwardly. - Different sealing elements or cups can be installed on the
base unit 152 for treatment flexibility. The geometries of the contoured sealing element 151 andcup 168, which can be replaced, can be selected to conform to a contour of a cutaneous layer. The sides, waistline, and other features of the contoured heads can be selected to facilitate conformation of heads to the contours of individual target areas. For example, the shape of a typical human torso may vary between having a relative large radius of curvature, e.g., on the stomach or back, and having a relatively small radius of curvature, e.g., on the abdominal sides. Moreover, the size of a cup having an approximately consistent curvature may vary. The sealing elements may be fitted to individual lipid-rich cell deposits to achieve an approximately air-tight seal, achieve the vacuum pressure for drawing tissue into an interior cavity for treatment, maintain suction to hold the tissue, massage tissue (e.g., by altering pressure levels), and use little or no force to maintain contact between an applicator and a patient. - Components can be attached and detached in a plurality of combinations to achieve a desired contour for a treatment. Accordingly, a single base unit and/or umbilical cable may be combined with a set of interchangeable heads and/or cups to form a wide variety of contours for treating different lipid-rich cell deposits in a cost effective manner. Further, a practitioner performing the treatment can demonstrate their expertise to the patient by tailoring the applicator contour to the specific body parts being treated. In this manner, the patient understands that their treatment is customized to their body for better comfort and for better treatment results.
- Tissue-receiving cavities disclosed herein can have substantially U-shaped cross sections, V-shaped cross sections, or partially circular/elliptical cross-sections, as well as or other cross sections suitable for receiving tissue. Thus, thermal properties, shape, and/or configuration of the
cup 168 can be selected based on, for example, target treatment temperatures and/or volume of the targeted tissue. Embodiments of the base units for treating large volumes of tissue (e.g., adipose tissue along the abdomen, hips, buttock, etc.) can have a maximum depth equal to or less than about 2 cm, 5 cm, 10 cm, 15 cm, 20 cm, or 30 cm, for example. Embodiments of the base units for treating small volumes (e.g., a small volume of submental tissue) can have a maximum depth equal to or less than about 0.5 cm, 2 cm, 2.5 cm, 3 cm, or 5 cm, for example. The maximum depth of the tissue-receivingcavity 170 can be selected based on, for example, the volume of targeted tissue, characteristics of the targeted tissue, and/or desired level of patient comfort. - At
block 504, a vacuum can be drawn while the sealing element 151 can be held against the subject. To draw the vacuum, the pressurization device 123 (FIG. 1 ) can operate to remove air from the tissue-receiving cavity 170 (FIG. 3 ) to urge tissue into theapplicator 102. The pressure level can be selected to partially or completely fill the tissue-receivingcavity 170 with tissue. If the vacuum level is too low, tissue will not be drawn adequately into thecavity 170. The vacuum level can be increased to reduce or eliminate gaps between the skin surface and the temperature-controlledsurface 174. If the vacuum level is too high, undesirable discomfort to the patient and/or tissue damage could occur. The vacuum level can be selected to comfortably pull the tissue into contact with the desired area of the applicator, and the skin and underlying tissue can be pulled away from the subject's body which can assist in cooling underlying tissue by, e.g., lengthening the distance between targeted subcutaneous fat and the muscle tissue. - In some treatments, tissue can be drawn into the tissue-receiving
cavity 170 such that substantially all of the skin surface within thecavity 170 overlies the temperature-controlledsurface 174. For example, 90%, 95%, 95%, or more of the surface area of the skin located in thecavity 170 can overlie the temperature-controlledsurface 174. The number and dimensions of the air-egress features 180 can be increased or decreased to achieve desired thermal contact for a particular vacuum level. After a sufficient amount of tissue fills most or all of thecavity 170, the pressure level can be controlled to comfortably hold the tissue. - At
block 506, theapplicator 102 can extract heat from the tissue. Thecup 168 can be designed for rapid cooling and/or heating to, for example, reduce treatment times and/or produce generally flat temperature profiles over the heat-exchangingsurface 174 or a portion thereof. Because the subject's body heat can be rapidly conducted to thecup 168, the cooled skin can be kept at a generally flat temperature profile (e.g., ±3° C. of a target temperature) even though regions of the skin, or underlying tissue, may experience different amounts of blood flow. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells can be injured selectively while maintaining the non-lipid-rich cells (e.g., non-lipid-rich cells in the dermis and epidermis). Accordingly, subcutaneous lipid-rich cells in a subcutaneous layer can be cooled an amount sufficient to be biologically effective in affecting (e.g., damaging and/or reducing) such lipid-rich cells without affecting non-target cells to the same or greater extent. During cooling/heating, the tissue can fill substantially theentire cavity 170. In various embodiments, the air-egress features 180 can maintain airflow paths extending to the peripheral portion of thecup 168 such that the tissue occupies at least 80%, 90%, 92.5%, or 95% of the volume of thecavity 170. Accordingly, the subject's tissue can substantially fill an entire volume of thecavity 170. In one application, the subject's tissue fills 90% or more of the volume of thecavity 170. - The temperature-controlled
surface 174 can thermally contact an area of the subject's skin equal to or less than about 20 cm2, 40 cm2, 80 cm2, 100 cm2, 140 cm2, 160 cm2, 180 cm2, 200 cm2, 300 cm2, 500 cm2, or other suitable area. For example, the temperature-controlled surface area can be, for example, equal to or less than 20 cm2, 40 cm2, 80 cm2, 100 cm2, 140 cm2, 160 cm2, 180 cm2, 200 cm2, 300 cm2, or another suitable area. The temperature-controlledconductive surface 174 can be cooled to a temperature equal to or less than a selected temperature (e.g., 5° C., 0° C., −2° C., −5° C., −7° C., −10° C., −15° C., −20° C., −25° C., etc.) to cool most of the skin surface of the retained tissue. In one embodiment, most of a heat-exchanging surface 161 can be cooled to a temperature equal to or less than about 0° C., −2° C., −5° C., −10° C., or −15° C. - In contrast to invasive procedures in which coolant is injected directly into targeted tissue, the smooth temperature-controlled surface 174 (
FIG. 7 ) can conductively cool tissue to produce a desired temperature in target tissue without bruising, pain, or other problems caused by injections and perfusion of injected fluid. For example, perfusion of injected fluid can affect the thermal characteristics of the treatment site and result in undesired temperature profiles. As such, the non-invasive conductive cooling provided by theapplicator 102 can be more accurate than invasive procedures that rely on injecting fluids. Targeted tissue can be cooled from about −20° C. to about 10° C., from about 0° C. to about 20° C., from about −15° C. to about 5° C., from about −5° C. to about 15° C., or from about −10° C. to about 0° C. In one embodiment, liner can be kept at a temperature less than about 0° C. to extract heat from subcutaneous lipid-rich cells such that those cells are selectively reduced or damaged. - Although the illustrated
applicator 102 ofFIG. 1 is positioned along the hips, applicators can also be positioned to treat tissue at the thighs, buttock, abdomen, submandibular region, neck region, or other target regions. Applicators can reduce localized adipose tissue along the abdomen, hips, submental region, or the like. In procedures for reducing a double chin, the applicator can be sized and then aligned with and placed generally at the submental region (i.e., the submental triangle). It will be appreciated that the applicators disclosed herein can be placed at other locations along the patient's body and the orientation of the applicator can be selected to facilitate a relatively close fit. - Other elements, materials, components (e.g., gel pads, absorbents, etc.) can be located between the skin and the applicators. U.S. Pub. No. 2007/0255362 and U.S. Patent Publication No. 2008/0077201 and U.S. application Ser. No. 14/610,807 disclose components, materials (e.g., coupling gels, cryoprotectants, compositions, etc.), and elements (e.g., coupling devices, liners/protective sleeves, absorbents, etc.) that can be placed between the skin and the applicator. The control module 106 (
FIG. 1 ) can automatically perform various acts. For example, upon installation of the head, thecontrol module 106 can automatically select a pressurization level suitable for drawing the liner into the base unit. Once the liner has been applied to the conductive cup, thecontrol module 106 can notify a user to, for example, inspect the liner, apply the applicator, or perform another task. The control module 106 (FIG. 1 ) can then command thepressurization device 123 to draw tissue into theapplicator 102. Thecontrol module 106 can notify the operator that theapplicator 102 is ready for treatment based on sensor reading. The operator can inspect theapplicator 102 and can begin treatment using thecontrol module 106. - It will be appreciated that while a region of the body has been cooled or heated to the target temperature, in actuality that region of the body may be close but not equal to the target temperature, e.g., because of the body's natural heating and cooling variations. Thus, although the
applicator 102 may attempt to heat or cool the target tissue to the target temperature or to provide a target heat flux, sensors 512 (FIGS. 4 ) may measure a sufficiently close temperature or heat flux. If the target temperature or heat flux has not been reached, operation of the cooling unit can be adjusted to change the heat flux to maintain the target temperature or “set-point” selectively to affect targeted tissue. When the prescribed segment duration expires, the next treatment profile segment can be performed. -
Sensors 512 can be temperature sensors, such as thermistors, positioned to detect temperature changes associated with warm tissue being drawn into and/or located in thecup 168. A control module (e.g.,control module 106 ofFIG. 1 ) can interpret the detected temperature increase associated with skin contact and can monitor, for example, the depth of tissue draw, tissue, freezing, thawing, or the like. In some embodiments,sensors 512 can be adjacent to the air-egress features 180 and can measure heat flux and/or pressure (e.g., contact pressure) with the skin of the patient. In yet further embodiments, thesensors 512 can be tissue impedance sensors, contact sensors, or other sensors used to determine the presence of tissue and/or whether tissue has been adequately drawn into the applicator so as to completely fill thecavity 170 to achieve a suitable level of thermal contact, limit or reduce voids or gaps, and/or hold tissue while limiting or reducing, for example, pooling of blood, discomfort, and so forth. - Sensor feedback can be collected in real-time and used in concert with treatment administration to efficaciously target specific tissue. The sensor measurements can also indicate other changes or anomalies that can occur during treatment administration. For example, an increase in temperature detected by the
sensors 512 can indicate either a freezing event at the skin or movement of theapplicator 102. An operator can inspect the subject's skin and/orapplicator 102 in response to a detected increase in temperature. Methods and systems for collection of feedback data and monitoring of temperature measurements are described in commonly assigned U.S. Pat. No. 8,285,390. - The treatment procedures disclosed herein can also involve use of cryoprotectant between the applicator and skin. The cryoprotectant can be a freezing point temperature depressant that may additionally include a thickening agent, a pH buffer, a humectant, a surfactant, and/or other additives. The temperature depressant may include, for example, polypropylene glycol (PPG), polyethylene glycol (PEG), dimethyl sulfoxide (DMSO), or other suitable alcohol compounds. In a particular embodiment, a cryoprotectant may include about 30% polypropylene glycol, about 30% glycerin (a humectant), and about 40% ethanol. In another embodiment, a cryoprotectant may include about 40% propylene glycol, about 0.8% hydroxyethylcellulose (a thickening agent), and about 59.2% water. In a further embodiment, a cryoprotectant may include about 50% polypropylene glycol, about 40% glycerin, and about 10% ethanol. Other cryoprotectants or agents can also be used and can be carried by a cotton pad or other element. U.S. application Ser. No. 14/610,807 is incorporated by reference in its entirety and discloses various compositions that can be used as cryoprotectants.
- It may take a few days to a few weeks, or longer, for the adipocytes to break down and be absorbed. A significant decrease in fat thickness may occur gradually over 1-3 months following treatment. Additional treatments can be performed until a desired result is achieved. For example, one or more treatments can be performed to substantially reduce (e.g., visibly reduce) or eliminate targeted tissue.
- During a treatment session, contoured heads, line assemblies, and other components can be quickly replaced any number of times. Other types of heads, contours, and engagement features can be attached to the
base unit 103. For example, contour elements disclosed in U.S. Publication 2010/0280582 can be used with thebase unit 103, which may have magnets or other alignment features and can provide desired sealing, including generally air-tight seal cincturing. U.S. Publication 2010/0280582 is incorporated by reference in its entirety. - Liners can be used and can include films, sheets, sleeves, or other components suitable for defining an interface surface to prevent direct contact between surfaces of the applicator and the subject's skin to reduce the likelihood of cross-contamination between patients, minimize cleaning requirements, etc. Exemplary protective liners can be sheets, sleeves, or other components constructed from latex, rubber, nylon, Kevlar®, or other substantially impermeable or semi-permeable material. For example, the liner can be a latex sheet coated with a pressure-sensitive adhesive. Further details regarding a patient protection device may be found in U.S. Patent Publication No. 2008/0077201. In some procedures, a liner or protective sleeve may be positioned between an absorbent and the applicator to shield the applicator and to provide a sanitary barrier that is, in some embodiments, inexpensive and thus disposable. After installing the liner assembly, gel traps, filters, valves, and other components can be installed to keep applied substances (e.g., coupling gels, cryoprotectants, etc.) from being sucked into and/or through the
base unit 103. In some embodiments, the liner 119 is configured to allow air to pass when drawing a vacuum and to restrict passage of a gel. - Embodiments according to the present disclosure may provide one or more additional advantages. For example, the size, shapes, and other physical properties of the base units, liner assemblies, sealing members, gaskets, contoured heads, and components of the applicators may be selected to accommodate heat removal sources (e.g., thermal devices, cooling devices, etc.) that may be used/reused with individual applicators. Modifications to flexible portions of individual applicators may enable the use of a standard heat removal source and accommodate different contours of individual cutaneous layers. In turn, this may make it possible to reuse base units, sealing members, liners, and/or contoured heads for different treatments. The rigid portions of the applicators (e.g., edge or mounting region of base unit), which are relatively stiff with respect to the flexible portions, provide an attachment point for heat removal sources that may resist bowing into the interior cavity and possibly separating from the heat removal sources when a vacuum (including a partial vacuum) is drawn into the applicators. Disposing temperature sensors inside the applicators, along temperature-controlled surfaces, within contoured heads, along liner assemblies, etc. may more accurately measure the temperature of skin surface, subcutaneous tissue, and so forth. The flexible portions of the applicator (e.g., flexible mouth) also allows some compliance to different subject body contours or geometries.
-
FIG. 20 is a schematic block diagram illustrating subcomponents of a controller in accordance with an embodiment of the disclosure. The controller can be part of the control module 106 (FIG. 1 ). For example, a controller 790 can be thecontroller 114 ofFIG. 1 or can be incorporated into the applicators or other components disclosed herein. The controller 790 can include acomputing device 800 having aprocessor 801, amemory 802, input/output devices 803, and/or subsystems and other components 804. Thecomputing device 800 can perform any of a wide variety of computing processing, storage, sensing, imaging, and/or other functions. Components of thecomputing device 800 may be housed in a single unit or distributed over multiple, interconnected units (e.g., though a communications network). The components of thecomputing device 800 can accordingly include local and/or remote memory storage devices and any of a wide variety of computer-readable media. - As illustrated in
FIG. 20 , theprocessor 801 can include a plurality offunctional modules 806, such as software modules, for execution by theprocessor 801. The various implementations of source code (i.e., in a conventional programming language) can be stored on a computer-readable storage medium or can be embodied on a transmission medium in a carrier wave. Themodules 806 of the processor can include aninput module 808, adatabase module 810, aprocess module 812, anoutput module 814, and, optionally, adisplay module 816. - In operation, the
input module 808 accepts anoperator input 819 via the one or more input devices, and communicates the accepted information or selections to other components for further processing. Thedatabase module 810 organizes records, including patient records, treatment data sets, treatment profiles and operating records and other operator activities, and facilitates storing and retrieving of these records to and from a data storage device (e.g.,internal memory 802, an external database, etc.). Any type of database organization can be utilized, including a flat file system, hierarchical database, relational database, distributed database, etc. - In the illustrated example, the
process module 812 can generate control variables based onsensor readings 818 from sensors and/or other data sources, and theoutput module 814 can communicate operator input to external computing devices and control variables to the controller. Thedisplay module 816 can be configured to convert and transmit processing parameters,sensor readings 818, output signals 820, input data, treatment profiles and prescribed operational parameters through one or more connected display devices, such as a display screen 118 (FIG. 1 ), printer, speaker system, etc. - In various embodiments, the
processor 801 can be a standard central processing unit or a secure processor. Secure processors can be special-purpose processors (e.g., reduced instruction set processor) that can withstand sophisticated attacks that attempt to extract data or programming logic. The secure processors may not have debugging pins that enable an external debugger to monitor the secure processor's execution or registers. In other embodiments, the system may employ a secure field programmable gate array, a smartcard, or other secure devices. - The
memory 802 can be standard memory, secure memory, or a combination of both memory types. By employing a secure processor and/or secure memory, the system can ensure that data and instructions are both highly secure and sensitive operations such as decryption are shielded from observation. In various embodiments, thememory 802 can be flash memory, secure serial EEPROM, secure field programmable gate array, or secure application-specific integrated circuit. Thememory 802 can store instructions for causing the applicators to cool/heat tissue, pressurization devices to draw a vacuum, or other acts disclosed herein. Vacuum levels can be selected based on characteristics of the applicator, airflow features, and/or treatment site. In one embodiment, thememory 802 stores instructions executable by the controller 790 for the thermal device to sufficiently cool conductive cups disclosed herein such that vacuum applicators non-invasively cool the subcutaneous lipid-rich cells to a desired temperature, such as a temperature less than about 0° C. In some embodiments, thememory 802 can contain liner installation or draw instructions for causing the liner to drawn into a, tissue draw instructions for causing the applicator to draw tissue into the applicator, treatment instructions for heating/cooling tissue, tissue release instructions for releasing tissue, and instructions for monitoring treatment. For example, the liner installation or draw instructions can be executed by the controller 790 to command thepressurization device 123 to suck the liner against a conductive surface of the conductive cup. - The input/
output device 118 can include, without limitation, a touchscreen, a keyboard, a mouse, a stylus, a push button, a switch, a potentiometer, a scanner, an audio component such as a microphone, or any other device suitable for accepting user input and can also include one or more video monitor, a medium reader, an audio device such as a speaker, any combination thereof, and any other device or devices suitable for providing user feedback. For example, if an applicator moves an undesirable amount during a treatment session, the input/output device 803 can alert the subject and/or operator via an audible alarm. The input/output device 118 can be a touch screen that functions as both an input device and an output device. The control panel can include visual indicator devices or controls (e.g., indicator lights, numerical displays, etc.) and/or audio indicator devices or controls. The control panel may be a component separate from the input/output device 118 and/or output device 120, may be integrated applicators, may be partially integrated with one or more of the devices, may be in another location, and so on. In alternative embodiments, thecontroller 114 can be contained in, attached to, or integrated with the applicators. Further details with respect to components and/or operation of applicators, control modules (e.g., treatment units), and other components may be found in commonly-assigned U.S. Patent Publication No. 2008/0287839. - The controller 790 can include any processor, Programmable Logic Controller, Distributed Control System, secure processor, and the like. A secure processor can be implemented as an integrated circuit with access-controlled physical interfaces; tamper resistant containment; means of detecting and responding to physical tampering; secure storage; and shielded execution of computer-executable instructions. Some secure processors also provide cryptographic accelerator circuitry. Suitable computing environments and other computing devices and user interfaces are described in commonly assigned U.S. Pat. No. 8,275,442, entitled “TREATMENT PLANNING SYSTEMS AND METHODS FOR BODY CONTOURING APPLICATIONS,” which is incorporated herein in its entirety by reference.
- The treatment systems, applicators, and methods of treatment can be used reduce adipose tissue or treat subcutaneous tissue, acne, hyperhidrosis, wrinkles, structures (e.g., structures in the epidermis, dermis, subcutaneous fat, muscle, nerve tissue, etc.), and so on. Systems, components, and techniques for reducing subcutaneous adipose tissue are disclosed in U.S. Pat. No. 7,367,341 titled “METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al., U.S. Patent Publication No. US 2005/0251120 titled “METHODS AND DEVICES FOR DETECTION AND CONTROL OF SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al., and U.S. Patent Publication No. 2007/0255362 titled “CRYOPROTECTANT FOR USE WITH A TREATMENT DEVICE FOR IMPROVED COOLING OF SUBCUTANEOUS LIPID-RICH CELLS,” the disclosures of which are incorporated herein by reference in their entireties. Vacuum applicators can stretch, stress, and/or mechanically alter skin to increase damage and fibrosis in the skin, affect glands, control freeze events (including initiating freeze events), etc. Methods for cooling tissue and related devices and systems in accordance with embodiments of the present invention can at least partially address one or more problems associated with conventional technologies as discussed above and/or other problems whether or not such problems are stated herein.
- Unless the context clearly requires otherwise, throughout the description, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in a sense of “including, but not limited to.” Words using the singular or plural number also include the plural or singular number, respectively. Use of the word “or” in reference to a list of two or more items covers all of the following interpretations of the word: any of the items in the list, all of the items in the list, and any combination of the items in the list. Furthermore, the phrase “at least one of A, B, and C, etc.” is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.).
- Any patents, applications and other references, including any that may be listed in accompanying filing papers, are incorporated herein by reference. Aspects of the described technology can be modified, if necessary, to employ the systems, functions, and concepts of the various references described above to provide yet further embodiments. These and other changes can be made in light of the above Detailed Description. While the above description details certain embodiments and describes the best mode contemplated, no matter how detailed, various changes can be made. Implementation details may vary considerably, while still being encompassed by the technology disclosed herein. As noted above, particular terminology used when describing certain features or aspects of the technology should not be taken to imply that the terminology is being redefined herein to be restricted to any specific characteristics, features, or aspects of the technology with which that terminology is associated.
Claims (20)
1. An apparatus for treating a human subject, comprising:
an applicator configured to cool the subject's skin and including
a cup defining a tissue-receiving cavity and including a temperature-controlled surface,
at least one vacuum port, and
air-egress features extending along the temperature-controlled surface to provide airflow paths to the at least one vacuum port for removing air between the subject's skin and the cup while the at least one vacuum port provides a vacuum to draw the subject's tissue toward the temperature-controlled surface, and wherein the air-egress features include channels and/or ridges.
2. The apparatus of claim 1 , wherein the cup and vacuum port are configured such that when a vacuum is applied the subject's tissue substantially fills an entire volume of the tissue-receiving cavity except for small gaps created by the air-egress features formed on a surface of the cup.
3. The apparatus of claim 1 , further comprising:
a pressurization device in fluid communication with the tissue-receiving cavity via the at least one vacuum port; and
a controller programmed to cause the pressurization device to operate to hold the subject's skin in thermal contact with the temperature-controlled surface while the cup conductively cools the tissue.
4. The apparatus of claim 3 , wherein regions of the temperature-controlled surface are located between adjacent air-egress features, and wherein the controller is programmed to cause the pressurization device to provide a sufficient vacuum to keep substantially all of each region in thermal contact with the subject's skin.
5. The apparatus of claim 1 , further comprising a pressurization device configured to draw a sufficient vacuum to eliminate air gaps between the subject's tissue and the temperature-controlled surface such that substantially no air gaps impair non-invasively cooling of the subject's subcutaneous lipid-rich cells to a temperature lower than about 0° C.
6. The apparatus of claim 1 , wherein the air-egress features are configured to maintain airflow paths to the at least one vacuum port when the subject's tissue is operably received within the tissue-receiving cavity and a 12 inches Hg vacuum is drawn.
7. The apparatus of claim 1 , wherein the cup is configured to non-invasively cool the subject's tissue, which is held in the tissue-receiving cavity, an amount sufficient to be biologically effective in damaging and/or reducing subcutaneous lipid-rich cells in the subject's tissue.
8. The apparatus of claim 1 , wherein most of the temperature-controlled surface is located directly between the air-egress features.
9. The apparatus of claim 1 , wherein a ratio of a sum of areas of regions of the temperature-controlled surface located directly between air-egress features to a total area of the temperature-controlled surface is greater than 0.5.
10. The apparatus of claim 1 , wherein the air-egress features extend across most of a width and extend across most of a length of the tissue-receiving cavity.
11. The apparatus of claim 1 , wherein the air-egress features are a network of elongate ridges and/or channels.
12. The apparatus of claim 1 , wherein each of the air-egress features includes a first end spaced apart from a mouth of the cup, a second end positioned proximate the at least one vacuum port, and a main portion extending between the first and second ends and being dimensioned to allow thermal contact to be maintained between the subject's skin and an area of the temperature-controlled surface surrounding the first end and the main portion.
13. The apparatus of claim 1 , wherein the air-egress features spread outwardly from a central region of the cup.
14. The apparatus of claim 1 , wherein each of the air-egress features has a height of about 1 mm to 2 mm, a width about 1 mm to 2 mm, and a length of at least 10 mm.
15. The apparatus of claim 1 , wherein the at least one vacuum port includes a plurality of vacuum ports each located at an end of a respective one of the air-egress features.
16. An apparatus for treating a human subject, comprising:
an applicator configured to cool the subject's tissue and including
a cup having an interior surface at least partially defining a tissue-receiving cavity, wherein at least a portion of the interior surface is temperature-controlled, and
a vacuum port extending through a central portion of the interior surface,
wherein a topography of the interior surface is configured to form airflow paths extending between the vacuum port and a peripheral portion of the interior surface when the subject's tissue is operably received within the cavity, the cup and vacuum port being configured such that when a vacuum is applied the subject's tissue substantially fills an entire volume of the cup except for small gaps created by air-egress features formed on a surface of the cup.
17. The apparatus of claim 16 , further comprising airflow elements positioned along the interior surface and extending between the vacuum port and the peripheral portion and having heights sufficient to maintain the airflow paths when the subject's skin is drawn against most of the interior surface.
18. A method for treating a human subject, comprising:
applying an applicator to the subject's skin;
drawing a vacuum in a tissue-receiving cavity of the applicator to draw the subject's tissue toward a conductive surface of a temperature-controlled cup of the applicator to substantially fill an entire volume of the cup while air-egress features facing the tissue-receiving cavity maintain egress airflow paths for removing air located between the subject's skin and the temperature-controlled cup; and
extracting heat from the subject's tissue via the conductive surface to cool the tissue an amount sufficient to be biologically effective in selectively damaging and/or reducing the subject's subcutaneous lipid-rich cells.
19. The method of claim 18 , further comprising maintaining a sufficient vacuum to hold the subject's skin in thermal contact with substantially all of the conductive surface facing the tissue-receiving cavity while extracting heat from the subject's tissue.
20. The method of claim 18 , further comprising drawing tissue into the tissue-receiving cavity such that substantially all of the subject's skin located within the tissue-receiving cavity is in thermal contact with the conductive surface.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/350,972 US20220039818A1 (en) | 2017-04-26 | 2021-06-17 | Shallow surface cryotherapy applicators and related technology |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762490421P | 2017-04-26 | 2017-04-26 | |
US15/962,811 US11076879B2 (en) | 2017-04-26 | 2018-04-25 | Shallow surface cryotherapy applicators and related technology |
US17/350,972 US20220039818A1 (en) | 2017-04-26 | 2021-06-17 | Shallow surface cryotherapy applicators and related technology |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/962,811 Continuation US11076879B2 (en) | 2017-04-26 | 2018-04-25 | Shallow surface cryotherapy applicators and related technology |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220039818A1 true US20220039818A1 (en) | 2022-02-10 |
Family
ID=63916348
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/962,811 Active 2039-06-19 US11076879B2 (en) | 2017-04-26 | 2018-04-25 | Shallow surface cryotherapy applicators and related technology |
US17/350,972 Pending US20220039818A1 (en) | 2017-04-26 | 2021-06-17 | Shallow surface cryotherapy applicators and related technology |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/962,811 Active 2039-06-19 US11076879B2 (en) | 2017-04-26 | 2018-04-25 | Shallow surface cryotherapy applicators and related technology |
Country Status (1)
Country | Link |
---|---|
US (2) | US11076879B2 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8192474B2 (en) | 2006-09-26 | 2012-06-05 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US9132031B2 (en) | 2006-09-26 | 2015-09-15 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US20080287839A1 (en) | 2007-05-18 | 2008-11-20 | Juniper Medical, Inc. | Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator |
EP2182898B1 (en) | 2007-08-21 | 2018-10-03 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
CN102596116B (en) | 2009-04-30 | 2015-01-14 | 斯尔替克美学股份有限公司 | Device, system and method of removing heat from subcutaneous lipid-rich cells |
DE102012013534B3 (en) | 2012-07-05 | 2013-09-19 | Tobias Sokolowski | Apparatus for repetitive nerve stimulation for the degradation of adipose tissue by means of inductive magnetic fields |
WO2015117026A2 (en) | 2014-01-31 | 2015-08-06 | Zeltiq Aesthetics, Inc. | Treating systems and methods for treating cellulite and providing other treatments |
US10935174B2 (en) | 2014-08-19 | 2021-03-02 | Zeltiq Aesthetics, Inc. | Stress relief couplings for cryotherapy apparatuses |
US10568759B2 (en) | 2014-08-19 | 2020-02-25 | Zeltiq Aesthetics, Inc. | Treatment systems, small volume applicators, and methods for treating submental tissue |
US11491342B2 (en) | 2015-07-01 | 2022-11-08 | Btl Medical Solutions A.S. | Magnetic stimulation methods and devices for therapeutic treatments |
US10695575B1 (en) | 2016-05-10 | 2020-06-30 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US10695576B2 (en) | 2015-07-01 | 2020-06-30 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US10821295B1 (en) | 2015-07-01 | 2020-11-03 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US10471269B1 (en) | 2015-07-01 | 2019-11-12 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US11266850B2 (en) | 2015-07-01 | 2022-03-08 | Btl Healthcare Technologies A.S. | High power time varying magnetic field therapy |
US10709894B2 (en) | 2015-07-01 | 2020-07-14 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US20180001107A1 (en) | 2016-07-01 | 2018-01-04 | Btl Holdings Limited | Aesthetic method of biological structure treatment by magnetic field |
US10478633B2 (en) | 2015-07-01 | 2019-11-19 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US11154418B2 (en) | 2015-10-19 | 2021-10-26 | Zeltiq Aesthetics, Inc. | Vascular treatment systems, cooling devices, and methods for cooling vascular structures |
US11253717B2 (en) | 2015-10-29 | 2022-02-22 | Btl Healthcare Technologies A.S. | Aesthetic method of biological structure treatment by magnetic field |
US11464993B2 (en) | 2016-05-03 | 2022-10-11 | Btl Healthcare Technologies A.S. | Device including RF source of energy and vacuum system |
US11247039B2 (en) | 2016-05-03 | 2022-02-15 | Btl Healthcare Technologies A.S. | Device including RF source of energy and vacuum system |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
US10709895B2 (en) | 2016-05-10 | 2020-07-14 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US10682297B2 (en) | 2016-05-10 | 2020-06-16 | Zeltiq Aesthetics, Inc. | Liposomes, emulsions, and methods for cryotherapy |
US10555831B2 (en) | 2016-05-10 | 2020-02-11 | Zeltiq Aesthetics, Inc. | Hydrogel substances and methods of cryotherapy |
US11534619B2 (en) | 2016-05-10 | 2022-12-27 | Btl Medical Solutions A.S. | Aesthetic method of biological structure treatment by magnetic field |
US10583287B2 (en) | 2016-05-23 | 2020-03-10 | Btl Medical Technologies S.R.O. | Systems and methods for tissue treatment |
US10556122B1 (en) | 2016-07-01 | 2020-02-11 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US11076879B2 (en) | 2017-04-26 | 2021-08-03 | Zeltiq Aesthetics, Inc. | Shallow surface cryotherapy applicators and related technology |
US10492844B2 (en) * | 2017-05-25 | 2019-12-03 | Channel Medsystems, Inc. | Tethered system for cryogenic treatment |
PL4066887T3 (en) | 2019-04-11 | 2024-03-04 | Btl Medical Solutions A.S. | Devices for aesthetic treatment of biological structures by radiofrequency and magnetic energy |
US11779364B2 (en) | 2019-11-27 | 2023-10-10 | Neuravi Limited | Actuated expandable mouth thrombectomy catheter |
US11839725B2 (en) | 2019-11-27 | 2023-12-12 | Neuravi Limited | Clot retrieval device with outer sheath and inner catheter |
US11944327B2 (en) | 2020-03-05 | 2024-04-02 | Neuravi Limited | Expandable mouth aspirating clot retrieval catheter |
US11883043B2 (en) | 2020-03-31 | 2024-01-30 | DePuy Synthes Products, Inc. | Catheter funnel extension |
BR112022022112A2 (en) | 2020-05-04 | 2022-12-13 | Btl Healthcare Tech A S | DEVICE FOR UNASSISTED PATIENT TREATMENT |
US11878167B2 (en) | 2020-05-04 | 2024-01-23 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
CN113855374A (en) * | 2020-06-30 | 2021-12-31 | 微创医美科技(嘉兴)有限公司 | Fat-reducing therapeutic device and freezing fat-reducing instrument |
US20220047315A1 (en) | 2020-08-14 | 2022-02-17 | Zeltiq Aesthetics, Inc. | Multi-applicator system and method for body contouring |
US11872354B2 (en) | 2021-02-24 | 2024-01-16 | Neuravi Limited | Flexible catheter shaft frame with seam |
US11937839B2 (en) | 2021-09-28 | 2024-03-26 | Neuravi Limited | Catheter with electrically actuated expandable mouth |
US11896816B2 (en) | 2021-11-03 | 2024-02-13 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150223975A1 (en) * | 2014-02-12 | 2015-08-13 | The General Hospital Corporation | Method and apparatus for affecting pigmentation of tissue |
Family Cites Families (653)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1681806A (en) | 1928-08-21 | Ments | ||
GB387960A (en) | 1932-09-17 | 1933-02-16 | William Hipon Horsfield | Electro-therapeutic massaging appliance |
FR854937A (en) | 1939-05-19 | 1940-04-27 | Suction massage device | |
US2516491A (en) | 1945-10-08 | 1950-07-25 | Henry A Swastek | Massage and shampoo device |
US2521780A (en) | 1947-06-12 | 1950-09-12 | Bertha A Dodd | Cushion or receptacle |
US2889810A (en) | 1951-05-02 | 1959-06-09 | Parker Pen Co | Base for fountain pen desk set |
US2726658A (en) | 1953-04-27 | 1955-12-13 | Donald E Chessey | Therapeutic cooling devices for domestic and hospital use |
NL177982B (en) | 1953-04-29 | Siemens Ag | INFUSION DEVICE. | |
US2766619A (en) | 1953-06-26 | 1956-10-16 | Tribus Myron | Ice detecting apparatus |
CH333982A (en) | 1954-06-11 | 1958-11-15 | Usag Ultraschall Ag | Ultrasonic irradiation device |
US3093135A (en) | 1962-01-29 | 1963-06-11 | Max L Hirschhorn | Cooled surgical instrument |
US3132688A (en) | 1963-04-08 | 1964-05-12 | Welville B Nowak | Electronic cold and/or hot compress device |
US3282267A (en) | 1964-05-05 | 1966-11-01 | Eidus William | Thermoelectric hypothermia instrument |
US3502080A (en) | 1965-06-28 | 1970-03-24 | Max L Hirschhorn | Thermoelectrically cooled surgical instrument |
US3341230A (en) | 1965-10-23 | 1967-09-12 | Swivelier Company Inc | Swivel unit |
US3591645A (en) | 1968-05-20 | 1971-07-06 | Gulf Research Development Co | Process for preparing a halogenated aromatic |
US3566871A (en) | 1968-06-11 | 1971-03-02 | American Cyanamid Co | Hydrophilic medical sponge and method of using same |
FR1595285A (en) | 1968-12-18 | 1970-06-08 | ||
US3703897A (en) | 1969-10-09 | 1972-11-28 | Kendall & Co | Hydrophobic non-adherent wound dressing |
US3587577A (en) | 1970-05-09 | 1971-06-28 | Oleg Alexandrovich Smirnov | Device for applying selective and general hypothermy to and reheating of human body through the common integuments thereof |
US3710784A (en) | 1972-04-03 | 1973-01-16 | C Taylor | Massaging device |
US4002221A (en) | 1972-09-19 | 1977-01-11 | Gilbert Buchalter | Method of transmitting ultrasonic impulses to surface using transducer coupling agent |
US3827436A (en) | 1972-11-10 | 1974-08-06 | Frigitronics Of Conn Inc | Multipurpose cryosurgical probe |
US3786814A (en) | 1972-12-15 | 1974-01-22 | T Armao | Method of preventing cryoadhesion of cryosurgical instruments and cryosurgical instruments |
US3942519A (en) | 1972-12-26 | 1976-03-09 | Ultrasonic Systems, Inc. | Method of ultrasonic cryogenic cataract removal |
DE2343910C3 (en) | 1973-08-31 | 1979-02-15 | Draegerwerk Ag, 2400 Luebeck | Cryomedical facility |
US4269068A (en) | 1974-02-21 | 1981-05-26 | Rockwell International Corporation | Ultrasonic couplant compositions and method for employing same |
SU532976A1 (en) | 1974-05-05 | 1978-11-05 | Киевский Государственный Институт Усовершенстовования Врачей Министерства Здравоохранения Ссср | Apparatus for local refrigeration of tissue |
US3993053A (en) | 1974-08-05 | 1976-11-23 | Murray Grossan | Pulsating massage system |
US3986385A (en) | 1974-08-05 | 1976-10-19 | Rosemount Engineering Company Limited | Apparatus for determining the freezing point of a liquid |
JPS5417360B2 (en) | 1974-08-15 | 1979-06-29 | ||
US4008910A (en) | 1975-05-16 | 1977-02-22 | Roche Thomas F | Universal electrical swivel |
US4026299A (en) | 1975-09-26 | 1977-05-31 | Vari-Temp Manufacturing Co. | Cooling and heating apparatus |
US4202336A (en) | 1976-05-14 | 1980-05-13 | Erbe Elektromedizin Kg | Cauterizing probes for cryosurgery |
US4140130A (en) | 1977-05-31 | 1979-02-20 | Storm Iii Frederick K | Electrode structure for radio frequency localized heating of tumor bearing tissue |
US4149529A (en) | 1977-09-16 | 1979-04-17 | Jobst Institute, Inc. | Portable thermo-hydraulic physiotherapy device |
US4178429A (en) | 1978-11-17 | 1979-12-11 | Scheffer Karl D | Catalyst for curing resins |
DE2851602A1 (en) | 1978-11-29 | 1980-06-12 | Messerschmitt Boelkow Blohm | Medical cooling device for localised inflammation - with Peltier element between heat conductive block and cooling pad applied to patient's skin |
US4381009A (en) | 1980-01-28 | 1983-04-26 | Bon F Del | Hand-held device for the local heat-treatment of the skin |
US4428368A (en) | 1980-09-29 | 1984-01-31 | Masakatsu Torii | Massage device |
US4470263A (en) | 1980-10-14 | 1984-09-11 | Kurt Lehovec | Peltier-cooled garment |
US4396011A (en) | 1981-01-09 | 1983-08-02 | Clairol Incorporated | Heating pad |
US4459854A (en) | 1981-07-24 | 1984-07-17 | National Research Development Corporation | Ultrasonic transducer coupling member |
US4528979A (en) | 1982-03-18 | 1985-07-16 | Kievsky Nauchno-Issledovatelsky Institut Otolaringologii Imeni Professora A.S. Kolomiiobenka | Cryo-ultrasonic surgical instrument |
JPS58187454A (en) | 1982-04-27 | 1983-11-01 | Nippon Kayaku Co Ltd | Anthraquinone compound |
US4555313A (en) | 1982-10-21 | 1985-11-26 | The United States Of America As Represented By The United States Department Of Energy | Method of forming a continuous polymeric skin on a cellular foam material |
US4548212A (en) | 1982-10-29 | 1985-10-22 | Leung Frank K | Apparatus for thermographic examinations |
US4483341A (en) | 1982-12-09 | 1984-11-20 | Atlantic Richfield Company | Therapeutic hypothermia instrument |
US4531524A (en) | 1982-12-27 | 1985-07-30 | Rdm International, Inc. | Circuit apparatus and method for electrothermal treatment of cancer eye |
US4644955A (en) | 1982-12-27 | 1987-02-24 | Rdm International, Inc. | Circuit apparatus and method for electrothermal treatment of cancer eye |
US4961422A (en) | 1983-01-21 | 1990-10-09 | Marchosky J Alexander | Method and apparatus for volumetric interstitial conductive hyperthermia |
DE3308553C2 (en) | 1983-03-10 | 1986-04-10 | Udo Prof. Dr.med. 4130 Moers Smidt | Means for reducing the human body weight |
US4614191A (en) | 1983-09-02 | 1986-09-30 | Perler Robert F | Skin-cooling probe |
JPS6094113A (en) | 1983-10-26 | 1985-05-27 | Kobe Steel Ltd | Mobile dust collector |
EP0160703B1 (en) | 1983-10-26 | 1990-05-02 | Nihonkenkozoshinkenkyukai Co. Ltd. | Magnetic field generating therapeutic appliance |
US5158070A (en) | 1983-12-14 | 1992-10-27 | Edap International, S.A. | Method for the localized destruction of soft structures using negative pressure elastic waves |
EP0168483A4 (en) | 1984-01-18 | 1987-01-20 | Bailey David F | Multi-layer disposable medical thermal blanket. |
US4603076A (en) | 1985-03-04 | 1986-07-29 | Norwood Industries, Inc. | Hydrophilic foam |
US4869250A (en) | 1985-03-07 | 1989-09-26 | Thermacor Technology, Inc. | Localized cooling apparatus |
US4664110A (en) | 1985-03-18 | 1987-05-12 | University Of Southern California | Controlled rate freezing for cryorefractive surgery |
US4585002A (en) | 1985-04-22 | 1986-04-29 | Igor Kissin | Method and apparatus for treatment of pain by frequently alternating temperature stimulation |
JPS6282977A (en) | 1985-10-07 | 1987-04-16 | オムロン株式会社 | Heating/cooling low frequency medical treatment apparatus |
US4700701A (en) | 1985-10-23 | 1987-10-20 | Montaldi David H | Sterilization method and apparatus |
JPH0765230B2 (en) | 1986-09-19 | 1995-07-12 | 三菱マテリアル株式会社 | Method for forming porous layer on metal surface |
EP0270553B1 (en) | 1986-05-16 | 1991-08-21 | TERM-ac S.A. | Therapeutic device including a mass of a thermally active material |
SU1563684A1 (en) | 1986-05-26 | 1990-05-15 | Томский государственный медицинский институт | Cryosurgical scalpel |
GB8620227D0 (en) | 1986-08-20 | 1986-10-01 | Smith & Nephew Ass | Wound dressing |
US4880564A (en) | 1986-09-29 | 1989-11-14 | Ciba-Geigy Corporation | Antifoams for aqueous systems and their use |
US4741338A (en) | 1986-10-06 | 1988-05-03 | Toshiaki Miyamae | Thermoelectric physical remedy apparatus |
US5018521A (en) | 1986-10-24 | 1991-05-28 | Campbell William P | Method of and apparatus for increased transfer of heat into or out of the body |
US4764463A (en) | 1986-10-30 | 1988-08-16 | The University Of Tennessee Research Corporation | Platelet cyropreservation |
US4906463A (en) | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
CN86200604U (en) | 1987-01-10 | 1987-10-14 | Zhichang Yang | Apparatus for freezing freckle and treating some skin diseases with freezing |
US4962761A (en) | 1987-02-24 | 1990-10-16 | Golden Theodore A | Thermal bandage |
US4846176A (en) | 1987-02-24 | 1989-07-11 | Golden Theodore A | Thermal bandage |
GB8706141D0 (en) | 1987-03-16 | 1987-04-23 | Thorner D | Treatment of damaged limb |
US4935345A (en) | 1987-04-07 | 1990-06-19 | Arizona Board Of Regents | Implantable microelectronic biochemical sensor incorporating thin film thermopile |
US4802475A (en) | 1987-06-22 | 1989-02-07 | Weshahy Ahmed H A G | Methods and apparatus of applying intra-lesional cryotherapy |
US5084671A (en) | 1987-09-02 | 1992-01-28 | Tokyo Electron Limited | Electric probing-test machine having a cooling system |
US5143063A (en) | 1988-02-09 | 1992-09-01 | Fellner Donald G | Method of removing adipose tissue from the body |
JPH01223961A (en) | 1988-03-02 | 1989-09-07 | Kineshio:Kk | Method for improvement of muscle subcutaneous tissue and subcutaneous tissue activating device |
US5065752A (en) | 1988-03-29 | 1991-11-19 | Ferris Mfg. Co. | Hydrophilic foam compositions |
DK161260C (en) | 1988-05-06 | 1991-12-30 | Paul Verner Nielsen | flow measurement |
US4930317A (en) | 1988-05-20 | 1990-06-05 | Temperature Research Corporation | Apparatus for localized heat and cold therapy |
DE3821219C1 (en) | 1988-06-23 | 1989-08-24 | Phywe Systeme Gmbh, 3400 Goettingen, De | |
US5108390A (en) | 1988-11-14 | 1992-04-28 | Frigitronics, Inc. | Flexible cryoprobe |
US4905697A (en) | 1989-02-14 | 1990-03-06 | Cook Pacemaker Corporation | Temperature-controlled cardiac pacemaker responsive to body motion |
US5024650A (en) | 1989-02-15 | 1991-06-18 | Matsushita Electric Works, Ltd. | Stress dissolving refreshment system |
DE8905769U1 (en) | 1989-05-09 | 1989-07-13 | Schulte, Franz-Josef, Dipl.-Ing., 5787 Olsberg, De | |
US5200170A (en) | 1989-07-18 | 1993-04-06 | Mcdow Ronald A | Medical process--use of dichlorodifluoromethane (CCl2 F2) and chlorodifluoromethane (CHClF2) as cryogens for treating skin lesions |
JP2625548B2 (en) | 1989-07-19 | 1997-07-02 | 沖電気工業株式会社 | Image generation method and image generation device |
US5160312A (en) | 1990-02-09 | 1992-11-03 | W. R. Grace & Co.-Conn. | Cryopreservation process for direct transfer of embryos |
US5817149A (en) | 1990-02-26 | 1998-10-06 | Vesture Corporation | Heat application method |
US5575812A (en) | 1990-02-26 | 1996-11-19 | Vesture Corporation | Cooling pad method |
US5339541A (en) | 1990-02-26 | 1994-08-23 | Vesture Corporation | Footwear with therapeutic pad |
JPH03259975A (en) | 1990-03-09 | 1991-11-20 | Matsushita Refrig Co Ltd | Water-repellent coating composition and heat exchanger coated therewith |
FR2659851A1 (en) | 1990-03-20 | 1991-09-27 | Karagozian Serge | MASSAGE APPARATUS. |
US5362966A (en) | 1990-06-27 | 1994-11-08 | Rosenthal Robert D | Measurement of finger temperature in near-infrared quantitative measurement instrument |
US5148804A (en) | 1990-06-28 | 1992-09-22 | Hill Dennis M | Device, system, and methods for applying cryotherapy |
JPH0493597A (en) | 1990-08-08 | 1992-03-26 | Matsushita Refrig Co Ltd | Water repellent coating composition and heat exchanger coated with water repellant coating composition |
US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
GB2248183A (en) | 1990-09-25 | 1992-04-01 | Lin Ju Nin | Facial sauna apparatus |
US5221726A (en) | 1990-10-09 | 1993-06-22 | Mcneil-Ppc, Inc. | Hydrophilic materials useful in preparing fluid-absorbent products |
US5342617A (en) | 1990-12-03 | 1994-08-30 | Medical Polymers, Inc. | Water-based human tissue lubricant |
US5139496A (en) | 1990-12-20 | 1992-08-18 | Hed Aharon Z | Ultrasonic freeze ablation catheters and probes |
JP3217386B2 (en) | 1991-04-24 | 2001-10-09 | オリンパス光学工業株式会社 | Diagnostic system |
US5358467A (en) | 1991-05-05 | 1994-10-25 | Anatole Milstein | Method for vacuum mechanothermal stimulation of the body surface |
US5207674A (en) | 1991-05-13 | 1993-05-04 | Hamilton Archie C | Electronic cryogenic surgical probe apparatus and method |
WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
US20010031459A1 (en) | 1991-07-08 | 2001-10-18 | The American National Red Cross | Method of preparing tissues for vitrification |
DE4125463A1 (en) | 1991-08-01 | 1993-02-04 | Deutsches Inst Lebensmitteltec | METHOD AND DEVICE FOR CONTINUOUS, CONTROLLED STRUCTURING, IN PARTICULAR CRYSTALLIZATION OF SUBSTANCE SYSTEMS IN A FLOWABLE CONDITION, PARTICULARLY FATTY MEASURES, LIKE CHOCOLATE MATERIAL |
US5352711A (en) | 1991-08-12 | 1994-10-04 | The Proctor & Gamble Company | Method for hydrophilizing absorbent foam materials |
US5169384A (en) | 1991-08-16 | 1992-12-08 | Bosniak Stephen L | Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue |
US5514105A (en) | 1992-01-03 | 1996-05-07 | The Procter & Gamble Company | Resilient plastic web exhibiting reduced skin contact area and enhanced fluid transfer properties |
US5531742A (en) | 1992-01-15 | 1996-07-02 | Barken; Israel | Apparatus and method for computer controlled cryosurgery |
GB9201940D0 (en) | 1992-01-28 | 1992-03-18 | S I Ind Limited | Cooling or heating arrangement |
IT1259424B (en) | 1992-03-11 | 1996-03-18 | CONTAINMENT AND COOLING ELEMENT TO APPLY TO ARTS AFFECTED BY TRAUMAS | |
WO1993019705A1 (en) | 1992-03-31 | 1993-10-14 | Massachusetts Institute Of Technology | Apparatus and method for acoustic heat generation and hyperthermia |
US5954680A (en) | 1992-06-19 | 1999-09-21 | Augustine Medical, Inc. | Near hyperthermic heater wound covering |
DE4224595A1 (en) | 1992-07-23 | 1994-01-27 | Steindorf Susanne Ruth | Surgical instrument for treating diseased tissue esp. prostate - has heating system located in probe within body opening and-or diseased organs adjacent to body openings |
EP0654987A4 (en) | 1992-08-17 | 1995-12-13 | Mehl Thomas L | Hand-held, multi-purpose portable steamer. |
US5327886A (en) | 1992-08-18 | 1994-07-12 | Chiu Cheng Pang | Electronic massage device with cold/hot compress function |
WO1994007935A1 (en) | 1992-10-02 | 1994-04-14 | Beiersdorf Ag | Hydrophilic polyurethane gel foams, particularly for treating deep wounds, wound dressing based on hydrophilic polyurethane gel foams and method of manufacture |
GB9222335D0 (en) | 1992-10-23 | 1992-12-09 | Unilever Plc | Acyl lactylates as skin elasticity enhancing agents |
US5314423A (en) | 1992-11-03 | 1994-05-24 | Seney John S | Cold electrode pain alleviating tissue treatment assembly |
DE4238291A1 (en) | 1992-11-13 | 1994-05-19 | Diehl Gmbh & Co | Cryo-therapy system for small areal freezing of surfaces esp. for skin alterations - has cold probe and heat exchanger which are connected heat-conducting with each other by Peltier elements having heat contact surfaces |
US5333460A (en) | 1992-12-21 | 1994-08-02 | Carrier Corporation | Compact and serviceable packaging of a self-contained cryocooler system |
US5277030A (en) | 1993-01-22 | 1994-01-11 | Welch Allyn, Inc. | Preconditioning stand for cooling probe |
US5386837A (en) | 1993-02-01 | 1995-02-07 | Mmtc, Inc. | Method for enhancing delivery of chemotherapy employing high-frequency force fields |
US6620188B1 (en) | 1998-08-24 | 2003-09-16 | Radiant Medical, Inc. | Methods and apparatus for regional and whole body temperature modification |
US5902256A (en) | 1993-02-12 | 1999-05-11 | Jb Research, Inc. | Massage unit with replaceable hot and cold packs |
US5433717A (en) | 1993-03-23 | 1995-07-18 | The Regents Of The University Of California | Magnetic resonance imaging assisted cryosurgery |
US5456703A (en) | 1993-04-28 | 1995-10-10 | Therabite Corporation | Apparatus for application of heat/cold to target regions of the human anatomy |
AU6831294A (en) | 1993-05-12 | 1994-12-12 | Jeffrey S. Yablon | Portable therapeutic device |
RU2047298C1 (en) | 1993-05-27 | 1995-11-10 | Специализированное конструкторско-технологическое бюро "Норд" | Device for cryomassage |
PT701455E (en) | 1993-06-04 | 2001-09-27 | Biotime Inc | PLASMA SIMPLE SOLUTION |
US5411541A (en) | 1993-08-05 | 1995-05-02 | Oansh Designs Ltd. | Portable fluid therapy device |
US5372608A (en) | 1993-08-12 | 1994-12-13 | Johnson; Bertrand L. | Circulating chilled-fluid therapeutic device |
US5334131A (en) | 1993-08-20 | 1994-08-02 | Omandam Ismael C | Strap-on massager with vibratory unbalanced weight |
US5891617A (en) | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
US5871526A (en) | 1993-10-13 | 1999-02-16 | Gibbs; Roselle | Portable temperature control system |
GB2283678B (en) | 1993-11-09 | 1998-06-03 | Spembly Medical Ltd | Cryosurgical catheter probe |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
JPH07194666A (en) | 1993-12-30 | 1995-08-01 | Daisee Kogyo Kk | Massaging appliance and method |
US5472416A (en) | 1994-01-10 | 1995-12-05 | Very Inventive Physicians, Inc. | Tumescent lipoplastic method and apparatus |
RU2036667C1 (en) | 1994-01-24 | 1995-06-09 | Олег Алексеевич Машков | Method for treating disseminated psoriasis |
US5497596A (en) | 1994-01-27 | 1996-03-12 | E. I. Du Pont De Nemours And Company | Method for reducing penetration of liquid through nonwoven film-fibril sheets pierced by fastening elements |
GB2286660A (en) | 1994-02-01 | 1995-08-23 | David Thorner | Peltier effect cooling apparatus for treating diseased or injured tissue |
US5647868A (en) | 1994-02-02 | 1997-07-15 | Chinn; Douglas Owen | Cryosurgical integrated control and monitoring system and method |
US5725483A (en) | 1994-02-22 | 1998-03-10 | Podolsky; Grigory | Massaging device |
US5363347A (en) | 1994-02-24 | 1994-11-08 | Hap Nguyen | Vending tanning timer |
US5833685A (en) | 1994-03-15 | 1998-11-10 | Tortal; Proserfina R. | Cryosurgical technique and devices |
US5507790A (en) | 1994-03-21 | 1996-04-16 | Weiss; William V. | Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism |
US5505726A (en) | 1994-03-21 | 1996-04-09 | Dusa Pharmaceuticals, Inc. | Article of manufacture for the photodynamic therapy of dermal lesion |
JPH07268274A (en) | 1994-04-01 | 1995-10-17 | Kansai Paint Co Ltd | Composition and method for imparting hydrophilicity |
JP3263275B2 (en) | 1994-04-05 | 2002-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Apparatus for laser treatment of living tissue and laser treatment apparatus for flame-like nevus |
US6230501B1 (en) | 1994-04-14 | 2001-05-15 | Promxd Technology, Inc. | Ergonomic systems and methods providing intelligent adaptive surfaces and temperature control |
US5792080A (en) | 1994-05-18 | 1998-08-11 | Matsushita Electric Works, Ltd. | Massaging apparatus having self-adjusting constant strength and non-adjust strength modes |
US5672172A (en) | 1994-06-23 | 1997-09-30 | Vros Corporation | Surgical instrument with ultrasound pulse generator |
US5505730A (en) | 1994-06-24 | 1996-04-09 | Stuart D. Edwards | Thin layer ablation apparatus |
IL110176A (en) | 1994-06-30 | 1999-12-31 | Israel State | Multiprobe surgical cryogenic apparatus |
US5529067A (en) | 1994-08-19 | 1996-06-25 | Novoste Corporation | Methods for procedures related to the electrophysiology of the heart |
US5967976A (en) | 1994-08-19 | 1999-10-19 | Novoste Corporation | Apparatus and methods for procedures related to the electrophysiology of the heart |
US5514170A (en) | 1994-08-25 | 1996-05-07 | Mauch; Rose M. | Cold pack device |
US5486207A (en) | 1994-09-20 | 1996-01-23 | Mahawili; Imad | Thermal pad for portable body heating/cooling system and method of use |
US5628769A (en) | 1994-09-30 | 1997-05-13 | Saringer Research, Inc. | Method and devices for producing somatosensory stimulation using temperature |
US5895418A (en) | 1994-09-30 | 1999-04-20 | Saringer Research Inc. | Device for producing cold therapy |
JPH10509610A (en) | 1994-11-09 | 1998-09-22 | クリ・ハークチ,ワリド | Wound repair dressings and their preservation methods |
DE4445627A1 (en) | 1994-12-21 | 1996-06-27 | Holland Letz Horst | Heat exchanger for thermal therapy pad |
US6426445B1 (en) | 1995-01-10 | 2002-07-30 | The Procter & Gamble Company | Absorbent members comprising an agglomerate of hydrogel-forming absorbent polymer and particulate hydrophilic foam |
US5735844A (en) | 1995-02-01 | 1998-04-07 | The General Hospital Corporation | Hair removal using optical pulses |
US5647051A (en) | 1995-02-22 | 1997-07-08 | Seabrook Medical Systems, Inc. | Cold therapy system with intermittent fluid pumping for temperature control |
US5635162A (en) | 1995-02-23 | 1997-06-03 | Ultradent Products, Inc. | Hemostatic composition for treating gingival area |
US5980561A (en) | 1995-03-01 | 1999-11-09 | Kolen; Paul T. | Applying thermal therapy to living tissue |
IES950163A2 (en) | 1995-03-01 | 1995-12-27 | Shannon Cool Limited | Cold therapy apparatus |
US5558376A (en) | 1995-03-02 | 1996-09-24 | Engineered Transitions Co., Inc. | Low profile swivel adapters |
US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
AU707710B2 (en) | 1995-04-28 | 1999-07-15 | Douglas O. Chinn | Cryosurgical integrated control monitoring system and method |
US5755753A (en) | 1995-05-05 | 1998-05-26 | Thermage, Inc. | Method for controlled contraction of collagen tissue |
US6241753B1 (en) | 1995-05-05 | 2001-06-05 | Thermage, Inc. | Method for scar collagen formation and contraction |
US6430446B1 (en) | 1995-05-05 | 2002-08-06 | Thermage, Inc. | Apparatus for tissue remodeling |
US6425912B1 (en) | 1995-05-05 | 2002-07-30 | Thermage, Inc. | Method and apparatus for modifying skin surface and soft tissue structure |
US5660836A (en) | 1995-05-05 | 1997-08-26 | Knowlton; Edward W. | Method and apparatus for controlled contraction of collagen tissue |
US5634890A (en) | 1995-05-09 | 1997-06-03 | Aquasage, Inc. | Water massage therapy device and method for using the same |
US5901707A (en) | 1995-05-19 | 1999-05-11 | Hpl Biomedical, Inc. | Silicone mask for cryosurgery and method |
US5769879A (en) | 1995-06-07 | 1998-06-23 | Medical Contouring Corporation | Microwave applicator and method of operation |
US5741248A (en) | 1995-06-07 | 1998-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Fluorochemical liquid augmented cryosurgery |
US5965438A (en) | 1995-06-07 | 1999-10-12 | Phyton, Inc. | Cryopreservation of plant cells |
JPH10509632A (en) | 1995-07-25 | 1998-09-22 | マサチューセッツ インスティチュート オブ テクノロジー | Enhanced transdermal delivery using ultrasound |
US5853364A (en) | 1995-08-07 | 1998-12-29 | Nellcor Puritan Bennett, Inc. | Method and apparatus for estimating physiological parameters using model-based adaptive filtering |
US5746736A (en) | 1995-08-09 | 1998-05-05 | Lumedics, Ltd. | Cryogenic laser lithotripsy with enhanced light absorption |
US5964749A (en) | 1995-09-15 | 1999-10-12 | Esc Medical Systems Ltd. | Method and apparatus for skin rejuvenation and wrinkle smoothing |
US5654546A (en) | 1995-11-07 | 1997-08-05 | Molecular Imaging Corporation | Variable temperature scanning probe microscope based on a peltier device |
US5733280A (en) | 1995-11-15 | 1998-03-31 | Avitall; Boaz | Cryogenic epicardial mapping and ablation |
US5634940A (en) | 1995-12-13 | 1997-06-03 | Panyard; Albert A. | Therapeutic structure and methods |
US5755755A (en) | 1995-12-13 | 1998-05-26 | Panyard; Albert A. | Therapeutic structure and method |
JPH09164163A (en) | 1995-12-15 | 1997-06-24 | Matsushita Electric Ind Co Ltd | Local part cooler-heater |
WO1997022262A2 (en) | 1995-12-19 | 1997-06-26 | Jie Hao | Soft ice |
WO1997024088A1 (en) | 1995-12-29 | 1997-07-10 | Life Resuscitation Technologies, Inc. | Total body cooling system |
US7022121B2 (en) | 1999-03-09 | 2006-04-04 | Thermage, Inc. | Handpiece for treatment of tissue |
US7267675B2 (en) | 1996-01-05 | 2007-09-11 | Thermage, Inc. | RF device with thermo-electric cooler |
US7473251B2 (en) | 1996-01-05 | 2009-01-06 | Thermage, Inc. | Methods for creating tissue effect utilizing electromagnetic energy and a reverse thermal gradient |
US6350276B1 (en) | 1996-01-05 | 2002-02-26 | Thermage, Inc. | Tissue remodeling apparatus containing cooling fluid |
US7006874B2 (en) | 1996-01-05 | 2006-02-28 | Thermage, Inc. | Treatment apparatus with electromagnetic energy delivery device and non-volatile memory |
US7189230B2 (en) | 1996-01-05 | 2007-03-13 | Thermage, Inc. | Method for treating skin and underlying tissue |
US7115123B2 (en) | 1996-01-05 | 2006-10-03 | Thermage, Inc. | Handpiece with electrode and non-volatile memory |
US7141049B2 (en) | 1999-03-09 | 2006-11-28 | Thermage, Inc. | Handpiece for treatment of tissue |
US7229436B2 (en) | 1996-01-05 | 2007-06-12 | Thermage, Inc. | Method and kit for treatment of tissue |
JP2000503154A (en) | 1996-01-11 | 2000-03-14 | エムアールジェイ インコーポレイテッド | System for controlling access and distribution of digital ownership |
US5651773A (en) | 1996-01-19 | 1997-07-29 | Perry; Larry C. | Skin protector for ultrasonic-assisted liposuction and accessories |
US5650450A (en) | 1996-01-25 | 1997-07-22 | Foamex L.P. | Hydrophilic urethane foam |
FR2744358B1 (en) | 1996-02-01 | 1998-05-07 | Biogenie Beaute Concept | MASSAGE HEAD COMBINING SUCTION MASSAGE AND ELECTROTHERAPY |
FR2745935B1 (en) | 1996-03-11 | 1998-05-22 | Ygk Holding S A | AUTOMATED TANNING EQUIPMENT |
US5654279A (en) | 1996-03-29 | 1997-08-05 | The Regents Of The University Of California | Tissue destruction in cryosurgery by use of thermal hysteresis |
US6180867B1 (en) | 1996-04-17 | 2001-01-30 | General Electric Company | Thermal sensor array and methods of fabrication and use |
SE510531C2 (en) | 1996-05-02 | 1999-05-31 | Sca Hygiene Prod Ab | Hollow-casing layer for absorbing articles, as well as ways of making the casing layer |
AU3399197A (en) | 1996-06-18 | 1998-01-07 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
US5944748A (en) | 1996-07-25 | 1999-08-31 | Light Medicine, Inc. | Photodynamic therapy apparatus and methods |
US5976123A (en) | 1996-07-30 | 1999-11-02 | Laser Aesthetics, Inc. | Heart stabilization |
US5966763A (en) | 1996-08-02 | 1999-10-19 | Hill-Rom, Inc. | Surface pad system for a surgical table |
US6102885A (en) | 1996-08-08 | 2000-08-15 | Bass; Lawrence S. | Device for suction-assisted lipectomy and method of using same |
US5840080A (en) | 1996-08-15 | 1998-11-24 | Der Ovanesian; Mary | Hot or cold applicator with inner element |
US5665053A (en) | 1996-09-27 | 1997-09-09 | Jacobs; Robert A. | Apparatus for performing endermology with ultrasound |
US5941825A (en) | 1996-10-21 | 1999-08-24 | Philipp Lang | Measurement of body fat using ultrasound methods and devices |
BE1010730A7 (en) | 1996-11-04 | 1998-12-01 | Pira Luc Louis Marie Francis | Cryoprobe based on peltier module. |
US5800490A (en) | 1996-11-07 | 1998-09-01 | Patz; Herbert Samuel | Lightweight portable cooling or heating device with multiple applications |
US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
US6517532B1 (en) | 1997-05-15 | 2003-02-11 | Palomar Medical Technologies, Inc. | Light energy delivery head |
US20060149343A1 (en) | 1996-12-02 | 2006-07-06 | Palomar Medical Technologies, Inc. | Cooling system for a photocosmetic device |
US7204832B2 (en) | 1996-12-02 | 2007-04-17 | Pálomar Medical Technologies, Inc. | Cooling system for a photo cosmetic device |
US5964092A (en) | 1996-12-13 | 1999-10-12 | Nippon Sigmax, Co., Ltd. | Electronic cooling apparatus |
ES2289192T3 (en) | 1996-12-31 | 2008-02-01 | Altea Therapeutics Corporation | TISSUE MICROPORATION FOR SUPPLY OF BIOACTIVE AGENTS. |
US6102875A (en) | 1997-01-16 | 2000-08-15 | Jones; Rick E. | Apparatus for combined application of massage, accupressure and biomagnetic therapy |
US5830208A (en) | 1997-01-31 | 1998-11-03 | Laserlite, Llc | Peltier cooled apparatus and methods for dermatological treatment |
JPH10216169A (en) | 1997-02-05 | 1998-08-18 | Kanae Kagawa:Kk | Cold-feeling/cooling sheet |
JPH10223961A (en) | 1997-02-10 | 1998-08-21 | Furukawa Electric Co Ltd:The | Optical amplifier |
US5925026A (en) | 1997-03-10 | 1999-07-20 | Kimberly-Clark Worldwide, Inc. | Apertured absorbent pads for use in absorbent articles |
US6032675A (en) | 1997-03-17 | 2000-03-07 | Rubinsky; Boris | Freezing method for controlled removal of fatty tissue by liposuction |
AU6865298A (en) | 1997-03-17 | 1998-10-12 | Boris Rubinsky | The use of cryoprotective agent compounds during cryosurgery |
GB2323659A (en) | 1997-03-25 | 1998-09-30 | Paul Weatherstone | Hand directable chilled air blower |
NL1007696C1 (en) | 1997-05-01 | 1998-11-03 | Inst Voor Agrotech Onderzoek | Controlled-release coated substance. |
EP0991372B1 (en) | 1997-05-15 | 2004-08-04 | Palomar Medical Technologies, Inc. | Apparatus for dermatology treatment |
US5817050A (en) | 1997-05-29 | 1998-10-06 | Klein; Jeffrey A. | Liposuction cannula |
CA2293388A1 (en) | 1997-06-17 | 1998-12-23 | Michael L. Barretti | Method and apparatus for temperature control of biologic tissue with simultaneous irradiation |
US6104959A (en) | 1997-07-31 | 2000-08-15 | Microwave Medical Corp. | Method and apparatus for treating subcutaneous histological features |
WO1999008598A1 (en) | 1997-08-19 | 1999-02-25 | Mendlein John D | Ultrasonic transmission films and devices, particularly for hygienic transducer surfaces |
FR2767476B1 (en) | 1997-08-25 | 1999-10-15 | Juliette Dubois | PHYSIOTHERAPEUTIC DEVICE FOR THE TREATMENT OF THE SKIN BY VACUUM AND ULTRASOUND SUCTION |
US6023932A (en) | 1997-08-25 | 2000-02-15 | Johnston; Robert | Topical cooling device |
US5802865A (en) | 1997-09-05 | 1998-09-08 | The Sharper Image | Evaporative personal cooler |
US6113558A (en) | 1997-09-29 | 2000-09-05 | Angiosonics Inc. | Pulsed mode lysis method |
US6623430B1 (en) | 1997-10-14 | 2003-09-23 | Guided Therapy Systems, Inc. | Method and apparatus for safety delivering medicants to a region of tissue using imaging, therapy and temperature monitoring ultrasonic system |
US6071239A (en) | 1997-10-27 | 2000-06-06 | Cribbs; Robert W. | Method and apparatus for lipolytic therapy using ultrasound energy |
GB9724186D0 (en) | 1997-11-14 | 1998-01-14 | British Tech Group | Low temperature coatings |
US6113559A (en) | 1997-12-29 | 2000-09-05 | Klopotek; Peter J. | Method and apparatus for therapeutic treatment of skin with ultrasound |
US6104952A (en) | 1998-01-07 | 2000-08-15 | Tu; Lily Chen | Devices for treating canker sores, tissues and methods thereof |
DE19800416C2 (en) | 1998-01-08 | 2002-09-19 | Storz Karl Gmbh & Co Kg | Device for the treatment of body tissue, in particular soft tissue close to the surface, by means of ultrasound |
US7458984B2 (en) | 1998-01-23 | 2008-12-02 | Innercool Therapies, Inc. | System and method for inducing hypothermia with active patient temperature control employing catheter-mounted temperature sensor and temperature projection algorithm |
US6251129B1 (en) | 1998-03-24 | 2001-06-26 | Innercool Therapies, Inc. | Method for low temperature thrombolysis and low temperature thrombolytic agent with selective organ temperature control |
IL126783A0 (en) | 1998-03-05 | 1999-08-17 | M T R E Advanced Technology Lt | System and method for heat control of a living body |
US6047215A (en) | 1998-03-06 | 2000-04-04 | Sonique Surgical Systems, Inc. | Method and apparatus for electromagnetically assisted liposuction |
AU3450799A (en) | 1998-03-12 | 1999-09-27 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation of the skin |
US6551349B2 (en) | 1998-03-24 | 2003-04-22 | Innercool Therapies, Inc. | Selective organ cooling apparatus |
CA2326120C (en) | 1998-03-27 | 2015-01-13 | The General Hospital Corporation | Method and apparatus for the selective targeting of lipid-rich tissues |
FR2776920B3 (en) | 1998-04-03 | 2000-04-28 | Elie Piana | VACUUM MASSAGE DEVICE |
US6569189B1 (en) | 1998-04-06 | 2003-05-27 | Augustine Medical, Inc. | Tissue treatment apparatus including a bandpass filter transparent to selected wavelengths of IR electromagnetic spectrum |
US6264649B1 (en) | 1998-04-09 | 2001-07-24 | Ian Andrew Whitcroft | Laser treatment cooling head |
US5997530A (en) | 1998-04-13 | 1999-12-07 | The Regents Of The University Of California | Apparatus and method to control atmospheric water vapor composition and concentration during dynamic cooling of biological tissues in conjunction with laser irradiations |
US6354297B1 (en) | 1998-04-16 | 2002-03-12 | The Uniformed Services University Of The Health Sciences | Method and device for destroying fat cells by induction of programmed cell death |
US6375673B1 (en) | 1998-04-23 | 2002-04-23 | The Board Of Regents Of The University Of Texas System | Heat transfer blanket for and method of controlling a patient's temperature |
US6113626A (en) | 1998-04-23 | 2000-09-05 | The Board Of Regents Of The University Of Texas System | Heat transfer blanket for controlling a patient's temperature |
EP1073388B1 (en) | 1998-04-23 | 2008-11-05 | The Board of Regents of the University of Texas System | Heat transfer blanket for and method of controlling a patient's temperature |
US6151735A (en) | 1998-05-05 | 2000-11-28 | Imak Corporation | Zone inflatable orthopedic pillow |
US6015390A (en) | 1998-06-12 | 2000-01-18 | D. Krag Llc | System and method for stabilizing and removing tissue |
US6039694A (en) | 1998-06-25 | 2000-03-21 | Sonotech, Inc. | Coupling sheath for ultrasound transducers |
US6312453B1 (en) | 1998-07-16 | 2001-11-06 | Olympic Medical Corp. | Device for cooling infant's brain |
US6673098B1 (en) | 1998-08-24 | 2004-01-06 | Radiant Medical, Inc. | Disposable cassette for intravascular heat exchange catheter |
US6620189B1 (en) | 2000-02-28 | 2003-09-16 | Radiant Medical, Inc. | Method and system for control of a patient's body temperature by way of a transluminally insertable heat exchange catheter |
US6093230A (en) | 1998-10-12 | 2000-07-25 | Allegiance Corporation | Filter assembly comprising two filter elements separated by a hydrophobic foam |
TW514521B (en) | 1998-10-16 | 2002-12-21 | Coolsystems Inc | Compliant heat exchange splint and control unit |
US6059820A (en) | 1998-10-16 | 2000-05-09 | Paradigm Medical Corporation | Tissue cooling rod for laser surgery |
US6150148A (en) | 1998-10-21 | 2000-11-21 | Genetronics, Inc. | Electroporation apparatus for control of temperature during the process |
IL126723A0 (en) | 1998-10-22 | 1999-08-17 | Medoc Ltd | Vaginal probe and method |
US6120519A (en) | 1998-12-02 | 2000-09-19 | Weber; Paul J. | Advanced fulcrum liposuction device |
US7785359B2 (en) | 1998-12-18 | 2010-08-31 | Traumatec, Inc. | Therapeutic cooling devices |
US6183773B1 (en) | 1999-01-04 | 2001-02-06 | The General Hospital Corporation | Targeting of sebaceous follicles as a treatment of sebaceous gland disorders |
JP2002534160A (en) | 1999-01-04 | 2002-10-15 | メディヴァンス インコーポレイテッド | Improved cooling / heating pads and systems |
US6306119B1 (en) | 1999-01-20 | 2001-10-23 | Pearl Technology Holdings, Llc | Skin resurfacing and treatment using biocompatible materials |
US6635053B1 (en) | 1999-01-25 | 2003-10-21 | Cryocath Technologies Inc. | Cooling system |
US6592577B2 (en) | 1999-01-25 | 2003-07-15 | Cryocath Technologies Inc. | Cooling system |
ES2173678T3 (en) | 1999-01-27 | 2002-10-16 | Idea Ag | VACCINATION NOT INVASIVE THROUGH THE SKIN. |
WO2000044346A1 (en) | 1999-02-03 | 2000-08-03 | Gerard Hassler | Lowering skin temperature |
US6200308B1 (en) | 1999-01-29 | 2001-03-13 | Candela Corporation | Dynamic cooling of tissue for radiation treatment |
US6468297B1 (en) | 1999-02-24 | 2002-10-22 | Cryovascular Systems, Inc. | Cryogenically enhanced intravascular interventions |
FR2789893B1 (en) | 1999-02-24 | 2001-05-11 | Serge Karagozian | COMBINATION DERMOTONY AND MAGNETOTHERAPY MASSAGE APPARATUS |
ES2240078T3 (en) | 1999-03-09 | 2005-10-16 | Thermage, Inc. | APPARATUS FOR TREATMENT OF FABRICS. |
US6678558B1 (en) | 1999-03-25 | 2004-01-13 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
JP3065657U (en) | 1999-04-07 | 2000-02-08 | 樋口 登 | Cool band |
WO2000065770A1 (en) | 1999-04-22 | 2000-11-02 | Veridicom, Inc. | High security biometric authentication using a public key/private key encryption pairs |
US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
WO2000067685A1 (en) | 1999-05-12 | 2000-11-16 | Burns Terrence R | Thermoregulation systems |
US6643535B2 (en) | 1999-05-26 | 2003-11-04 | Endocare, Inc. | System for providing computer guided ablation of tissue |
US6139544A (en) | 1999-05-26 | 2000-10-31 | Endocare, Inc. | Computer guided cryosurgery |
US20020198518A1 (en) | 1999-05-26 | 2002-12-26 | Mikus Paul W. | Entry position grid for computer guided cryosurgery |
US6694170B1 (en) | 1999-05-26 | 2004-02-17 | Endocare, Inc. | Computer guided surgery for prostatic nerve sparing |
US6357907B1 (en) | 1999-06-15 | 2002-03-19 | V & P Scientific, Inc. | Magnetic levitation stirring devices and machines for mixing in vessels |
AU2002359840A1 (en) | 1999-06-30 | 2003-07-09 | Thermage, Inc. | Liquid cooled RF handpiece |
KR200173222Y1 (en) | 1999-07-19 | 2000-03-15 | 이강민 | Supersonic skin massager |
US6547811B1 (en) | 1999-08-02 | 2003-04-15 | Arch Development Corporation | Method for inducing hypothermia |
JP2001046416A (en) | 1999-08-10 | 2001-02-20 | Try Company:Kk | Body cooling apparatus |
US6548728B1 (en) | 1999-08-11 | 2003-04-15 | Medical Products, Inc. | Wound dressing garment |
US6290713B1 (en) | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
IL131834A0 (en) | 1999-09-09 | 2001-03-19 | M T R E Advanced Technology Lt | Method and system for improving cardiac output of a patient |
US6471693B1 (en) | 1999-09-10 | 2002-10-29 | Cryocath Technologies Inc. | Catheter and system for monitoring tissue contact |
US6226996B1 (en) | 1999-10-06 | 2001-05-08 | Paul J. Weber | Device for controlled cooling of a surface |
GB9923804D0 (en) | 1999-10-08 | 1999-12-08 | Hewlett Packard Co | Electronic commerce system |
WO2001032114A1 (en) | 1999-11-02 | 2001-05-10 | Wizcare Ltd. | Skin-gripper |
GB2356145B (en) | 1999-11-10 | 2004-07-28 | Mas Mfg Ltd | Dressing |
US6743222B2 (en) | 1999-12-10 | 2004-06-01 | Candela Corporation | Method of treating disorders associated with sebaceous follicles |
US6402775B1 (en) | 1999-12-14 | 2002-06-11 | Augustine Medical, Inc. | High-efficiency cooling pads, mattresses, and sleeves |
JP2004159666A (en) | 1999-12-21 | 2004-06-10 | Ya Man Ltd | Laser epilation device |
JP4723707B2 (en) | 1999-12-22 | 2011-07-13 | パナソニック電工株式会社 | Slimming equipment |
US6699237B2 (en) | 1999-12-30 | 2004-03-02 | Pearl Technology Holdings, Llc | Tissue-lifting device |
US6840955B2 (en) | 2000-01-27 | 2005-01-11 | Robert J. Ein | Therapeutic apparatus |
US6551251B2 (en) | 2000-02-14 | 2003-04-22 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Passive fetal heart monitoring system |
FR2805989B1 (en) | 2000-03-10 | 2003-02-07 | Prod Ella Bache Laboratoire Su | PROCESS FOR TREATING INESTHETISMS OF SILHOUETTE OF THE HUMAN BODY AND DEVICE FOR IMPLEMENTING THE METHOD |
AU2001252914A1 (en) | 2000-03-14 | 2001-09-24 | Alnis Bioscience, Inc. | Cryoprotective system |
KR100367639B1 (en) | 2000-03-20 | 2003-01-14 | 안문휘 | Cryogenic stimulating device of acupuncture points |
US6311497B1 (en) | 2000-03-22 | 2001-11-06 | Young-Chun Chung | Device for cold and warm formentations |
US20020188478A1 (en) | 2000-03-24 | 2002-12-12 | Joe Breeland | Health-care systems and methods |
US6354099B1 (en) | 2000-04-11 | 2002-03-12 | Augustine Medical, Inc. | Cooling devices with high-efficiency cooling features |
ATE372754T1 (en) | 2000-04-20 | 2007-09-15 | Univ Leland Stanford Junior | METHOD AND DEVICE FOR COOLING THE BODY CORE |
US20020151830A1 (en) | 2000-04-28 | 2002-10-17 | Rocky Kahn | Hydrotherapy system with water pervious body support |
US6494844B1 (en) | 2000-06-21 | 2002-12-17 | Sanarus Medical, Inc. | Device for biopsy and treatment of breast tumors |
WO2002005736A2 (en) | 2000-07-13 | 2002-01-24 | Medtronic, Inc. | Non-invasive carotid cooler brain hypothermia medical device |
EP1463437B1 (en) | 2000-07-31 | 2012-01-04 | Galil Medical Ltd. | Facilitation system for cryosurgery |
US6795728B2 (en) | 2001-08-17 | 2004-09-21 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation |
US6697670B2 (en) | 2001-08-17 | 2004-02-24 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients |
US8251986B2 (en) | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
AU2001286515A1 (en) | 2000-08-17 | 2002-02-25 | Robert L. Campbell | Heat exchange element with hydrophilic evaporator surface |
US6892099B2 (en) | 2001-02-08 | 2005-05-10 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation |
US6458888B1 (en) | 2000-09-15 | 2002-10-01 | Isp Investments Inc. | Rheology modifier for use in aqueous compositions |
US6527765B2 (en) | 2000-10-06 | 2003-03-04 | Charles D. Kelman | Cryogenic surgical system and method of use in removal of tissue |
US6540694B1 (en) | 2000-10-16 | 2003-04-01 | Sanarus Medical, Inc. | Device for biopsy tumors |
JP3655820B2 (en) | 2000-10-23 | 2005-06-02 | 繁雄 小林 | Head cooling and heating device |
EP1201266A1 (en) | 2000-10-26 | 2002-05-02 | Compex SA | Method for programming stimulation data into a stimulation device |
DE10056242A1 (en) | 2000-11-14 | 2002-05-23 | Alstom Switzerland Ltd | Condensation heat exchanger has heat exchanger surfaces having a coating consisting of a alternating sequence of layers made up of a hard layer with amorphous carbon or a plasma polymer |
US6821274B2 (en) | 2001-03-07 | 2004-11-23 | Gendel Ltd. | Ultrasound therapy for selective cell ablation |
US7549987B2 (en) | 2000-12-09 | 2009-06-23 | Tsunami Medtech, Llc | Thermotherapy device |
US6626854B2 (en) | 2000-12-27 | 2003-09-30 | Insightec - Txsonics Ltd. | Systems and methods for ultrasound assisted lipolysis |
US6645162B2 (en) | 2000-12-27 | 2003-11-11 | Insightec - Txsonics Ltd. | Systems and methods for ultrasound assisted lipolysis |
ES2274915T3 (en) | 2000-12-28 | 2007-06-01 | Palomar Medical Technologies, Inc. | ELECTROMAGNETIC RADIATION TREATMENT DEVICE (EMR) OF THE SKIN. |
AU2002217412B2 (en) | 2001-01-03 | 2006-09-14 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
US6607498B2 (en) | 2001-01-03 | 2003-08-19 | Uitra Shape, Inc. | Method and apparatus for non-invasive body contouring by lysing adipose tissue |
US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
US6551348B1 (en) | 2001-01-26 | 2003-04-22 | Deroyal Industries, Inc. | Temperature controlled fluid therapy system |
JP2002224051A (en) | 2001-01-30 | 2002-08-13 | Yamaguchi Prefecture | Nonrestraint life monitor |
US20050145372A1 (en) | 2004-01-02 | 2005-07-07 | Noel Thomas P. | Method and thermally active multi-phase heat transfer apparatus and method for abstracting heat using liquid bi-phase heat exchanging composition |
US6904956B2 (en) | 2002-10-18 | 2005-06-14 | Thomas P. Noel | Method and thermally active convection apparatus and method for abstracting heat with circulation intermediate three dimensional-parity heat transfer elements in bi-phase heat exchanging composition |
JP4027049B2 (en) | 2001-02-28 | 2007-12-26 | 株式会社ニデック | Laser therapy device |
US6948903B2 (en) | 2001-03-15 | 2005-09-27 | Maxon Lift Corporation | Unitary liftgate |
JP4938177B2 (en) | 2001-03-22 | 2012-05-23 | 小林製薬株式会社 | Cold / warm pad |
JP2002290397A (en) | 2001-03-23 | 2002-10-04 | Iryo Joho Syst Kaihatsu Center | Secure communication method |
US7083580B2 (en) | 2001-04-06 | 2006-08-01 | Mattioli Engineering Ltd. | Method and apparatus for skin absorption enhancement and transdermal drug delivery |
WO2002087700A1 (en) | 2001-04-26 | 2002-11-07 | The Procter & Gamble Company | Method, kit and device for the treatment of cosmetic skin conditions |
FR2823973B1 (en) | 2001-04-27 | 2003-12-26 | Alain Meunier | MASSAGE APPARATUS FOR PERFORMING "PRESS-PRESS-TIRE" MASSAGE |
US6438954B1 (en) | 2001-04-27 | 2002-08-27 | 3M Innovative Properties Company | Multi-directional thermal actuator |
US6430956B1 (en) | 2001-05-15 | 2002-08-13 | Cimex Biotech Lc | Hand-held, heat sink cryoprobe, system for heat extraction thereof, and method therefore |
GB0111986D0 (en) | 2001-05-16 | 2001-07-04 | Optomed As | Cryosurgical apparatus and methods |
CN2514795Y (en) | 2001-05-18 | 2002-10-09 | 郑晓丹 | Multi-contact freezing beautifying pencil |
US7192426B2 (en) | 2001-05-31 | 2007-03-20 | Endocare, Inc. | Cryogenic system |
US20020188286A1 (en) | 2001-06-06 | 2002-12-12 | Quijano Rodolfo C. | Methods for treating vulnerable plaque |
US6551341B2 (en) | 2001-06-14 | 2003-04-22 | Advanced Cardiovascular Systems, Inc. | Devices configured from strain hardened Ni Ti tubing |
FR2826107A1 (en) | 2001-06-19 | 2002-12-20 | M D I C | Cold pack useful for cryotherapy or food preservation comprises sealed flexible casing containing aqueous composition, hydrocolloid thickener and freezing point depressant |
TW476644B (en) | 2001-06-28 | 2002-02-21 | Wen-Hu Liau | Portable first-aid cold hot compress pack |
JP3393128B1 (en) | 2001-07-18 | 2003-04-07 | 正雄 酒井 | Female wearing condom |
CN2514811Y (en) | 2001-07-31 | 2002-10-09 | 尹旭光 | Electrothermal device for heatig foot |
US20030032900A1 (en) | 2001-08-08 | 2003-02-13 | Engii (2001) Ltd. | System and method for facial treatment |
US20040260209A1 (en) | 2003-06-23 | 2004-12-23 | Engli (2001) Ltd. | System and method for face and body treatment |
US20040260210A1 (en) | 2003-06-23 | 2004-12-23 | Engii (2001) Ltd. | System and method for face and body treatment |
US6438964B1 (en) | 2001-09-10 | 2002-08-27 | Percy Giblin | Thermoelectric heat pump appliance with carbon foam heat sink |
US6572450B2 (en) | 2001-09-21 | 2003-06-03 | Iphotonics, Inc. | Roll format polishing process for optical devices |
US20030062040A1 (en) | 2001-09-28 | 2003-04-03 | Lurie Keith G. | Face mask ventilation/perfusion systems and method |
US20030114885A1 (en) | 2001-10-02 | 2003-06-19 | Nova Richard C. | System and device for implementing an integrated medical device component package |
ATE287904T1 (en) | 2001-10-05 | 2005-02-15 | Basf Ag | METHOD FOR CROSSLINKING HYDROGELS WITH MORPHOLINE-2,3-DIONES |
US6699267B2 (en) | 2001-10-11 | 2004-03-02 | Medivance Incorporated | Patient temperature control system with fluid temperature response |
US6660027B2 (en) | 2001-10-11 | 2003-12-09 | Medivance Incorporated | Patient temperature control system with fluid preconditioning |
US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
US20030125649A1 (en) | 2001-10-31 | 2003-07-03 | Mcintosh Laura Janet | Method and system apparatus using temperature and pressure for treating medical disorders |
US6889090B2 (en) | 2001-11-20 | 2005-05-03 | Syneron Medical Ltd. | System and method for skin treatment using electrical current |
CA2725655C (en) | 2001-11-20 | 2015-01-20 | Western Digital Technologies, Inc. | Access and control system for network-enabled devices |
US6648904B2 (en) | 2001-11-29 | 2003-11-18 | Palomar Medical Technologies, Inc. | Method and apparatus for controlling the temperature of a surface |
US6849075B2 (en) | 2001-12-04 | 2005-02-01 | Estech, Inc. | Cardiac ablation devices and methods |
US20030109910A1 (en) | 2001-12-08 | 2003-06-12 | Lachenbruch Charles A. | Heating or cooling pad or glove with phase change material |
US6755852B2 (en) | 2001-12-08 | 2004-06-29 | Charles A. Lachenbruch | Cooling body wrap with phase change material |
US6699266B2 (en) | 2001-12-08 | 2004-03-02 | Charles A. Lachenbruch | Support surface with phase change material or heat tubes |
US7762965B2 (en) | 2001-12-10 | 2010-07-27 | Candela Corporation | Method and apparatus for vacuum-assisted light-based treatments of the skin |
EP1627662B1 (en) | 2004-06-10 | 2011-03-02 | Candela Corporation | Apparatus for vacuum-assisted light-based treatments of the skin |
JP2003190201A (en) | 2001-12-26 | 2003-07-08 | Lion Corp | Body cooler and body warmer |
WO2003070105A1 (en) | 2002-02-20 | 2003-08-28 | Liposonix, Inc. | Ultrasonic treatment and imaging of adipose tissue |
US6523354B1 (en) | 2002-03-08 | 2003-02-25 | Deborah Ann Tolbert | Cooling blanket |
ATE386491T1 (en) | 2002-03-15 | 2008-03-15 | Gen Hospital Corp | DEVICES FOR THE SELECTIVE DESTRUCTION OF FAT TISSUE BY CONTROLLED COOLING |
US8840608B2 (en) | 2002-03-15 | 2014-09-23 | The General Hospital Corporation | Methods and devices for selective disruption of fatty tissue by controlled cooling |
US6662054B2 (en) | 2002-03-26 | 2003-12-09 | Syneron Medical Ltd. | Method and system for treating skin |
US20030236487A1 (en) | 2002-04-29 | 2003-12-25 | Knowlton Edward W. | Method for treatment of tissue with feedback |
US20040176667A1 (en) | 2002-04-30 | 2004-09-09 | Mihai Dan M. | Method and system for medical device connectivity |
US6746474B2 (en) | 2002-05-31 | 2004-06-08 | Vahid Saadat | Apparatus and methods for cooling a region within the body |
WO2003105400A1 (en) | 2002-06-07 | 2003-12-18 | ソニー株式会社 | Data processing system, data processing device, data processing method, and computer program |
JP3786055B2 (en) | 2002-06-07 | 2006-06-14 | ソニー株式会社 | Data processing system, data processing apparatus and method, and computer program |
BR0312430A (en) | 2002-06-19 | 2005-04-26 | Palomar Medical Tech Inc | Method and apparatus for treating skin and subcutaneous conditions |
EP1523283A1 (en) | 2002-06-19 | 2005-04-20 | Palomar Medical Technologies, Inc. | Method and apparatus for photothermal treatment of tissue at depth |
JP2004073812A (en) | 2002-06-20 | 2004-03-11 | Ya Man Ltd | Massager |
CA2490725A1 (en) | 2002-06-25 | 2003-12-31 | Ultrashape Inc. | Devices and methodologies useful in body aesthetics |
US6820961B2 (en) | 2002-06-28 | 2004-11-23 | Lexmark International, Inc. | Stationary ink mist chimney for ink jet printer |
US6969399B2 (en) | 2002-07-11 | 2005-11-29 | Life Recovery Systems Hd, Llc | Apparatus for altering the body temperature of a patient |
US7452712B2 (en) * | 2002-07-30 | 2008-11-18 | Applied Biosystems Inc. | Sample block apparatus and method of maintaining a microcard on a sample block |
US7250047B2 (en) | 2002-08-16 | 2007-07-31 | Lumenis Ltd. | System and method for treating tissue |
US6860896B2 (en) | 2002-09-03 | 2005-03-01 | Jeffrey T. Samson | Therapeutic method and apparatus |
US6789545B2 (en) | 2002-10-04 | 2004-09-14 | Sanarus Medical, Inc. | Method and system for cryoablating fibroadenomas |
EP1558339A1 (en) | 2002-10-07 | 2005-08-03 | Palomar Medical Technologies, Inc. | Apparatus for performing photobiostimulation |
US8226698B2 (en) | 2002-10-08 | 2012-07-24 | Vitalwear, Inc. | Therapeutic cranial wrap for a contrast therapy system |
US6994151B2 (en) | 2002-10-22 | 2006-02-07 | Cooligy, Inc. | Vapor escape microchannel heat exchanger |
US20040082886A1 (en) | 2002-10-24 | 2004-04-29 | Timpson Sandra Tee | Therapeutic device for relieving pain and stress |
GB2396109B (en) | 2002-12-12 | 2006-04-19 | Johnson & Johnson Medical Ltd | Absorbent multilayer hydrogel wound dressings |
CN1511503A (en) | 2002-12-30 | 2004-07-14 | 中国科学院理化技术研究所 | Fat reducer by applying cold and hot stimulation to skin alternatively |
US7976519B2 (en) | 2002-12-31 | 2011-07-12 | Kci Licensing, Inc. | Externally-applied patient interface system and method |
US7273479B2 (en) | 2003-01-15 | 2007-09-25 | Cryodynamics, Llc | Methods and systems for cryogenic cooling |
US7410484B2 (en) | 2003-01-15 | 2008-08-12 | Cryodynamics, Llc | Cryotherapy probe |
US7083612B2 (en) | 2003-01-15 | 2006-08-01 | Cryodynamics, Llc | Cryotherapy system |
US20050143781A1 (en) | 2003-01-31 | 2005-06-30 | Rafael Carbunaru | Methods and systems for patient adjustment of parameters for an implanted stimulator |
US20060234899A1 (en) | 2003-03-05 | 2006-10-19 | H.H. Brown Shoe Technologies Inc. D/B/A Dicon Technologies | Hydrophilic polyurethane foam articles comprising an antimicrobial compound |
WO2004080279A2 (en) | 2003-03-06 | 2004-09-23 | Spectragenics, Inc. | In the patent cooperation treaty application for patent |
US7037326B2 (en) | 2003-03-14 | 2006-05-02 | Hee-Young Lee | Skin cooling device using thermoelectric element |
DE10314138A1 (en) | 2003-03-25 | 2004-10-07 | Krüger & Gothe GmbH | Heating / cooling device |
US9149322B2 (en) | 2003-03-31 | 2015-10-06 | Edward Wells Knowlton | Method for treatment of tissue |
US20040206365A1 (en) | 2003-03-31 | 2004-10-21 | Knowlton Edward Wells | Method for treatment of tissue |
GB0307963D0 (en) | 2003-04-05 | 2003-05-14 | Eastman Kodak Co | A foamed material and a method of making thereof |
US7659301B2 (en) | 2003-04-15 | 2010-02-09 | The General Hospital Corporation | Methods and devices for epithelial protection during photodynamic therapy |
US7220778B2 (en) | 2003-04-15 | 2007-05-22 | The General Hospital Corporation | Methods and devices for epithelial protection during photodynamic therapy |
US20040210287A1 (en) | 2003-04-21 | 2004-10-21 | Greene Judy L. | Portable cooling or heating device for applying cryotherapy |
KR20040094508A (en) | 2003-05-02 | 2004-11-10 | 김창선 | Apparatus for Skin Treatment Using Ultra-sonic And Cold-Hot |
US20040249427A1 (en) | 2003-06-06 | 2004-12-09 | Yunes Nabilsi | Medical cooler device |
US7147610B2 (en) | 2003-06-19 | 2006-12-12 | Tarek Maalouf | Multiple combination heat/massage devices |
JP4504099B2 (en) | 2003-06-25 | 2010-07-14 | 株式会社リコー | Digital certificate management system, digital certificate management apparatus, digital certificate management method, update procedure determination method and program |
US7479104B2 (en) | 2003-07-08 | 2009-01-20 | Maquet Cardiovascular, Llc | Organ manipulator apparatus |
WO2005007060A2 (en) | 2003-07-18 | 2005-01-27 | Thermotek, Inc. | Compression sequenced thermal therapy system |
US8100956B2 (en) | 2006-05-09 | 2012-01-24 | Thermotek, Inc. | Method of and system for thermally augmented wound care oxygenation |
US20050043723A1 (en) | 2003-08-19 | 2005-02-24 | Schering-Plough Healthcare Products, Inc. | Cryosurgery device |
JP2005065984A (en) | 2003-08-25 | 2005-03-17 | Nikon Corp | Massage machine |
US20050049661A1 (en) | 2003-09-03 | 2005-03-03 | Koffroth Shirley B. | Ice belt to reduce body temperature |
US20050049526A1 (en) | 2003-09-03 | 2005-03-03 | Baer Mark P. | Massage devices and methods thereof |
CA2441489A1 (en) | 2003-09-12 | 2005-03-12 | Jocelyn Tortal | Inducing and contouring ice formation |
US7077858B2 (en) | 2003-09-22 | 2006-07-18 | Coolhead Technologies, Inc. | Flexible heat exchangers for medical cooling and warming applications |
WO2005033957A1 (en) | 2003-09-30 | 2005-04-14 | Sony Corporation | Content acquisition method |
JP2005110755A (en) | 2003-10-03 | 2005-04-28 | Shinko Denshi Kk | Heating/cooling apparatus for reducing muscular fatigue |
US7282036B2 (en) | 2003-10-24 | 2007-10-16 | Masatoshi Masuda | Cosmetic device having vibrator |
EP1527760A1 (en) | 2003-10-29 | 2005-05-04 | Normand, Jacques | Thermal pad and its use |
US7613523B2 (en) | 2003-12-11 | 2009-11-03 | Apsara Medical Corporation | Aesthetic thermal sculpting of skin |
US7857773B2 (en) | 2003-12-30 | 2010-12-28 | Medicis Technologies Corporation | Apparatus and methods for the destruction of adipose tissue |
WO2005065407A2 (en) | 2003-12-30 | 2005-07-21 | Liposonix, Inc. | Position tracking device |
BRPI0417907A (en) | 2003-12-30 | 2007-04-10 | Liposonix Inc | ultrasound head, energy applicator, means for maneuvering it, and method for distributing ultrasound energy to a body surface |
JP2007516809A (en) | 2003-12-30 | 2007-06-28 | ライポソニックス, インコーポレイテッド | Ultrasonic transducer components |
CA2546265A1 (en) | 2003-12-30 | 2005-07-21 | Liposonix, Inc. | Systems and methods for the destruction of adipose tissue |
US20050149153A1 (en) | 2004-01-07 | 2005-07-07 | Kazuo Nakase | Body temperature adjuster |
WO2005074627A2 (en) | 2004-02-02 | 2005-08-18 | Hydrophilix Corporation | Process for controlling the density, conformation and composition of the hydrophilic layer of a polyurethane composite |
JP2005237908A (en) | 2004-02-12 | 2005-09-08 | Tamotsu Nishizaki | Cryosurgical unit using heat exchanger |
US7052167B2 (en) | 2004-02-25 | 2006-05-30 | Vanderschuit Carl R | Therapeutic devices and methods for applying therapy |
JP4109640B2 (en) | 2004-02-25 | 2008-07-02 | 株式会社エム・アイ・ラボ | Automatic excitation massager |
US20060035380A1 (en) | 2004-03-12 | 2006-02-16 | L'oreal | Fake-proof marking of a composition |
JP2005312950A (en) | 2004-03-31 | 2005-11-10 | Terumo Corp | Medical tool for energy irradiation and medical energy irradiation device |
JP4971133B2 (en) | 2004-04-01 | 2012-07-11 | ザ ジェネラル ホスピタル コーポレイション | Equipment for dermatological treatment |
ES2611284T3 (en) | 2004-04-01 | 2017-05-08 | The General Hospital Corporation | Device for skin treatment and tissue remodeling |
US8571648B2 (en) | 2004-05-07 | 2013-10-29 | Aesthera | Apparatus and method to apply substances to tissue |
US7842029B2 (en) | 2004-05-07 | 2010-11-30 | Aesthera | Apparatus and method having a cooling material and reduced pressure to treat biological external tissue |
US20050251117A1 (en) | 2004-05-07 | 2005-11-10 | Anderson Robert S | Apparatus and method for treating biological external tissue |
JP2005323716A (en) | 2004-05-13 | 2005-11-24 | Takeshi Shimizu | Cold spot stimulation device |
JP4579603B2 (en) | 2004-07-14 | 2010-11-10 | 株式会社リブドゥコーポレーション | Non-woven fabric for skin cleaning |
US20060036300A1 (en) | 2004-08-16 | 2006-02-16 | Syneron Medical Ltd. | Method for lypolisis |
US7171508B2 (en) | 2004-08-23 | 2007-01-30 | Micron Technology, Inc. | Dual port memory with asymmetric inputs and outputs, device, system and method |
US8535228B2 (en) | 2004-10-06 | 2013-09-17 | Guided Therapy Systems, Llc | Method and system for noninvasive face lifts and deep tissue tightening |
US8690778B2 (en) | 2004-10-06 | 2014-04-08 | Guided Therapy Systems, Llc | Energy-based tissue tightening |
US8133180B2 (en) | 2004-10-06 | 2012-03-13 | Guided Therapy Systems, L.L.C. | Method and system for treating cellulite |
EP3682946A1 (en) | 2004-10-06 | 2020-07-22 | Guided Therapy Systems, L.L.C. | System for noninvasive tissue treatment |
JP2008522642A (en) | 2004-10-06 | 2008-07-03 | ガイデッド セラピー システムズ, エル.エル.シー. | Method and system for beauty enhancement |
US20060111744A1 (en) | 2004-10-13 | 2006-05-25 | Guided Therapy Systems, L.L.C. | Method and system for treatment of sweat glands |
US20120016239A1 (en) | 2004-10-06 | 2012-01-19 | Guided Therapy Systems, Llc | Systems for cosmetic treatment |
US20060094988A1 (en) | 2004-10-28 | 2006-05-04 | Tosaya Carol A | Ultrasonic apparatus and method for treating obesity or fat-deposits or for delivering cosmetic or other bodily therapy |
JP4324673B2 (en) | 2004-11-05 | 2009-09-02 | 国立大学法人東北大学 | Cryotherapy device with Peltier module |
US20060122509A1 (en) | 2004-11-24 | 2006-06-08 | Liposonix, Inc. | System and methods for destroying adipose tissue |
US7828831B1 (en) | 2004-12-06 | 2010-11-09 | Deroyal Industries, Inc. | Hot and cold fluid therapy system |
US7780656B2 (en) | 2004-12-10 | 2010-08-24 | Reliant Technologies, Inc. | Patterned thermal treatment using patterned cryogen spray and irradiation by light |
JP2008536527A (en) | 2005-01-24 | 2008-09-11 | キネティキュア リミテッド | Apparatus and method for applying vibration to a joint |
CA2609216A1 (en) | 2005-03-09 | 2006-09-14 | Ronald Allan Greenberg | An apparatus and method of body contouring and skin conditioning |
US9581942B1 (en) * | 2005-03-23 | 2017-02-28 | Shippert Enterprises, Llc | Tissue transfer method and apparatus |
EP1865541A4 (en) | 2005-03-31 | 2017-06-14 | Nikon Corporation | Exposure method, exposure apparatus and device manufacturing method |
US7975702B2 (en) | 2005-04-05 | 2011-07-12 | El.En. S.P.A. | System and method for laser lipolysis |
EP2305188B1 (en) | 2005-04-27 | 2015-06-03 | ZOLL Circulation, Inc. | Apparatus for providing enhanced heat transfer from a body |
US7217265B2 (en) | 2005-05-18 | 2007-05-15 | Cooltouch Incorporated | Treatment of cellulite with mid-infrared radiation |
US7850683B2 (en) | 2005-05-20 | 2010-12-14 | Myoscience, Inc. | Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat) |
US7713266B2 (en) | 2005-05-20 | 2010-05-11 | Myoscience, Inc. | Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat) |
WO2006127897A2 (en) | 2005-05-24 | 2006-11-30 | Uab Research Foundation | Surgical delivery devices and methods |
CN2843367Y (en) | 2005-07-01 | 2006-12-06 | 李铁军 | The refrigerating plant that is used for the treatment of skin vegetations |
WO2007012083A2 (en) | 2005-07-20 | 2007-01-25 | Verimatrix, Inc. | Network user authentication system and method |
US7955262B2 (en) | 2005-07-26 | 2011-06-07 | Syneron Medical Ltd. | Method and apparatus for treatment of skin using RF and ultrasound energies |
US20070032561A1 (en) | 2005-08-05 | 2007-02-08 | I-Sioun Lin | Modified hydrophilic polyurethane memory foam, application and manufacturing method thereof |
US20070055173A1 (en) | 2005-08-23 | 2007-03-08 | Sanarus Medical, Inc. | Rotational core biopsy device with liquid cryogen adhesion probe |
CN2850585Y (en) | 2005-09-05 | 2006-12-27 | 李钟俊 | Novel freezing skin-softening cosmetic instrument with magnetic field |
CN2850584Y (en) | 2005-09-05 | 2006-12-27 | 李钟俊 | Freezing skin-softening cosmetic instrument |
GB2431108A (en) | 2005-09-07 | 2007-04-18 | Mohammed Firoz Hussein | Applicator for dispensing cryogenic fluid |
US8518069B2 (en) | 2005-09-07 | 2013-08-27 | Cabochon Aesthetics, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US7967763B2 (en) | 2005-09-07 | 2011-06-28 | Cabochon Aesthetics, Inc. | Method for treating subcutaneous tissues |
US20070078502A1 (en) | 2005-10-05 | 2007-04-05 | Thermage, Inc. | Method and apparatus for estimating a local impedance factor |
US7572268B2 (en) | 2005-10-13 | 2009-08-11 | Bacoustics, Llc | Apparatus and methods for the selective removal of tissue using combinations of ultrasonic energy and cryogenic energy |
US7729773B2 (en) | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
US8108047B2 (en) | 2005-11-08 | 2012-01-31 | Newlife Sciences Llc | Device and method for the treatment of pain with electrical energy |
US20080014627A1 (en) | 2005-12-02 | 2008-01-17 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US9248317B2 (en) | 2005-12-02 | 2016-02-02 | Ulthera, Inc. | Devices and methods for selectively lysing cells |
US20080195036A1 (en) * | 2005-12-02 | 2008-08-14 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US20070135876A1 (en) | 2005-12-08 | 2007-06-14 | Weber Paul J | Acne and skin defect treatment via non-radiofrequency electrical current controlled power delivery device and methods |
US7799018B2 (en) | 2006-01-06 | 2010-09-21 | Olga Goulko | Cryogenic applicator for rejuvenating human skin and related method |
US20090312676A1 (en) | 2006-02-02 | 2009-12-17 | Tylerton International Inc. | Metabolic Sink |
CN100362067C (en) | 2006-02-08 | 2008-01-16 | 舒宏纪 | Interface paint with high hydrophobicity, heat conductivity and adhesion |
US7824437B1 (en) | 2006-02-13 | 2010-11-02 | Gina Saunders | Multi-functional abdominal cramp reducing device and associated method |
US8133191B2 (en) | 2006-02-16 | 2012-03-13 | Syneron Medical Ltd. | Method and apparatus for treatment of adipose tissue |
US7854754B2 (en) | 2006-02-22 | 2010-12-21 | Zeltiq Aesthetics, Inc. | Cooling device for removing heat from subcutaneous lipid-rich cells |
JP4903471B2 (en) | 2006-03-30 | 2012-03-28 | 東急建設株式会社 | Building wall material and wireless transmission system |
US20070249519A1 (en) | 2006-04-20 | 2007-10-25 | Kalypsys, Inc. | Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease |
US20070255187A1 (en) | 2006-04-26 | 2007-11-01 | Branch Alan P | Vibrating therapy device |
KR101039758B1 (en) | 2006-04-28 | 2011-06-09 | 젤티크 애스세틱스, 인코포레이티드. | Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells |
US7615036B2 (en) | 2006-05-11 | 2009-11-10 | Kalypto Medical, Inc. | Device and method for wound therapy |
US20070282318A1 (en) | 2006-05-16 | 2007-12-06 | Spooner Gregory J | Subcutaneous thermolipolysis using radiofrequency energy |
US20070270925A1 (en) | 2006-05-17 | 2007-11-22 | Juniper Medical, Inc. | Method and apparatus for non-invasively removing heat from subcutaneous lipid-rich cells including a coolant having a phase transition temperature |
KR100746322B1 (en) | 2006-06-12 | 2007-08-06 | 주식회사 바이오스마트 | Rod type skin treatment device for cryo-surgery and cryo-skin treatment |
KR100746323B1 (en) | 2006-06-12 | 2007-08-06 | 주식회사 바이오스마트 | Roller type skin treatment device for cryo-surgery and cryo-skin treatment |
US8246611B2 (en) | 2006-06-14 | 2012-08-21 | Candela Corporation | Treatment of skin by spatial modulation of thermal heating |
US8460352B2 (en) | 2006-07-05 | 2013-06-11 | Kaz Usa, Inc. | Site-specific pad with notch |
US20080046047A1 (en) | 2006-08-21 | 2008-02-21 | Daniel Jacobs | Hot and cold therapy device |
WO2008025511A1 (en) | 2006-08-28 | 2008-03-06 | Liquid Ice Cosmedicals Gmbh | Improved preparation for reducing and/or preventing body fat and respective uses, in particular together with a dressing material |
US20090171253A1 (en) | 2006-09-06 | 2009-07-02 | Cutera, Inc. | System and method for dermatological treatment using ultrasound |
ATE489048T1 (en) | 2006-09-08 | 2010-12-15 | Arbel Medical Ltd | DEVICE FOR COMBINED TREATMENT |
US20080097207A1 (en) | 2006-09-12 | 2008-04-24 | Siemens Medical Solutions Usa, Inc. | Ultrasound therapy monitoring with diagnostic ultrasound |
US8192474B2 (en) | 2006-09-26 | 2012-06-05 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US9132031B2 (en) | 2006-09-26 | 2015-09-15 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US20080077201A1 (en) | 2006-09-26 | 2008-03-27 | Juniper Medical, Inc. | Cooling devices with flexible sensors |
WO2008055243A2 (en) | 2006-10-31 | 2008-05-08 | Zeltiq Aesthetics, Inc. | Method and apparatus for cooling subcutaneous lipid-rich cells or tissue |
CN200970265Y (en) | 2006-11-09 | 2007-11-07 | 韩秀玲 | Freezing therapeutic device |
US20080140371A1 (en) | 2006-11-15 | 2008-06-12 | General Electric Company | System and method for treating a patient |
EP2097133A1 (en) | 2006-12-18 | 2009-09-09 | Koninklijke Philips Electronics N.V. | Cell lysis or electroporation device comprising at least one pyroelectric material |
US20080161892A1 (en) | 2006-12-28 | 2008-07-03 | John Anthony Mercuro | Facial Cold -Pack Holder |
US8128401B2 (en) * | 2006-12-29 | 2012-03-06 | Clifford J. Ruddle | Cannula for a combined dental irrigator and vacuum device |
US8414631B2 (en) | 2007-02-13 | 2013-04-09 | Thermotek, Inc. | System and method for cooled airflow for dermatological applications |
JP2010534076A (en) | 2007-02-16 | 2010-11-04 | ケー. パール,ポール | An apparatus and method that applies non-invasive ultrasound to shape the body using skin contact cooling. |
CN101259329A (en) | 2007-03-08 | 2008-09-10 | 德切勒·克里斯托夫·迪亚特曼 | Plush toy warming device |
WO2009075903A1 (en) | 2007-04-19 | 2009-06-18 | The Foundry, Inc. | Systems and methods for creating an effect using microwave energy to specified tissue |
US8688228B2 (en) * | 2007-04-19 | 2014-04-01 | Miramar Labs, Inc. | Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy |
US9149331B2 (en) | 2007-04-19 | 2015-10-06 | Miramar Labs, Inc. | Methods and apparatus for reducing sweat production |
US20080287839A1 (en) | 2007-05-18 | 2008-11-20 | Juniper Medical, Inc. | Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator |
WO2008151260A2 (en) | 2007-06-04 | 2008-12-11 | Farr Laboratories, Llc | Skin care method and kit using peltier thermoelectric device |
KR20100041753A (en) | 2007-06-08 | 2010-04-22 | 싸이노슈어, 인코포레이티드 | Coaxial suction system for laser lipolysis |
US20080312651A1 (en) | 2007-06-15 | 2008-12-18 | Karl Pope | Apparatus and methods for selective heating of tissue |
US20090012434A1 (en) | 2007-07-03 | 2009-01-08 | Anderson Robert S | Apparatus, method, and system to treat a volume of skin |
KR20090000258U (en) | 2007-07-06 | 2009-01-09 | 주식회사 바이오스마트 | Roller type skin treatment device for cryo-surgery and cryo-skin treatment |
US20090018626A1 (en) | 2007-07-13 | 2009-01-15 | Juniper Medical, Inc. | User interfaces for a system that removes heat from lipid-rich regions |
US8523927B2 (en) | 2007-07-13 | 2013-09-03 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
WO2009011708A1 (en) | 2007-07-13 | 2009-01-22 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
US20090018627A1 (en) | 2007-07-13 | 2009-01-15 | Juniper Medical, Inc. | Secure systems for removing heat from lipid-rich regions |
US20090018624A1 (en) | 2007-07-13 | 2009-01-15 | Juniper Medical, Inc. | Limiting use of disposable system patient protection devices |
US20090018625A1 (en) | 2007-07-13 | 2009-01-15 | Juniper Medical, Inc. | Managing system temperature to remove heat from lipid-rich regions |
EP2182898B1 (en) | 2007-08-21 | 2018-10-03 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
US8433400B2 (en) | 2007-10-24 | 2013-04-30 | Marina Prushinskaya | Method and portable device for treating skin disorders |
US20090149930A1 (en) | 2007-12-07 | 2009-06-11 | Thermage, Inc. | Apparatus and methods for cooling a treatment apparatus configured to non-invasively deliver electromagnetic energy to a patient's tissue |
ES2471971T3 (en) | 2007-12-12 | 2014-06-27 | Miramar Labs, Inc. | System and apparatus for non-invasive treatment of tissue using microwave energy |
WO2009095894A2 (en) | 2008-02-01 | 2009-08-06 | Alma Lasers Ltd. | Apparatus and method for selective ultrasonic damage of adipocytes |
JP2009189757A (en) | 2008-02-15 | 2009-08-27 | Akira Hirai | Fever relieving device |
WO2009111793A2 (en) | 2008-03-07 | 2009-09-11 | Myoscience, Inc. | Subdermal tissue remodeling using myostatin, methods and related systems |
EP2271276A4 (en) | 2008-04-17 | 2013-01-23 | Miramar Labs Inc | Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy |
US8449590B2 (en) | 2008-04-30 | 2013-05-28 | Eric William BRADER | Apparatus and method for preventing brain damage during cardiac arrest, CPR, or severe shock |
JP2011528919A (en) | 2008-05-07 | 2011-12-01 | サヌウェーブ,インク. | Medical treatment system comprising an auxiliary medical treatment device with an associated data storage medium |
US20090299234A1 (en) | 2008-05-28 | 2009-12-03 | Nuga Medical Co., Ltd | Fat remover |
KR102479936B1 (en) | 2008-06-06 | 2022-12-22 | 얼테라, 인크 | Ultrasound treatment system |
US20090306749A1 (en) | 2008-06-07 | 2009-12-10 | Damalie Mulindwa | Therapeutic hot and cold water belt |
US20090312693A1 (en) | 2008-06-13 | 2009-12-17 | Vytronus, Inc. | System and method for delivering energy to tissue |
CN102143724B (en) | 2008-08-07 | 2015-02-25 | 通用医疗公司 | Method and apparatus for dermatological hypopigmentation |
WO2010017556A1 (en) | 2008-08-08 | 2010-02-11 | Palomar Medical Technologies, Inc | Method and apparatus for fractional deformation and treatment of cutaneous and subcutaneous tissue |
US8672931B2 (en) | 2008-08-18 | 2014-03-18 | 3JT Enterprises, LLC | Cryosurgical device with metered dose |
US9149386B2 (en) | 2008-08-19 | 2015-10-06 | Niveus Medical, Inc. | Devices and systems for stimulation of tissues |
EP2330995B1 (en) | 2008-09-03 | 2015-08-05 | Endocare, Inc. | A cryogenic system and method of use |
US8409184B2 (en) | 2009-09-09 | 2013-04-02 | Cpsi Holdings Llc | Cryo-medical injection device and method of use |
EP2346428B1 (en) | 2008-09-25 | 2019-11-06 | Zeltiq Aesthetics, Inc. | Treatment planning systems and methods for body contouring applications |
US20100087806A1 (en) | 2008-10-07 | 2010-04-08 | Vandolay, Inc. | Automated Cryogenic Skin Treatment |
US8387631B1 (en) * | 2008-12-10 | 2013-03-05 | Western Digital Technologies, Inc. | HDA vacuum cleaning machine for manufacturing of HDD |
US8603073B2 (en) | 2008-12-17 | 2013-12-10 | Zeltiq Aesthetics, Inc. | Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells |
EP2373240B1 (en) | 2008-12-22 | 2015-04-29 | Myoscience, Inc. | Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments |
WO2010075547A2 (en) | 2008-12-24 | 2010-07-01 | Guided Therapy Systems, Llc | Methods and systems for fat reduction and/or cellulite treatment |
US20100168726A1 (en) | 2008-12-31 | 2010-07-01 | Marc Arthur Brookman | Cryogenic Dispensing System and Method for Treatment of Dermatological Conditions |
US7981080B2 (en) | 2009-01-07 | 2011-07-19 | Halaka Folim G | Skin cooling apparatus and method |
US8372130B2 (en) | 2009-01-23 | 2013-02-12 | Forever Young International, Inc. | Temperature controlled facial mask with area-specific treatments |
WO2010096776A2 (en) | 2009-02-20 | 2010-08-26 | Niveus Medical, Inc. | Systems and methods of powered muscle stimulation using an energy guidance field |
US20110313412A1 (en) | 2009-02-23 | 2011-12-22 | Miramar Labs, Inc. | Tissue interface system and method |
US8298225B2 (en) | 2009-03-19 | 2012-10-30 | Tyco Healthcare Group Lp | System and method for return electrode monitoring |
DE102009014976B3 (en) | 2009-03-30 | 2010-06-02 | Jutta Munz | Applicator device for applying e.g. cream on eye portion of human body, has activator device provided in upper housing part, and producing heat or coldness that is transmitted to substance contained in substance chamber |
WO2010125531A1 (en) | 2009-04-30 | 2010-11-04 | Alma Lasers Limited | Devices and methods for dermatological treatment |
CN102596116B (en) * | 2009-04-30 | 2015-01-14 | 斯尔替克美学股份有限公司 | Device, system and method of removing heat from subcutaneous lipid-rich cells |
FR2946845B1 (en) | 2009-06-18 | 2011-08-19 | Oreal | DEVICE FOR TREATING HUMAN KERATINIC MATERIALS |
US9919168B2 (en) | 2009-07-23 | 2018-03-20 | Palomar Medical Technologies, Inc. | Method for improvement of cellulite appearance |
US8523791B2 (en) | 2009-08-11 | 2013-09-03 | Laboratoire Naturel Paris, Llc | Multi-modal drug delivery system |
US8152904B2 (en) | 2009-09-29 | 2012-04-10 | Liposonix, Inc. | Liquid degas system |
US20110112520A1 (en) | 2009-11-11 | 2011-05-12 | Invasix Corporation | Method and device for fat treatment |
WO2011091293A1 (en) | 2010-01-21 | 2011-07-28 | Zeltiq Aesthetics, Inc. | Compositions for use with a system for improved cooling of subcutaneous lipid-rich tissue |
US9844461B2 (en) | 2010-01-25 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants |
US8785487B2 (en) | 2010-01-25 | 2014-07-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
DE102010007177B4 (en) | 2010-02-08 | 2017-06-22 | Siemens Healthcare Gmbh | Display method for an image of the interior of a vessel located in front of a widening device and display device corresponding thereto |
US20110196438A1 (en) | 2010-02-10 | 2011-08-11 | Lukas Mnozil | Therapy device and method for treating underlying tissue using electrical and acoustic energies |
WO2011100692A1 (en) | 2010-02-15 | 2011-08-18 | The General Hospital Corporation | Methods and devices for selective disruption of visceral fat by controlled cooling |
US20110257642A1 (en) | 2010-04-16 | 2011-10-20 | Griggs Iii Charles Sherman | Method for producing a permanent or nearly permanent skin image, design or tattoo by freezing the skin |
US20120158100A1 (en) | 2010-06-21 | 2012-06-21 | Kevin Schomacker | Driving Microneedle Arrays into Skin and Delivering RF Energy |
US8676338B2 (en) | 2010-07-20 | 2014-03-18 | Zeltiq Aesthetics, Inc. | Combined modality treatment systems, methods and apparatus for body contouring applications |
FR2967893B1 (en) | 2010-11-25 | 2013-10-18 | Zadeh David Khorassani | MASSAGE APPARATUS COMPRISING A SUCTION SYSTEM |
AU2011253768B2 (en) | 2010-12-01 | 2016-08-11 | Gold Rythmn Pty Ltd | Product or process for modifying skin |
WO2012094426A2 (en) | 2011-01-04 | 2012-07-12 | Schwartz Alan N | Gel-based seals and fixation devices and associated systems and methods |
US10722395B2 (en) | 2011-01-25 | 2020-07-28 | Zeltiq Aesthetics, Inc. | Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells |
ES2718651T3 (en) * | 2011-01-28 | 2019-07-03 | Massachusetts Gen Hospital | Method and apparatus for discontinuous dermabrasion |
US20120209363A1 (en) | 2011-02-10 | 2012-08-16 | R2T2 Solutions Llc | Hot and cold therapy device |
US9038640B2 (en) | 2011-03-31 | 2015-05-26 | Viora Ltd. | System and method for fractional treatment of skin |
US20120310232A1 (en) | 2011-06-06 | 2012-12-06 | Danny Erez | System and method for treating a tissue using multiple energy types |
EP2734067A4 (en) | 2011-07-20 | 2015-03-25 | Scr Inc | Athletic cooling and heating systems, devices and methods |
US9314301B2 (en) | 2011-08-01 | 2016-04-19 | Miramar Labs, Inc. | Applicator and tissue interface module for dermatological device |
EP2564895B1 (en) | 2011-09-05 | 2015-11-18 | Venus Concept Ltd | An improved esthetic device for beautifying skin |
US20130073017A1 (en) | 2011-09-15 | 2013-03-21 | Fong Yu Liu | Thermal vacuum therapy and apparatus thereof |
KR20130043299A (en) | 2011-10-20 | 2013-04-30 | 김기태 | Medical skin beauty care apparatus for heating and stimulating skin using thermoelectric module and ultra-sonic vibrator |
CN116236338A (en) | 2011-11-16 | 2023-06-09 | 通用医疗公司 | Method and device for the cryogenic treatment of skin tissue |
KR102359731B1 (en) | 2011-11-16 | 2022-02-08 | 더 제너럴 하스피탈 코포레이션 | Method and apparatus for cryogenic treatment of skin tissue |
GB2505058A (en) | 2012-06-22 | 2014-02-19 | Physiolab Technologies Ltd | Manifold assembly for a thermoregulation system |
KR20140038165A (en) | 2012-09-20 | 2014-03-28 | (주)휴톤 | Multi function apparatus for treating skin |
KR20140092121A (en) | 2013-01-15 | 2014-07-23 | 삼성전자주식회사 | Method for cooling ultrasound treatment apparatus, ultrasound treatment apparatus by using the same |
US9545523B2 (en) | 2013-03-14 | 2017-01-17 | Zeltiq Aesthetics, Inc. | Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue |
US9844460B2 (en) | 2013-03-14 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same |
WO2015117005A1 (en) | 2014-01-31 | 2015-08-06 | The General Hospital Corporation | Cooling device to disrupt function sebaceous glands |
WO2015117026A2 (en) | 2014-01-31 | 2015-08-06 | Zeltiq Aesthetics, Inc. | Treating systems and methods for treating cellulite and providing other treatments |
US10935174B2 (en) | 2014-08-19 | 2021-03-02 | Zeltiq Aesthetics, Inc. | Stress relief couplings for cryotherapy apparatuses |
US10568759B2 (en) | 2014-08-19 | 2020-02-25 | Zeltiq Aesthetics, Inc. | Treatment systems, small volume applicators, and methods for treating submental tissue |
US20160089550A1 (en) | 2014-09-25 | 2016-03-31 | Zeltiq Aesthetics, Inc. | Treatment systems, methods, and apparatuses for altering the appearance of skin |
WO2017053324A1 (en) | 2015-09-21 | 2017-03-30 | Zeltiq Aesthetics, Inc. | Transcutaneous treatment systems and cooling devices |
US11154418B2 (en) | 2015-10-19 | 2021-10-26 | Zeltiq Aesthetics, Inc. | Vascular treatment systems, cooling devices, and methods for cooling vascular structures |
EP3399950A1 (en) | 2016-01-07 | 2018-11-14 | Zeltiq Aesthetics, Inc. | Temperature-dependent adhesion between applicator and skin during cooling of tissue |
US10765552B2 (en) | 2016-02-18 | 2020-09-08 | Zeltiq Aesthetics, Inc. | Cooling cup applicators with contoured heads and liner assemblies |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
US20170326346A1 (en) | 2016-05-10 | 2017-11-16 | Zeltiq Aesthetics, Inc. | Permeation enhancers and methods of cryotherapy |
US10682297B2 (en) | 2016-05-10 | 2020-06-16 | Zeltiq Aesthetics, Inc. | Liposomes, emulsions, and methods for cryotherapy |
US10555831B2 (en) | 2016-05-10 | 2020-02-11 | Zeltiq Aesthetics, Inc. | Hydrogel substances and methods of cryotherapy |
US20180263677A1 (en) | 2017-03-16 | 2018-09-20 | Zeltiq Aesthetics, Inc. | Adhesive liners for cryotherapy |
WO2018175111A1 (en) | 2017-03-21 | 2018-09-27 | Zeltiq Aesthetics, Inc. | Use of saccharides for cryoprotection and related technology |
US11076879B2 (en) | 2017-04-26 | 2021-08-03 | Zeltiq Aesthetics, Inc. | Shallow surface cryotherapy applicators and related technology |
-
2018
- 2018-04-25 US US15/962,811 patent/US11076879B2/en active Active
-
2021
- 2021-06-17 US US17/350,972 patent/US20220039818A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150223975A1 (en) * | 2014-02-12 | 2015-08-13 | The General Hospital Corporation | Method and apparatus for affecting pigmentation of tissue |
Also Published As
Publication number | Publication date |
---|---|
US11076879B2 (en) | 2021-08-03 |
US20180310950A1 (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220039818A1 (en) | Shallow surface cryotherapy applicators and related technology | |
US20210045912A1 (en) | Cooling cup applicators with contoured heads and liner assemblies | |
US20230320894A1 (en) | Treatment systems, small volume applicators, and methods for treating submental tissue | |
US20180263677A1 (en) | Adhesive liners for cryotherapy | |
US10806500B2 (en) | Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments | |
US11452634B2 (en) | Device, system and method of removing heat from subcutaneous lipid-rich cells | |
US10935174B2 (en) | Stress relief couplings for cryotherapy apparatuses | |
US9545523B2 (en) | Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue | |
US10092346B2 (en) | Combined modality treatment systems, methods and apparatus for body contouring applications | |
US10952891B1 (en) | Treatment systems with adjustable gap applicators and methods for cooling tissue | |
US10675176B1 (en) | Treatment systems, devices, and methods for cooling targeted tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: ZELTIQ AESTHETICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YEE, PETER;FRANGINEAS, GEORGE, JR.;ROOT, AUSTIN;SIGNING DATES FROM 20180905 TO 20180906;REEL/FRAME:060235/0875 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |